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Abstract 
The aim of this work was to establish an analytical method for the simultaneous detection of five major 
opium alkaloids in poppy seeds by liquid chromatography-electrospray ionisation-mass spectrometry (LC-
ESI-MS). Once opium alkaloids were detected in poppy seeds, toxicological studies were carried out to 
establish if these compounds were detected in oral fluid (OF) of participants who ingested muffins 
containing poppy seeds.    
It is known that the ingestion of poppy seeds has caused positive opiate drug test results and much work 
has been reported in the scientific literature in the last 20 years. Researchers in the field have 
investigated alternatives to differentiate between heroin administration and that of other opiate drugs 
versus poppy seed ingestion. Most of the work which has been carried out relates to establishing illicit 
heroin use by examining biological matrices for the presence of acetylcodeine, thebaine, papaverine, 
noscapine and their associated metabolites. 
The research methodology consisted of establishing an LC-ESI-MS method for the simultaneous detection 
of five major opium alkaloids (morphine, codeine, thebaine, papaverine and noscapine). A deuterated 
internal standard (morphine-d3) was used for the quantitation of alkaloids in harvested poppy seeds and 
oral fluid samples. Due to technical difficulties, 3 LC-MS instruments were employed in this work. 
Electrospray ionisation was employed in all mass spectrometers but the analysers included an ion trap 
with octopole, a triple quadrupole and a hybrid quadrupole Orbitrap. 
Suitable extraction procedures were determined and harvested seeds purchased from a number of 
supermarkets were analysed for the presence of five alkaloid compounds using the LC-MS method. A 
small scale pilot study with 6 participants was carried out to establish if it was possible to fail an OF drug 
test for opiates after consuming poppy seed muffins. OF samples were collected post ingestion using 
Quantisal™ kits and the level of each of the opiates was monitored. 
The findings were that an LC-ESI-MS method was established for the simultaneous detection and 
quantitation of five major alkaloids. However, the method development process involved finding a 
solution to co-elution of morphine and codeine. The process also included resolving the issue of thebaine 
producing two peaks with identical mass spectra and separated by a difference of 6 minutes in retention 
time.   
Varying levels of alkaloids were identified in harvested poppy seeds: levels of these compounds differed 
considerably within and between batches of poppy seeds. These findings could be attributed to a number 
of factors, for example, where and how the plants were grown and methods of harvesting. 
Two poppy seed muffins were consumed as part of a toxicology study. Morphine was detected in the 5 
minute sample in 5 out of the 6 participants with concentrations in OF of 0.5-0.8 ng mL-1; codeine was 
detected in 2 of the 6 participants at 1.5 and 2.6 ng mL-1. Thebaine, noscapine and papaverine were also 
detected in OF of a number of participants, which has not been previously reported in the literature. 
However, it should be noted that the values calculated are only estimated since the peak area ratios 
obtained were found to be less than the lowest concentration (10 ng mL-1) in the linear calibration range. 
In conclusion, an LC-ESI-MS method for the simultaneous detection and quantitation of five major opium 
alkaloids has been established and has been used to detect alkaloids in harvested poppy seeds and oral 
fluid samples. From a small pilot toxicology study, oral fluid results indicate that levels of morphine and 
codeine do not exceed the SAMSHA 40 ng mL-1 cut-off after ingestion of a realistic amount of poppy seeds 
contained within bakery products. 
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1. OPIUM AND OPIATES  
 History of opium poppies 1.1.
1.1.1. In the beginning…  
Poppies have been grown and used in daily culture for many thousands of years but the 
exact date or place of origin has not been established: it is however proposed by a number 
of scholars that Papaver somniferum L., the opium poppy originated in Sumer, a region in 
ancient Mesopotamia (modern day Iraq and Kuwait) around 5000 BC.1 Much has been 
written with respect to the opium poppy over the many years since this time and the 
writings relate not only to the cultivation and harvest of this crop but to the investigations 
of the chemistry of the plant and its medicinal uses and to the wars that have been 
fought.1-11 Opium, a latex based product of the opium poppy has been the basis for the two 
Opium wars (1839-1842 and 1856-1860) fought between Great Britain and China but also 
many a personal war has been fought against the addiction to opium and the alkaloid 
compounds extracted and further synthesised from it.5,12 
Although other writings have been published before this time, Hippocrates (450-380 BC) a 
Greek physician, was one of the first people to highlight and document the importance of 
the poppy in its many forms for medical purposes 2,3,13 and as such, the use of the poppy for 
anaesthesia was well documented in the Corpus Hippocraticum.14 This is a collection of 60 
documents detailing medical practices and procedures, not all written by Hippocrates 
himself, but as a collection form the basis of some modern medical practices.13 Poppies 
were also recommended as treatment where pain was recorded as one of the patient’s 
symptoms in a number of passages from these documents.14 However from history, the 
opium poppy disappeared for almost 1000 years with no real reason or explanation as to 
why. 
 
1.1.2. 10th – 12th centuries  
In between the 10th and 12th centuries it has been reported that the opium poppy was 
cultivated in the Abbasid Caliphate (what now covers Iraq, Afghanistan, Turkey and India): 
most of what was produced in this region however was predominantly used in “home-use” 
as poppy cake (this is now used as livestock feed) or was taken to local markets and sold. 
Arab traders however commenced the first “trafficking” of opium to other parts of the 
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world, such as, to Indonesia, China and along the North African coast to Moorish Spain. 
Since opium was not a common product at this time in many parts of the world, some 
people were sceptical about its use, but the Arab traders continued with their plight and 
persevered and eventually opium became welcomed rather than feared.15 
The routes that were taken by these Arab traders crossed many a desert or other arid 
landscape and they also encountered bandits: in order to make sure their product arrived 
at its destination safely, these traders would choose routes that were not on maps of the 
time and thus made their trek even more inhospitable.  These routes are still used in what 
is now modern day Afghanistan and are still used to traffic opium and its subsequent 
products through to other parts of the world.16 
Opium became widely known and used as an analgesic in areas where the opium was 
harvested and trafficked. It was not only found to be of use as an analgesic but was also 
found to be useful in managing many other ailments. At this point, Egypt and Mesopotamia 
were the leaders in the opium growing areas of the world and this eventually greatly aided 
the international trade in opium.17 
The Crusades (1095-1291) were military campaigns that were initially sanctioned by the 
Roman Catholic Church to ensure access for Christians to the Holy Lands of Jerusalem.18 
With the West involved in fighting with the East, it was possible for opium to make its way 
back to Europe with the return of those who had been fighting in the Holy Lands and it has 
been reported that the Arab traders pushed this process forward. Due to the nature of the 
voyage, the opium that eventually reached Europe was not found to be in the best 
condition but was opium nonetheless: at this point in history, the demand for opium 
greatly increased.15,19  
 
1.1.3. Paracelsus 
Philippus Aureolus Theophrastus Bombastus von Hohenheim (1493-1541 AD), a Swiss-
German alchemist and physician also known as Paracelsus, has the title of founding father 
of toxicology attributed to him.20 Amongst his many contributions to toxicology and 
medicine, he is reported to have introduced laudanum, at this time a solid form of opium 
latex derived from poppies. He studied the effects of laudanum on many people, including 
himself which he characterised as causing sleep: he is reported to have said that “an ideal 
medicine puts the disease to sleep without killing the patient”.15 He is also widely reported 
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to have prescribed the opium product as a treatment for many forms of pain throughout 
the body. He recorded many of his prescriptions and had a number of apprentices. After 
the death of Paracelsus, many scholars and followers of Paracelsus started to disseminate 
his teachings throughout parts of Europe.21 
 
1.1.4. The (very) political years    
By the early 17th century, laudanum became a reference to a liquid preparation of opium 
and alcohol, also known as a tincture of opium.22 Thomas Sydenham (1618-1683), a British 
physician whose aim was to relieve suffering, produced the opium tincture that was easily 
prepared and would in the end, be easy to administer to all patient types. Sydenham made 
this tincture of opium a proprietary medication sold as Sydenham’s Laudanum with this 
preparation sold as a “cure all”.23 One of the apprentices of Sydenham, Thomas Dover 
(1660-1742) later went on to produce an opium based powder and between Sydenham’s 
Laudanum and Dover’s Powder (Figure 1.1 showing both preparations), opium took its 
place firmly in the legitimate pharmacies of the time.24,25 Whether the ready availability 
and affordability of opium aided the popularity of the two preparations or the preparations 
aided the availability of the opium in the UK is not clear, however what is clear is that from 
this point onwards in history, the relationship of the West with opium spirals out to include 
drug addiction and war on grand scales which have continued to the present day.     
 
a.    b.  
Figure 1.1 (a) Antique bottle of Sydenham’s laudanum 26 and (b) antique bottle of Dover’s Powders 27 
 
For many hundreds of years, the opium poppy had been cultivated and harvested in India: 
as previously mentioned as was the case in Abassid Cailphate, the opium grown in India 
was a product used by families as a remedy for all things. After the Battle of Plassey (a 
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battle between the British and the Nawal of Bengal and his French allies which resulted in 
significant control over the Indian subcontinent by colonial powers) in 1757 the Honourable 
East India Company of England was established and this association of businessmen and 
aristocrats ensured that trade in products such as cotton, silk, tea, and most importantly, 
opium was successful.28,29 English Governors in India were introduced, with one of the roles 
being to oversee the cultivation and harvest of the opium crop. 
 There were numerous challenges faced by the English governors, the local Indian farmers 
and both governments, but by the 1780’s it is estimated that the area of land used in the 
cultivation and harvest of opium poppy was approximately 250,000 acres.15 The expanse 
and size of this kind of operation resulted in a change in the harvesting methods in order to 
standardise the process and make the product more stable to transport and eventually to 
sell at auction in Calcutta. From reports of the time it is estimated that the annual income 
from opium was thought to be in excess of £2 million with the largest customer of India 
being China in the East leaving the Anatolian Plateau, or more specifically Turkey, to 
become the main supplier of opium to the West.30 
In Turkey around the 1780’s and probably before, all parts of the plant were utilised, from 
the poppy seed oil used in cooking and lighting to the poppy cake being used by poorer 
families to bulk out their bread. It has been reported31 that at this time, Turkish opium was 
far more potent than the Indian variety, with the plants growing 6-8 feet in height (in 
comparison to Indian plants which would typically grow 3-6 feet) and containing around 
10-13% by weight morphine in comparison to 4-8% in the Indian variety: this was 
determined by analysis of the product years later.32 This Turkish opium was transported 
from Smyrna to predominantly the British ports of Dover, Bristol, Liverpool but mostly to 
London.15 
British people at the time did not wish to purchase opium from Turkey and preferred that 
their opium was “home” grown, whether that be from the UK or from one of the other 
countries within the British Empire. Prizes were offered for studies on the growing of 
medicinal plants and for opium, with a number of eminent British scientists proving that it 
was possible to grow opium on British land, including the cold Scottish countryside.33 
However what was problematic were the yields that could be produced: these yields would 
not be as profitable as imported opium from other countries since the cost of producing 
the opium would be much higher in the UK. The reasons for this were the yield was lower 
and the cost of labour was higher, even if women and children were employed to carry out 
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the laborious task of harvesting.34 It was also found that if appropriate harvesting 
techniques were not used, some of the crop would be lost, further reducing the yield. 
Some of the home-grown opium was used and Britain continued to import opium from 
Turkey but by the year 1805, the British had begun to export approximately a quarter of 
this opium to the United States of America.35 
 
1.1.5. The chemical years 
It was also in 1805 when German pharmacist Freidrich Sertürner (1783-1841) reported his 
findings of his isolation of the alkaloid morphine from opium.1,11 He had seen the use of 
opium with his sister who had died of consumption (pulmonary tuberculosis) but he had 
also noted that the opium had eventually lost its effectiveness. He decided to investigate 
this phenomenon by carrying out many experiments to identify the extracts of the opium. 
Sertürner published a paper outlining his findings from opium extracts and showed that his 
“poppy acid” showed different chemical reactions than with opium alone and stated that 
the “cause was something non-acidic but biologically active”. In terms of scientific 
deductions this is a significant one as at this time in history; it was assumed that all 
pharmacologically active compounds were acidic in nature with the acidity of the 
compound being directly related to the strength of the biological activity.36 It took a 
number of years and much devotion from Sertürner before he could convince the scientific 
community to accept his findings, however he eventually proved that he had isolated a 
compound, which he called principum somniferum (later called morphine) by carrying out a 
chlorate precipitation. He also proved that by weight, the product was more than ten times 
more active than the same weight of opium. These results were determined by 
experimenting with the morphine and the opium on himself and others and although he 
was probably addicted to the alkaloid compounds, he established that morphine could 
have many practical uses in treating pain and beyond.37 It eventually took the efforts of 
Joseph-Louis Gay-Lussac, a renowned chemist, to help Sertürner to be acknowledged for 
the work but that would not happen for a further 10 years when his patience was 
rewarded.38 
Morphine was not fully appreciated pharmaceutically until the invention of the hypodermic 
needle in 1853, long after the death of Sertürner.39,40 Morphine was initially used to cure 
addictions to alcohol, opium and laudanum amongst other preparations but it was not 
known at this time that morphine itself was highly addictive.23,33 
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The work of Sertürner began a renewed interest in organic chemistry over the following 
years, which resulted in other alkaloid compounds being isolated from opium: the most 
notable of these being narcotine (noscapine) in 1817 and codeine in 1832, both by French 
chemist Pierre Jean Robiquet (who had been a student under the tutelage of Gay-Lussac) 
41, thebaine (in 1832 by Pierre-Joseph Pelletier and Thibournery who was the manager of 
his factory 19), and papaverine in 1849 (by Georg Merck 42, son of Emanuel Merck founder 
of the Merck Pharmaceutical and Chemical Company).  
 
1.1.6. The Opium Wars (1839-1842 and 1856-60) 
In the early 19th century, many chemical advancements were made with regards to 
understanding opium alkaloids but also at this time the two Opium Wars were being fought 
between Britain and China. By the 1830’s, China was almost being destroyed by opium as it 
was heavily used as a recreational drug and a high proportion of the population were 
addicted.23 The Emperor asked Queen Victoria for assistance to stop the opium being 
brought in to China but this request was ignored and action was taken by the Emperor to 
ban the importation and use of opium. However opium was a very lucrative business for all 
and because imports of opium by British merchants (as well as other countries) to China 
were banned therefore losing money, the British decided to try to rectify the situation: they 
used the fact that the Chinese wished British merchants to comply with “barbaric Chinese 
law” as the reason for citing a war.43 Britain won the war resulting in the legalisation of 
opium in China but the situation also began changes to world politics and international 
trade.19 The second opium war was waged against China by France and Britain and resulted 
in the continued legalisation of opium and a large payment to both France and Britain. 
 
1.1.7. The discovery of diacetylmorphine 
Diacetylmorphine, the major pharmacological active compound of heroin, was synthesised 
from morphine in 1874 by Charles Romley Alder Wright, a British scientist who was 
investigating a non-addictive alternative to morphine.4,6 The general synthetic process for 
the synthesis of diacetylmorphine from opium is shown in Figure 1.2. 
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Figure 1.2 Basic synthetic route from opium to diacetylmorphine 
 
In 1898, the German chemical company of Bayer introduced diacetylmorphine to the 
market as Heroin (Figure 1.3a). This product was hailed as a wonder drug and one that did 
not have the same side effects as shown by morphine. It also appeared not to show the 
same addictive properties as morphine and was used in the treatment of morphine 
addiction (known as demorphinisation).4 It was later found that patients treated with 
heroin did not desist in their use of the preparation once their ‘treatment’ phase had 
concluded but continued to self-administer the drug.19 Bayer Company went on to use 
diacetylmorphine in other preparations alongside their other new drug aspirin (Figure 
1.3b). 
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a. b.  
Figure 1.3 (a) Antique bottle of Heroin from Bayer Pharmaceutical Company 44 and (b) Label from a product 
from Bayer Pharmaceutical Company containing aspirin and heroin 45 
 
It wasn’t until 1899 that physician Horatio C. Wood (1841-1921) found that in order to 
maintain the same level of effect on an individual over a lengthy time, the dose of heroin 
had to be increased. He also proposed that there was not enough experimental data to 
make an accurate conclusion that heroin was not an addictive compound.46 
It was proven over the years that heroin was far more addictive than morphine but that its 
properties were of far more use than morphine. It was proposed that to reduce the 
possibility of addiction that heroin should not be used in the treatment of minor ailments 
such as coughs, but to be prescribed only in severe acute pain (not in cases of chronic pain). 
However, heroin was found to be a most effective drug and physicians and pharmacists 
were at odds about using it since no other drug of the time equalled the pharmacological 
effects of heroin: they therefore continued to use it.47 Many other heroin preparations 
became commercially available, including mixtures with other drugs such as cocaine, 
cannabis and the less problematic ipecacuanha (an expectorant).48 
Over a number of years, physicians realised the devastating effect of heroin and its 
addictive properties. However, smugglers and other criminals of the time took very little 
time in comparison to realise just how much of a commodity heroin was.33 They recognised 
heroin’s pharmacological effectiveness, in comparison to morphine, but also the power of 
exploitation they had with heroin. Around 1924, the legitimate manufacture of heroin by 
the pharmaceutical companies ceased and most of the heroin was provided by smugglers.49 
Public perception of the drug changed from one extreme to the other and over time, 
heroin produced worldwide criminal organisations of such magnitude that modern day 
society is still dealing with it today.     
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1.1.8. Modern uses of the opium poppy 
In the 21st century, the two main legitimate uses of the opium poppy are as a source of 
alkaloid compounds for the pharmaceutical industry and as a source of poppy seeds for the 
food industry.50 In addition, this plant is used illicitly in the manufacture of 
diacetylmorphine.51  
 
 Papaver somniferum L. 1.2.
Of the plant family Papaveraceae (common name poppy) the genus Papaver has two 
species containing morphine, codeine, thebaine, noscapine (also called narcotine) and 
papaverine: Papaver somniferum L.  (Figure 1.4) and Papaver setigerum D.C. 52-54 Thebaine 
has been reported in Papaver orientale L. and Papaver bracteatum Lindl. but no 
biosynthetic interconversion to codeine and morphine has been found in these species.55  
 
 
Figure 1.4 A lanced poppy with a flower in Myanmar 56 
 
It is a continual debate as to whether Papaver setigerum D.C. is a subspecies of Papaver 
somniferum L. or whether Papaver setigerum D.C. is a separate species altogether as it is 
thought that Papaver somniferum L. is the product of many years of optimized breeding 
but for clarity, in this work it is assumed that they are separate species.52,53,55,57  
 
1.2.1. Opium, opiates and their uses 
Although it is known that alkaloid compounds can be found in both Papaver somniferum L. 
and Papaver setigerum D.C., Papaver somniferum L. has considerably higher levels of the 
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five major alkaloids by percent weight of opium than that present in setigerum, as can be 
seen in Table 1.1.  
Table 1.1 Alkaloid content by % weight of opium in Papaver setigerum  by electrophoresis 58 and Papaver 
somniferum  by HPLC 59 
 Papaver subspecies 
Alkaloid Setigerum  Somniferum 
Morphine 2.3 % 7.65 - 25.15 % 
Codeine 2.6 % 1.21 - 6.37 % 
Thebaine Detected but not quantified 0.97 - 6.38 % 
Papaverine 4.7 % 0.51 - 5.33 % 
Noscapine 10.2 % 4.03 - 15.22 % 
 
Papaver somniferum L., is an annual crop cultivated worldwide but is legitimately grown by 
the pharmaceutical and food industries in France, Spain, Turkey, Holland, Hungary, Poland, 
Romania, Czechoslavakia, Yugoslavia, India, Central and Southern America, Canada, 
Australia and Iran.2,60 The world’s illicit crop of opium originates predominantly in an area 
well known for the production of opium and heroin known as the “Golden Triangle” (see 
Figure 1.5) and Afghanistan. These areas are also well known for drug smuggling. 
 
 
Figure 1.5 Map showing the Golden Triangle: Myanmar, Lao People’s Democratic Republic (Laos) and 
Thailand 
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Papaver somniferum L. is an herbaceous plant that when grown in the southern 
hemisphere is generally sown in July, with the crop managed between August and 
December, and harvested between January and April.  This final phase includes harvesting, 
assessment of crop quality and payment. In the northern hemisphere the crop is generally 
sown in late autumn/early winter.11 The plants emerge in the spring when flowering occurs, 
subsequently forming ripe capsules in May/June. In this growth process, the capsules will 
change from blue/green to yellow. There is a limited window for harvesting of the latex: 
this is 5-10 days after the flowering petals fall from the plant. The dried latex product is 
called opium from which morphine and other alkaloid compounds can be extracted. If left 
to fully mature, the plant will form poppy seeds (Figure 1.6) within the capsule which can 
be mechanically harvested and collected by a sieving process.3,11  
 
 
Figure 1.6 Poppy seeds inside a mature poppy pod 61 
 
Harvesting methods have been shown to greatly affect the level of alkaloids in the final 
opium product. If the opium is harvested too early in the process the product is found to be 
watery and too late in harvesting produces opium with significantly lower levels of 
alkaloids.62 Poor practices in collection also reduce the size and quality of the crop: for 
example if the incision made in the pod is too deep, the pod is punctured and the latex lost, 
ultimately resulting in loss of opium. When carried out skilfully, most of the pods will be 
incised more than once during the harvesting of an opium field. The whole process will 
typically last several days to weeks, depending upon the size of the field.51 
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1.2.2. Pharmaceutical industry  
In modern day society, opium continues to have many uses; in particular it is used as a 
source of narcotic raw material (NRM) from which the pharmaceutical industry synthesises 
active pharmaceutical ingredients (API).  See Figure 1.7 for the general pharmaceutical 
process from field to API. 
 
Figure 1.7 General process from field to API used by the pharmaceutical industry 
 
Papaver somniferum L. with higher levels of morphine and codeine (but predominantly 
morphine) were historically grown by the pharmaceutical industries however, products 
from crop (opium and poppy straw) of this strain were open to exploitation by less than 
salubrious individuals/groups who could produce heroin (diacetylmorphine). Strains of 
Papaver somniferum L. were bred to contain higher levels of thebaine and also oripavine: 
these compounds are controlled by the International Narcotics Control Board (INCB) 
because of their convertibility to opioids subject to abuse (as are morphine and codeine 
due to their potential for abuse).60,63 The INCB is an independent body monitoring the 
implementation of The United Nations International Drug Control Conventions (Single 
Convention on Narcotic Drugs of 1961 as amended by 1972 Protocol, Convention on 
Psychotropic Substances 1971 and the United Nations Convention against Illicit Traffic in 
Narcotic Drugs and Psychotropic Substances 1988).64,65  
The main countries licitly producing Papaver somniferum L. crops for the pharmaceutical 
industry are shown in Table 1.2. Most countries will grow crops higher in either morphine 
or thebaine content but some countries produce both. The annual crop in tons is also 
provided in Table 1.2 showing the values for 2013 but also the values estimated for 2014.60 
Poppy field crop 
(opium, poppy straw, 
concentrate of poppy 
straw) 
Narcotic raw material 
Morphine 
Codeine 
Thebaine 
Oripavine 
Active pharmaceutical 
ingredient 
Morphine sulphate 
Codeine phosphate 
Oxycodone HCl 
Hydrocodone 
Buprenorphine 
Naloxone 
Naltrexone 
Buprenorphine HCl 
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Table 1.2 Countries (and amount in tons) producing opiate raw materials rich in morphine and thebaine.  
 Crop rich in morphine Crop rich in thebaine 
Country of 
origin 
2013 2014* 2013 2014* 
Australia 184 220 268 311 
France 131 145 15 29 
Hungary 27 20 3 10 
India 32 51 3 5 
Spain 116 143 58 61 
Turkey 65 108 n/a n/a 
Other 38 22 1 1 
*these values have been estimated by the INCB; n/a – not applicable 
 
Most of the morphine and codeine (83% and 91%, respectively) produced worldwide by the 
pharmaceutical industries is obtained from poppy straw with the remaining portions 
extracted from opium. Poppy straw comprises all parts of the Papaver somniferum L. crop 
after mowing but it does not include the seeds. Poppy straw can be obtained from all of the 
countries listed in Table 1.2 but India is the only country permitted to supply opium to the 
world’s pharmaceutical market.66 
 
1.2.3. Food industry  
It is not clear at what point poppy seeds were included in food preparation but 
archaeological artefacts found in an area of Lucerne, Switzerland dating from 
approximately 6000 years ago (the Neolithic period) identified evidence of poppy 
cultivation.19 The artefacts included poppy cake and poppy heads.67,68 Other archaeological 
artefacts have been identified from other sites that include items with poppy head symbols 
but the Swiss find is the first evidence of the use in food preparation.7,69 It is possible to 
surmise that if our ancestors were growing a crop that they would have used as much of 
the product of their labours as was possible and so the use of seeds in cooking would have 
been a natural evolution.       
Papaver somniferum L. is cultivated for the pharmaceutical industry but a by-product of the 
process of harvesting poppy straw is poppy seeds.60 This source of poppy seeds is used by 
the food industry and are included in cakes, on bread products and sold to supermarkets 
and specialist shops for use in cooking/baking recipes.  It was initially thought that the 
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seeds and any products derived from them would not contain any alkaloid compounds due 
to the fact that the seeds develop after the latex.10,11 In the late 1970’s, it was noted that 
poppy seeds contained alkaloids found in opium. However it was not until the 1980’s that 
research in this field escalated and in 1998 a paper was published by Meadway, et al.70 
which highlighted that it was possible to fail a urine drug test after the consumption of a 
bread product containing poppy seeds.52,70-77 
Over the last 10-15 years it has become increasingly apparent that the presence of 
alkaloids in the food chain is a problem and can potentially lead to serious repercussions. 
52,70-72,76-87 In Germany in particular, where poppy seeds are used and readily incorporated 
into food products, measures have been considered for some time to try to reduce the 
amount of morphine present in poppy seeds intended for the food chain. It has been 
reported that poppy seeds used for decorative purposes can contain up to 100 mg/kg of 
morphine however German authorities have recommended a limit of 20 mg/kg.75  
In 2011 the European Food Safety Authority (EFSA) published information relating to 
alkaloids in food products and provided a risk assessment with respect to public health.88  
The information was gathered from a call from EFSA regarding any data relating to levels of 
morphine, codeine, thebaine, noscapine and papaverine from poppy seeds destined for the 
food market.  From this research, it was noted that poppy seed use in food preparation 
varies considerably in European countries, and they are culturally and traditionally used in 
Central-Eastern Europe in many food products such as bread, desserts and fine bakery 
wares (bakery products containing sugar and fat at more than 5% by dry weight of fat). In 
comparison, poppy seeds are not used as extensively in other parts of Europe, such as in 
the United Kingdom. The panel assessing the data evaluated the potential dietary exposure 
to morphine as well as the morphine levels that were found in biological material post-
consumption of the poppy seed products: they considered morphine only due to the higher 
pharmacological activity of morphine in comparison to the other four opium alkaloids.  
A number of significant points were highlighted from this research; the first being that the 
estimated dietary morphine exposure. Based on information provided from three European 
countries where there is a higher consumption of poppy seed products and from data on 
the occurrence of morphine in poppy seeds, it was estimated that daily intake of morphine 
could be from 3 – 90 µg/kg body weight per day. It was also hypothesised, using the same 
data that portions of food items having high poppy seed content could provide morphine 
exposure from approximately 38 – 200 µg/kg body weight per portion for adults.  From 
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evaluation of extensive scientific literature sources, the EFSA panel concluded that it was 
possible for an individual to suffer effects from ingestion of poppy seed products but this 
was concluded from a number of cases reported from Germany only.88 
It has also been shown that washing and other pre-treatments of the seeds can reduce 
morphine levels by up to 90% as it is believed that the alkaloid content found when 
analysing poppy seeds is due to external contamination from the pod previously containing 
the latex and not from the inside of the seeds.76 
 
1.2.4. Opiates and abuse  
Currently, the control of opium falls under the responsibility of the United Nations under 
the Single Convention on Narcotic Drugs 196189 and is monitored by the International 
Narcotics Control Board (INCB). There are a number of pieces of legislation that have been 
written pertaining to the control of drugs which make reference to opium, or are specific to 
opium and are shown in Table 1.3.  
As previously mentioned  (section 1.3.1), there are a wide range of countries cultivating 
Papaver somniferum L. legitimately for the pharmaceutical and food industries with the 
illicit crops being grown in the Golden Triangle and Afghanistan. The crops destined for the 
pharmaceutical and food markets are tightly controlled since farmers cultivating, 
harvesting and selling the plant and its products must possess a licence.64 On the other 
hand, monitoring and controlling the illicit crops is a far more difficult task.51  
 
Table 1.3 Legislation/treaties relating to control of opium 
Act Year 
Pharmacy Act 90 1868 
Poisons & Pharmacy Act 91 1908 
International Opium Convention 92 1912 
Dangerous Drugs Act 93 1920 
Single Convention on Narcotic Drugs 89 1961 
(as amended in 1971) 
Misuse of Drugs Act 94 1971  
United Nations Convention against Illicit 
Traffic in Narcotic Drugs and Psychotropic 
Substances 95 
1988 
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The UNODC World Drug Report provides an annual review of international drug markets 
and in the latest report, opiates and opioids continue to be the principal drugs causing the 
most concern and drug-related deaths globally. It has been highlighted that Afghanistan is 
the major producer of illicit opium crops and this has continued to be the case for the last 
three years where the area under cultivation is estimated to have been 209,000 ha in 2013. 
In comparison, the global area under cultivation for the illicit market was estimated to be 
296,700 ha. From this area in Afghanistan, it is estimated in the report that the total 
amount of the opium product is 5,500 tons with the potential to produce 560 tons of 
heroin of unknown purity.51 
 
 Opium and opiates 1.3.
Opium is the raw material that is formed from a milky exudate obtained by incising the 
unripe capsules of Papaver Somniferum L. when it is air dried (Figure 1.8).11 
 
 
Figure 1.8 Latex being collected from incised pods and opium collected 56 
 
More than 100 alkaloids have been identified from opium, with five of them accounting for 
almost all of the quantitative alkaloid content.50,96 These alkaloid compounds can very 
broadly be classed as phenanthrene or isoquinoline alkaloids, with general structures 
shown in Figures 1.9 and 1.10, respectively. 
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 Figure 1.9 General phenanthrene structure 
 
 
Figure 1.10 General isoquinoline structure 
 
Of the five major alkaloids, morphine, codeine and thebaine are classed as phenanthrene 
alkaloids; the other two (papaverine and noscapine) fall into the benzoisoquinoline 
category.97 Structures of all of these alkaloids are shown in Figure 1.11. The other minor 
alkaloids exist in one of the two categories but have been reported in trace levels only.11 
         
 
Figure 1.11 Chemical structures of the major opium alkaloids 
 
N
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 Alkaloid biosynthesis in Papaver somniferum L. 1.4.
Of the many alkaloid compounds present in Papaver somniferum L. the five major alkaloids 
of interest in this work are morphine, codeine, thebaine, papaverine and noscapine. These 
compounds comprise the largest percent, by weight, of dried opium as shown in Table 
1.1.58,59 These compounds are the most pharmacologically active compounds, some more 
than others, and have throughout the years found uses in the pharmaceutical industry (see 
section 1.3.2). The biosynthesis of the morphine, codeine, thebaine, papaverine and 
noscapine are important in this context for this research and will be further discussed. 
 
1.4.1. Biosynthesis of major opium alkaloids 
Morphine, codeine, thebaine, papaverine and noscapine are derived from amino acids such 
as L-phenylalanine and L-tyrosine and share a heterocyclic ring with nitrogen. The 
biosynthesis of alkaloid compounds in general, begins from a number of biosynthetic 
pathways in plants which can start from photosynthesis which the alkaloid syntheses 
occurring via the acetate, mevalonate, deoxyxylulose or shikimate pathways. For the opium 
alkaloids of interest here, the shikimate pathway is the significant one. Shikimic, chorismic 
and prephenic acids (Figure 1.12) are the precursors to many natural products which 
contain an aromatic benzene ring. 98 
 
 
Figure 1.12 Chemical structures of shikimic, chorismic and prephenic acids 
 
The initial alkaloid synthesis within the Papaver somniferum L. starts from shikimic acid 
which is biosynthesised to produce chorismic acid then prephenic acid. From prephenic 
acid, the amino acid, phenylalanine is produced by the mechanisms shown in Figure 1.13.98 
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 Figure 1.13 Biosynthetic route from prephenic acid to phenylalanine  
 
Phenylalanine is the amino acid from which the opium alkaloids are further biosynthesised. 
From L-phenylalanine, L-tyrosine is formed via phenylalanine hydroxylase (PAH) which is 
further synthesised to L-dopa, also known as (R)-3,4-dihydroxyphenylalanine.99  L-Dopa is 
then further biosynthesised by enzymatic metabolism to produce papaverine with the 
biosynthetic pathway shown in Figure 1.14.   Figure 1.14 also shows the pathway from (S)-
coclaurine to (S)-reticuline, which is the central biosynthetic pathway intermediate through 
which thebaine, morphine and codeine, via (R)-reticuline is shown in Figure 1.15. The 
synthesis of noscapine, formed via (S)-scoularine is shown in Figure 1.16.
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 Figure 1.14 Biosynthesis from L-dopa to (S)-scoulerine and (R)-reticuline in alkaloid production in Papaver somniferum. Enzyme abbreviations are as follows, BBE: berberine bridge enzyme, 
CNMT: coclaurine N-methyltransferases, CYP80B3: N-methylcoclaurine 3’-hydroxylase, DRR: 1,2-dehydroreticuline reductase, DRS: 1,2-dehydroreticuline synthase, NCS: norcoclaurine 
synthase, 4’-OMT: 3’-hydroxy-N-methyltransferase 4’-O-methyltransferase, 6OMT: 6-O-methyltransferase, TYDC: tyrosine decarboxylase. Adapted from 99-101 
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 Figure 1.15 Biosynthetic interconversion from (R)-reticuline to form thebaine, codeine and morphine in Papaver somniferum. Enzyme abbreviations are as follows, COR: codeinone 
reductase, CYP719B1: salutaridine synthase, SaIAT: salutaridinol 7-O-acetyltransferase, SaIR: salutaridine:NADH 7-oxidoreductase.  Adapted from 99-101 
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 Figure 1.16 Biosynthetic interconversion from (S)-scoularine to form noscapine in Papaver somniferum. Adapted from 99-101 Enzyme abbreviations are as follows: CYP719A21: (S)-canadine 
synthase, CYP82X2: secoberbine intermediates 3-hydroxylase, PSCXE1: papaveroxine carboxylestaerase, PSMT1: (S)-scoulerine-9-O-methyltransferase, PSMT2: papaveroxine intermediate 4'-
O-methyltransferase, PSSDR1: noscapine synthase, TNMT: tetrahydroprotoberbine cis-N-methyltransferase.
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 Toxicology  1.5.
Within the field of toxicology, the processes of absorption, distribution, metabolism and 
elimination (ADME) of substances are studied. The route of administration, or the way in 
which a substance enters the body will greatly affect the bioavailability of the compounds 
present. In order for a compound to have an effect on an individual the compound and/or 
its metabolites must enter the flow of blood around the body. The blood then carries the 
compound(s) to sites of action where the resultant effect is produced.102,103 
The main routes of administration are intravenously (I.V.), inhalation, orally, 
subcutaneously, intramuscularly and dermal sorption although other routes of 
administration are possible. A process known as first-pass metabolism can be seen for 
some compounds when administered orally. This process is one where a portion, 
sometimes large, of the original dose of the compound will be lost before it reaches the 
stomach and is seen in the oral administration of some opiate drugs. This loss occurs where 
the drug compound is transported from the gastrointestinal tract via the hepatic portal 
vein to the liver where it is metabolised.104   
 
1.5.1. Toxicology of the opium alkaloids 
Morphine, codeine, thebaine, papaverine and noscapine are the five major opium alkaloids 
of interest in this work and their physical and structural properties as well as their 
associated toxicology, where appropriate, are discussed below. As a group of drugs having 
originated from opium, they are classed as opiates; drugs synthetically derived from these 
opiate compounds, for example diacetylmorphine, are called opioids. The term opioid is 
used generally to include all drug compounds that work to relieve pain at the opioid 
receptors in the body.105 
 
1.5.1.1. Pain and analgesia 
Pain can be the response to external stimuli, such as, from an injury, from a fall or a burn 
and is typically associated with the peripheral nervous system (see Figure 1.17). This type 
of pain is generally termed nociceptive pain and the pain is generally associated with tissue 
damage. Nociceptive pain can be managed or treated with paracetamol, non-steroidal anti-
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inflammatory drugs (NSAIDS) such as ibuprofen and aspirin or codeine or morphine (or 
other opioid analgesics), depending upon the severity of the pain.104,106 
 
 
Figure 1.17 Central and peripheral nervous systems107  
 
On the other hand, severe chronic pain can occur as a result of damage to the brain or 
nervous system, such as is found in cases of patients suffering a stroke. This type of pain is 
generally termed neuropathic pain and is typically managed with tricyclic antidepressants 
or a combination of other drugs since conventional analgesics have not proved useful in 
treating this type of pain.106  
The effects that opioid analgesics have on the body have been identified as being due to 
the interactions of these compounds with the endogenous opioid system. There are three 
classical opioid receptors within the central nervous system (CNS) as well as in the 
peripheral tissues however most of the analgesia produced occurs by inhibiting the 
nociceptive transmission in the CNS. The opioid receptors in the CNS are classified as delta 
(δ), kappa (κ) and mu (μ) with the μ-receptors thought to provide most of the analgesic 
effects.105 All of the receptors are responsible for different aspects of analgesia and 
sedation, although the effects of the δ-receptors are not fully understood.108 
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 Opioids can be categorised with respect to their effect at the opiate receptors: they are 
classified as an agonist, a partial agonist or an antagonist. Agonists interact with a receptor 
to produce an optimum response from that specific receptor, partial agonists bind to the 
specific receptors but cause only a partial functional response, irrespective of the amount 
of drug administered and, antagonists bind to specific receptors but produce no functional 
response. At the same time, antagonists prevent an agonist from binding to that specific 
receptor.105,108 
All opioids are metabolised predominantly by the cytochrome P450 (CYP450) enzyme 
system but the UDP-glucuronosyltransferases (UGTs) also play a minor role, in particular 
the formation of glucuronides by UGT2B7.109 
 
1.5.1.2. Morphine 
Morphine is the classic opioid analgesic and the one to which all other painkillers are 
compared.105  It is a μ-opioid agonist and is well known that of the phenanthrene opium 
derived alkaloids, morphine is the most potent in activity.104,110,111 Morphine is used in the 
treatment of moderate to severe pain and is used in palliative care of cancer patients, for 
pain management.  It is well known that repeated morphine administration may cause 
tolerance and dependence in individuals therefore tends not to be prescribed for long 
periods of time; however this is not considered such a problem when used in palliative 
care. 108,112,113   The chemical structure of morphine is shown in Figure 1.18 and it can be 
seen that morphine has two planar and two aliphatic ring structures that are approximately 
perpendicular to the rest of the molecule. It has a phenolic hydroxyl group and an alcohol 
group in position 6, with the phenolic functional group contributing to the analgesic 
properties of morphine.11   
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 Figure 1.18 Structural differences between morphine, codeine and thebaine 
 
Routes of administration for morphine can vary and can include oral, transdermal and 
parenterally although with all drugs, route of administration can greatly affect the 
bioavailability. When administered parenterally, morphine is rapidly absorbed but orally 
administered morphine is prone to first-pass metabolism103,104 with approximately 40-50% 
of the original dose reaching the CNS within 30 minutes for immediate release and within 
90 minutes for extended release forms.108 Morphine is distributed around the body into the 
kidneys, liver, lungs and because morphine crosses the blood-brain barrier, it is also found 
in the brain.103 
90% of the morphine dose is metabolised by phase II conjugation to form morphine-3-
glucuronide (M3G) and morphine-6-glucuronide (M6G). M6G has been shown to have 
potent analgesic properties and is itself a μ-opioid agonist but the same is not true for 
M3G.104,112,114 Other minor metabolites of morphine are formed and are shown in Figure 
1.20.   
After parenteral administration, up to 90% of the dose of morphine is eliminated in the 
urine in 24 hours with approximately 10% as free morphine and 65-70% as conjugated 
morphine. The rest is composed of other minor metabolites.103 
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1.5.1.3. Codeine 
Codeine is used in the treatment of mild to moderate pain but the side effects caused by 
long-term use of the drug, as well as dependency and tolerance, means that codeine is not 
prescribed for long periods of time.  
Like morphine, codeine is a μ-opioid agonist but to a lesser extent.111  The main difference 
in chemical structure between the two is that codeine is the methyl ether form of 
morphine and is structurally a modification of an hydroxyl (-OH) group on the C3 of the 
phenanthrene to a methoxy (-OCH3) group. This methoxy group reduces the overall 
pharmacological activity of codeine (in comparison to morphine) but because 10% of the 
dose of codeine administered is metabolised to morphine, it is an effective analgesic.115 
Codeine has been shown to have approximately half of the pharmacological potency of 
morphine.108 
The main route for administration for codeine is orally and via this route it is well 
absorbed.103 Approximately 5% of the codeine dose is metabolised to the active metabolite 
morphine by CYP2D6 by O-demethylation104,111 with approximately 80% of the codeine 
dose being metabolised to form codeine-6-glucuronide (C6G) by UGT2B7.115 Due to the 
similarities in chemical structure to M6G, C6G also has pharmacological properties, 
although again to a lesser extent. 116 Between 10-15% of the codeine administered is 
converted to normorphine via CYP3A4 which is in turn glucuronidated to form 
normorphine-6-glucuronide (N6G). The main metabolic pathways for codeine are shown in 
Figure 1.20. 
Around 86% of the orally administered dose of codeine is eliminated in the urine in 24 
hours with 40-70% of this as free or conjugated codeine; 5-15% as free or conjugated 
morphine and 10-20% as free or conjugated normorphine.103 
 
1.5.1.4. Thebaine 
Thebaine has no therapeutic uses but is used by the pharmaceutical industry as a starting 
material from which other opioid drugs are synthesised.63 The main compounds 
synthesised from thebaine are morphine, codeine, oxycodone, hydrocodone and 
buprenorphine.117 
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From codeine to thebaine, the difference in chemical structure is the modification from an 
hydroxyl group on the C3 position of the phenanthrene to a methoxy group. There is also a 
change of position of double bond from the C7-C8 position to the C8-C14 position, shown 
in Figure 1.18.  The structural differences at the phenolic hydroxyl group and the C3 
position are known to greatly to affect the biological activity and subsequent metabolism of 
the opioids and in the case of thebaine, the changes produce a compound with no 
therapeutic properties.63 
 
1.5.1.5. Papaverine 
Papaverine is an antispasmodic which induces smooth muscle relaxation and vasodilation 
and has been used in the past in the treatment of erectile dysfunction118 and treating heart 
arrhythmias.119 It has few uses nowadays although there have been a few publications 
highlighting the use of papaverine in some medical cases particularly in cases of stroke and 
as an antispasmodic.120-124 
Papaverine is structurally different to the phenanthrene alkaloids such as morphine. It falls 
into the benzylisoquinoline group of alkaloids and has methoxy groups in the C6, C7, C3’ 
and C4’ positions. The chemical structure of papaverine is shown in Figure 1.19.  
 
 
Figure 1.19 Chemical structure of papaverine 
 
There is little information with respect to the structure activity relationship (SAR) of 
papaverine although it is known that papaverine works by inhibiting cyclic adenosine 
monophosphate (cAMP) and cyclic guanosine monophosphate (cGMP) phosphodiasterases 
present in smooth muscle. It has also been identified that papaverine blocks calcium ion 
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channels, inhibiting the release of calcium; this along with the inhibition of  cAMP and 
cGMP induces vasodilation and relaxation in the smooth muscle.120  
Papaverine can be administered orally but also by intracavernosal injection for treating 
erectile dysfunction.125 It is well absorbed after oral administration but undergoes 
extensive first-pass metabolism. The main metabolites produced are 4’-hydroxypapaverine 
and 6-hydroxypapaverine with 50-80% of the original dose eliminated in the urine within 
48 hours and the 6-hydroxy form accounting for more than 30%.103,126 
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 Figure 1.20 Main metabolic pathways for morphine and codeine. “Glu” denotes a glucuronide group
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1.5.1.6. Noscapine   
Noscapine (Figure 1.21) has been used as an antitussive and recently has been studied as a 
treatment for some cancers.127,128  Noscapine can be orally administered although the 
mechanism of action is not fully understood.129 The main metabolites of noscapine have 
been identified as cotarnine, meconine, narcotoline and nornoscapine130,131, also shown in 
Figure 1.21.  
 
 
Figure 1.21 Chemical structure of noscapine and its metabolites 
 
The main routes of elimination for noscapine and its metabolites are not well understood 
and little is available in the literature, possibly due to the limited applications, at the 
current time. However it has been highlighted recently that in in vitro tests and when 
applied to mice, the main enzymes involved in the metabolism of noscapine were found to 
be CYP3A4/5 for the formation of narcotoline but many phase I isoenzymes were involved 
in the production of cotarnine and meconine.128  
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1.5.1.7. Diacetylmorphine 
Diacetylmorphine is a powerful opioid agonist that is used legitimately to aid in pain 
management in palliative care but due to the severe tolerance and dependency properties, 
has few other uses medically.132 It is considered a pro-drug as it has a short half-life and is 
quickly metabolised to 6-monoacetylmorphine and then onto morphine: it is rarely found 
in biological matrices.133   Diacetylmorphine is the active compound present in street heroin 
samples however these “street” samples of heroin more often than not contain other 
analgesics, other alkaloids extracted from opium, caffeine, sugars and other non-active 
compounds to dilute the heroin and make it go further.134   
The chemical structure of diacetylmorphine, shown in Figure 1.22,  differs from the 
morphine structure (see Figure 1.18) in that the phenolic hydroxyl group of morphine in the 
C3 position and the hydroxyl group in the C6 position are replaced by acetyl functional 
groups.  
 
 
Figure 1.22 Chemical structure of diacetylmorphine 
 
The main metabolic pathways for diacetylmorphine are shown in Figure 1.20. The main 
metabolite used to confirm the ingestion of diacetylmorphine is 6-monoacetylmorphine (6-
MAM).135,136 6-MAM has a relatively short half-life of 6-25 minutes103 and is generally found 
in blood for between 30 minutes to 1 hour after administration which means that there is a 
short window of detection for positively identifying heroin administration.137,138  
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1.5.2. Poppy seed ingestion versus heroin use 
Poppy seeds are used in many foodstuffs, predominantly bread products but are also 
incorporated into desserts and other cake recipes, worldwide.139 In parts of Eastern Europe, 
poppy seeds are also used in pasta and noodle dishes and are incorporated to add a nutty 
flavour to a dish. 
It is known that the ingestion of poppy seeds has caused positive opiate drug test results 
and much work has been reported in the scientific literature in the last 20 years.70-
72,74,77,78,80,85-87,140-142 The positive opiate results have been found in urine, blood and oral 
fluid but when confirming opiate drugs in biological matrices, codeine and morphine 
presence are identified and quantified. When it is necessary to confirm administration of 
heroin (diacetylmorphine as the pharmacological active), 6-monoacetylmorphine presence 
will be investigated in the biological matrix but it is not always possible to detect this 
compound. Researchers in the field have investigated alternatives to differentiate between 
heroin administration and that of other opiate drugs versus poppy seed ingestion. Most of 
the work which has been carried out relates to establishing illicit heroin use by examining 
biological matrices for the presence of acetylcodeine (an impurity of illicit heroin), thebaine, 
papaverine, noscapine and their associated metabolites.143 A study published by Hill, et 
al.141 in 2005 highlighted the possibility of differentiation of heroin use and poppy seed 
ingestion using hair and urine as the matrices. It was suggested that 6-MAM could be used 
as the marker for heroin administration since it was detected in hair of heroin users versus 
not in the urine of individuals ingesting poppy seeds. However, the comparison of data in 
two different matrices is unusual and it is not really possible to draw any meaningful 
interpretation from these findings: it would have been better if a direct comparison of the 
results between heroin users and individuals ingesting poppy seeds in the same matrix was 
carried out.  
Thebaine has also been investigated as a potential marker for poppy seed ingestion due to 
the fact that it has been found in many poppy seeds analysed but not in street heroin 
samples.140 To complicate the matter, ElSohly et al.140 published a paper in 1988 
highlighting that it was not possible to detect thebaine in urine of individuals ingesting 
poppy seeds however Cassella et al.78 subsequently published a paper in 1997 reporting 
that it was possible. This discrepancy could be due to an increased sensitivity of the gas 
chromatograph – mass spectrometer (GC-MS) used in the more recent of the papers.  
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It has been suggested that the use of morphine and codeine concentration ratios in 
biological matrices may also be used to indicate the difference between heroin and poppy 
seeds: it was noted in a short communication published in Forensic Toxicology in 2011139 
that much lower concentrations of morphine and codeine were found in urine in 
comparison to those of heroin users. It was noted in this communication that further 
investigation was required before any meaningful interpretation could be deduced from 
these findings. However, many parameters could have affected the findings that were not 
discussed. It is neither possible to establish a “standard” dose of diacetylmorphine present 
in street heroin nor is it possible to ascertain an exact dose of morphine and codeine 
provided from poppy seeds therefore the findings reported cannot be considered 
completely reliable. No further publication reporting any advancement in the study has 
been published, to date.  
At this current time, it is not possible to differentiate between heroin administration and 
poppy seed ingestion other than by the detection of 6-MAM. Although other biological 
markers have been investigated, no other compound is a serious candidate when 6-MAM is 
no longer detectable. 
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2. OPIATES IN ORAL FLUID 
 Biological matrices and drug testing 2.1.
For toxicology testing, blood is by far the best matrix as it can provide information on what 
compounds are present in the body at a given time: this makes it easier to interpret 
symptoms or effects that may be experienced by the individual.144 However, blood is not an 
easy matrix to collect either at the roadside (e.g. for the assessment of driving under the 
influence of drink or drugs) or in workplaces where random or organised drug screening 
takes place. Blood collection requires the services of a trained individual, such as a 
phlebotomist who can take the blood samples which is something that is not very practical 
at the roadside. The use of blood as a biological matrix also brings with it many potential 
health and safety issues particularly relating to pathogens that may be present in blood and 
the subsequent endangering of the collector. As a result, alternative matrices have been 
considered for both roadside and workplace testing.82 
For workplace drug testing, urine was always the preferred specimen collected; however 
this matrix has a number of negative factors associated with interpretation: urine is a 
predominantly water based product eliminated from the body over a period of time and 
can therefore only provide information within the last 24 hours.145 Urine was the matrix of 
choice for roadside drug testing in some countries (e.g. Belgium and France)146 but an 
alternative non-invasive, easy to collect specimen and sampling method with little or no 
embarrassment on the part of the collector or individual providing the specimen is 
preferred.  For these and many other reasons, alternative matrices have been sought for 
both workplace and roadside drug testing.  
When considering alternative matrices, urine can be eliminated as a potential matrix of 
choice as it poses problems with collection, particularly at the roadside. It is also difficult to 
control collection to reduce adulteration without severe embarrassment for both collector 
and individual providing the specimen.147 Hair has been shown to be useful in providing 
information on drug use in a window of between a few weeks and a few months, 
depending upon the length of hair of the individual. However, since for both workplace and 
roadside drug testing it is necessary to establish if an individual has recently taken drugs or 
has drugs in their system at the time of testing, hair is also not an appropriate matrix of 
choice.82,145 Sweat has been investigated by a number of researchers145,148-151 as an 
alternative matrix for current drug use. PharmChek® drugs of abuse sweat patch and 
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AlcoPro sweat patch drug test are two commercially available patches which can be 
returned to the company for analysis by GC-MS however, like hair, sweat patches tend to 
be used to provide drug information over a longer window of detection than is required for 
roadside and workplace drug testing.152 
Oral fluid, as an alternative matrix for drug testing has been investigated over a number of 
years by many researchers and is proving to be an excellent choice with respect to being 
able to provide information about current drug use.74,79,83,84,86,153-157 Oral fluid is also easier 
to collect than blood and does not require a trained practitioner as is required for blood 
collection.158 
 
2.1.1. Saliva vs oral fluid 
Saliva contains 99% water with the rest comprising proteins (largely α-amylase which aids 
in the preliminary digestion of food in the oral cavity), mucins and electrolytes dissolved in 
the aqueous phase (most importantly Ca2+, Cl-, HCO3-, K+, Mg2+, Na+ and NH3/NH4+).159,160  
Saliva originates from three major salivary glands called the parotid, submandibular and 
sublingual glands (see Figure 2.1) and a number of minor glands collectively called the Von 
Ebner glands which are found in the connective tissue below the circumvallate papillae (the 
small raised bumps on the tongue towards the back of the mouth).161 The submandibular 
and sublingual glands are seromucous glands whereas the parotid and Von Ebner glands 
are completely serous glands.162 In unstimulated saliva, 65% of the secretions originates 
from the submandibular glands, 23% from the parotid glands, 8% from the Von Ebner 
glands and 4% from the sublingual glands.161 
 
Figure 2.1 Major saliva producing glands where (1) represents the parotid glands, (2) represents the 
submandibular glands and (3) represents the sublingual glands (Figure from Aps, 2005163) 
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The combination of salivary glands will produce between 0.5 and 1.5 L of saliva in a day; 
however, the production of saliva is affected by the circadian rhythm of salivation and can 
also be affected by disease and administration of prescription and illicit drugs.158,163,164 
For clarification, the term “oral fluid” will be used referring to the fluid that is collected 
from the mouth. This is because “saliva” refers only to the liquid that is secreted from the 
salivary glands in the mucous membranes of the mouth. Oral fluid (OF) refers to the liquid 
collected from the oral cavity that will contain the secretions from the salivary glands 
(saliva) but also other components such as cellular material, gingival crevicular fluid and 
blood. It was decided at the 1993 New York Academy of Sciences meeting on saliva testing 
that the term “saliva” referred to the fluid specifically collected from the salivary glands 
and that “oral fluid” referred to the whole sample collected from the mouth when 
adsorbents are placed into the oral cavity or when the sample is collected by expectoration 
(the process of allowing the saliva to collect in the oral cavity and allowing the fluid to drain 
from the mouth into a container).165 
 
2.1.2. Pharmacokinetics of drugs in oral fluid 
Over the years, a number of researchers have investigated the mechanism of transfer of 
drugs (and their metabolites, where appropriate) into oral fluid.86,153,155,156,158,164,166,167 From 
the majority of these studies, it has been shown that for the most part, oral fluid contains 
the parent drug as opposed to metabolite(s).164 It has also been highlighted that drugs can 
transfer from the blood plasma to the saliva as salivary glands are supplied by arterial 
blood permitting a relatively rapid transfer.83 
There are however, a number of factors which should be taken into account when 
considering the transfer of drugs from plasma to oral fluid: these include the level of health 
of the individual, other drugs being administered and also the chemistry of the drug being 
transferred. It was reported by Aps in 2005163 that disease such as multiple sclerosis, cystic 
fibrosis, diabetes mellitus, HIV, individuals with kidney dysfunction and alcoholic liver 
cirrhosis would have a difference in composition of saliva in comparison to a non-affected 
individual. For example, for individuals who have diabetes mellitus, a reduction in the flow 
of saliva is noted whereas individuals with a kidney dysfunction, an increase in salivary urea 
levels results in saliva with a higher pH than is normally expected.163 Unstimulated saliva 
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has a pH range of 6.0 - 7.2 but a salivary pH of 8.0 has been found in saliva which has been 
collected via stimulation.102 
There are a number of methods by which the transfer of drugs from plasma to saliva is 
facilitated: passive transcellular diffusion, ultra-filtration and active transport.168 Passive 
transcellular diffusion is the primary method of transfer of drugs from blood to saliva and  
depends upon factors such as the chemical properties of the drug, the pH of the saliva , 
concentration of un-ionized drug (since the ionized form of the drug will not passively 
diffuse across cellular membranes), drug-protein binding (only free-fraction can diffuse), 
and characteristics of the membrane.169 Most drugs are transferred by this mechanism, 
which transports the drug across cellular membranes down a concentration gradient 
without utilising energy.169  The mechanism of ultra-filtration allows small molecules of 
typically less than 300 Da to pass into the saliva, however molecules of up to 150 Da have 
been found to transfer minimally. Active transport is the main transport mechanism for 
many electrolytes and some proteins, but not drugs.83,169,170 
It is important to establish if drug compounds will cross the cell membranes from the 
plasma to the oral fluid. The pKa of a drug is the acid-base dissociation constant and is used 
to establish whether a drug molecule will be found in the ionised or unionised form at a 
particular pH. Unionised drugs cross cell membranes and the Henderson-Hasselbalch 
equation is used to determine the ionisation of a drug with a particular pKa value, at 
particular saliva pH values.171 
The equation for the ionisation, or dissociation, of an acid at equilibrium in aqueous 
solution is provided below (equation 2.1), where HA is the conjugate base, H+ represents 
the hydroxonium ions (H3O+) in aqueous solution and A- represents the weak acid in 
aqueous solution172: HA(aq)  ⇌  H+(aq) + A−(aq)   (2.1) 
 
From this the general Henderson-Hasselbalch173 equation can be derived (equation 2.2) 
pH = pKa +  log [A−][HA]   (2.2) 
 
Where Ka = dissociation constant of the weak acid 
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 pKa = -log Ka 
 pH = -log[H+] 
 [A-] = molarity of the weak acid 
 [HA] = molarity of the conjugate base 
 
It is possible to apply this acid-base theory to acidic and basic drugs which can transfer 
from the plasma to saliva and a value known as the saliva:plasma ratio (S/P) can be 
determined using the following equations. 
For basic drug compounds the following equation can be used: 
 
S/P =  1+10(pKd−pHs)x fp
1+ 10(pKd−pHp) x fs   (2.3) 
 
For acidic drug compounds the following equation can be used: 
 
S/P =  1+10(pHs−pKd)x fp
1+ 10(pHp−pKd) x fs    (2.4) 
 
Where S/P = concentration of drug in saliva to the concentration of drug in plasma 
pHs = pH of saliva 
 pHp = pH of plasma 
pKd = pKa value of the drug  
fp = fraction of drug unbound in plasma  
fs = fraction of drug unbound in saliva 
 
Morphine is an amphoteric basic molecule that possesses both an amine and a phenol 
group which are ionisable.174 In relation to the amine group, morphine has a pKa constant 
of 8.0 but with respect to the phenol group, morphine has a pKa constant of 9.9.103 The 
saliva:plasma (S/P) ratio for morphine is approximately 1.2, although this is an average 
value reported (range 0.3 – 34.3).175-177  
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Codeine has the presence of the amine group, as is the case with morphine, however 
codeine does not include an ionisable phenol group. Codeine has a methoxy (-OCH3) group 
in position 3 in place of the hydroxyl group present in morphine. The absence of phenolic 
group, or any other readily ionisable group, on codeine means that it is not amphoteric and 
has only one pKa constant of 8.2.173  For codeine, the S/P is approximately 3.3170 however a 
value of 3.7178 has also been reported.   
Thebaine, like both morphine and codeine has an amine group but has two methoxy 
groups in position 3 and 6 and has a pKa constant of 8.2.103  In comparison, 
diacetylmorphine has a pKa constant of 7.6103 and papaverine and noscapine have pKa 
constants of 6.4 and 6.2, respectively.103  The S/P ratios of thebaine, noscapine or 
papaverine have not been reported in the scientific literature, however the S/P ratio for 
diacetylmorphine has been reported as 2.13176 and a value of 6 for 6-MAM.170,176,179   
The physiological pH of saliva is typically pH 6.0 – 7.2102,167 and pH 7.4180 for plasma: when 
the pH value is lower than the pKa constant of a basic drug, the compound will become 
positively charged and therefore will be in an ionised state (Figure 2.2).172 
 
 
Figure 2.2 Ionisation of a weak base of pKa 8.5 with varying pH 
 
For morphine, codeine and thebaine where pKa constants are close to the physiological pH 
of saliva and plasma, they will exist in both the ionised and unionised form. Only the 
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unionised portion of these three compounds will readily transfer by passive diffusion from 
the plasma to the saliva.   
In the case of papaverine and noscapine where the pKa constants are 6.4 and 6.2, 
respectively, the pKa constants are below the pH values of saliva and plasma. This should 
mean that both of these compounds will be predominantly found in the unionised form 
and will, therefore more readily transfer from plasma to saliva by passive diffusion. 
 
 
2.1.2.1. Pharmacokinetics of opiates in oral fluid   
The fate of the major opium alkaloids found on entering the human body has been 
explained in section 1.6.1, however the explanation predominantly relates to the legitimate 
administration of the opiates from the perspective of pain management. The main route of 
administration of poppy seeds, and poppy seed containing food products, is oral and this 
method of administration brings with it some considerations when interpreting the results 
of the analyses of oral fluid samples. It is well established that when drugs are administered 
orally, they contaminate the oral cavity and lead to elevated S/P ratios immediately post 
consumption. 83,158,166  
More specifically, in relation to detecting opiates in oral fluid, the current scientific 
literature relates only to the presence of morphine and codeine and no, or very limited, 
data exist in relation to levels of thebaine, papaverine or noscapine in this biological matrix. 
Some publications have reported the findings in relation to the intra-venous administration 
and smoking of heroin but again, only morphine, codeine and associated metabolite 
presence have been reported.164,166,179  
With respect to the compounds observed in oral fluid, the parent compound is most often 
reported.164 In 1990, Cone published a study, where 20 mg and 10 mg of morphine 
sulphate were administered intra-muscularly to a participant and oral fluid was stimulated 
by sour candy, and found that morphine levels were at a peak in oral fluid 30 minutes post 
administration of the dose. Using GC-MS, it was established that after a 20 mg dose, peak 
oral fluid morphine level was 37.8 ng mL-1, 10.8 ng mL-1 after a 10 mg dose and thereafter 
declined in both cases. As part of the same study, a 120 mg and a 60 mg of an 
intramuscular dose of codeine phosphate was administered to an individual and peak oral 
fluid levels were obtained between 30 – 45 minutes post administration. The peak levels 
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for codeine were found to be 307.6 ng mL-1 and 183.9 ng mL-1, respectively: as was the case 
with morphine, the codeine levels rapidly declined.175 This study was fairly limited as it only 
included two participants with a known history of heroin abuse and was not repeated but, 
levels of morphine, codeine and their associated metabolites present in other biological 
matrices were included for comparison. 
Other more recent studies, involving the oral administration of codeine sulphate (120 
mg/70 kg and 60 mg/70 kg doses) with a larger number of participants did not find 
morphine in any of the oral fluid samples but found codeine in approximately 26% of the 
samples analysed: the codeine was found in a concentration range of 2.5 – 3961 ng mL-1 
using GC-MS.178,181  
In 2003, a study carried out by Rohrig and Moore74 investigated the implications of 
ingestion of both bakery products containing poppy seeds and raw poppy seeds.  Two sites 
were involved in the study: at site 1, 4 participants consumed 3 commercially available 
poppy seed bagels within 1 hour. At site 2, 3 participants consumed 1 poppy seed bagel 
plus as many raw poppy seeds as was possible (14.82 g, 9.82 g and 20.82 g were consumed 
by the participants). The study revealed that at site 1, morphine and codeine were not 
found in any of the oral fluid samples analysed; it should however be noted that the first 
specimen was collected 1 hour post ingestion of the poppy seed bagel. At site 2, codeine 
was not found in the oral fluid samples but morphine was found at a peak level 15 minutes 
post consumption for all 3 participants. The highest concentration obtained for one of the 
participants at this site was 205 ng mL-1.  
In a more recent publication by Newmeyer, et al. 177 in 2015 a controlled administration of 
two quantities of 45 g of raw poppy seeds was carried out and the levels of morphine and 
codeine in oral fluid were monitored with an immunoassay Dräger Drug Test® 5000 and LC-
MS. The authors reported that each of the 45 g quantities of poppy seeds contained 15.7 
mg of morphine and 3.1 mg of codeine and were administered 8 hours apart to 17 
participants. The findings of this study were that all oral fluid samples were deemed 
positive by falling above the 20 ng mL-1 analytical cut-off of the Dräger Drug Test 5000 for 
opiates. The peak oral fluid levels for morphine was obtained between 30 minutes and 1 
hour post administration and found to be 177 ng mL-1; for codeine the peak oral fluid level 
was obtained between 30 minutes and 2.5 hours post administration and was found to be 
32.6 ng mL-1. 
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 For comparison, diacetylmorphine and 6-monoacetylmorphine (6-MAM) have been 
detected in oral fluid after 2 minutes by GC-MS following administration by intra-venous 
injection or smoking of heroin.176  Higher levels of diacetylmorphine were observed where 
the heroin was smoked (3534 – 20,580 ng mL-1 at peak level), in comparison to intravenous 
injection (6-30 ng mL-1 at peak level). The authors of this study suggest the reason for this 
observation being that the oral cavity was contaminated in the smoking process.  6-MAM 
(640 – 3577 ng mL-1  at peak levels) and morphine (6 – 142 ng mL-1  at peak levels) were 
also observed in the oral fluid samples by both routes of administration however it was 
reported that the levels of each of the compounds decreased very quickly after the peak 
levels were obtained.  
 
2.1.3. Challenges of using oral fluid in drug testing 
Although more practical than urine for workplace and roadside testing, oral fluid has its 
disadvantages: as with many biological materials, this matrix poses some pathological 
problems with the risk of infection if not handled appropriately. Oral fluid contains mucins 
which make the matrix more viscous to handle in comparison to urine and for some 
individuals, the production of saliva is a problem (Section 2.1.2).  
The process of collecting the oral fluid sample has also been shown to greatly affect the 
drugs detected. In a review carried out by Crouch158 in 2005, it was highlighted, for 
example, that codeine concentrations detected in non-stimulated versus stimulated oral 
fluid, were 3.6 times higher in non-stimulated oral fluid. The main methods of collection of 
oral fluid are expectoration, stimulated expectoration (usually using citric acid), mechanical 
stimulation (involving the chewing of gum or other inert material), and using commercially 
available adsorbent collection pads.182 Over the last few years, commercially available 
collection kits have overtaken the other methods of collection; some of the gums used in 
mechanical stimulation were shown to adsorb some of the drug compounds, citric acid was 
shown to increase the rate of production of saliva therefore reducing the overall 
concentration of drug in oral fluid (impacting on interpretation of the S/P ratios of the 
drugs) and expectoration (which would involve allowing oral fluid to collect in the oral 
cavity and allowing the fluid to drain unaided into a collection pot) was found to be an 
unpopular method of collection.183,184 
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There are a number of commercially available oral fluid collection devices currently offered 
on the market. These kits tend to include an adsorbent pad which is used to collect the oral 
fluid and a buffer or preservative solution within a container for ease of transportation to 
the laboratory. 185 Three of these kits are shown in Figure 2.4 and include the Quantisal™, 
OraSure® and Intercept® collection kits. 
a.  b.  c.  
Figure 2.3 (a) Quantisal™, (b) OraSure® and (c) Intercept® oral fluid collection kits 
 
2.1.4. Extraction of drugs  
Extraction is a technique used to remove potentially interfering compounds from a matrix 
and to allow the concentration of target drug analytes.186,187 The two main methods of 
extraction of drugs from oral fluid, as with other biological matrices, are liquid-liquid 
extraction (LLE) and solid phase extraction (SPE).188 LLE is a technique employing an 
immiscible organic solvent of known polarity and typically involves altering the pH of the 
biological matrix such that either acidic/neutral analytes or basic analytes will be extracted 
into an appropriate organic solvent.102,189  LLE was traditionally employed in toxicology 
laboratories but due to the improvement of adsorbent bed chemistries, increased 
understanding of adsorption mechanisms, commercial availability and ease of use, SPE has 
become very popular.186,188,190-192 
Commonly employed chemistries involved in solid phase extractions are normal phase 
(NP), reversed  phase (RP), ion exchange and mixed mode.188 Normal phase SPE employs a 
polar packing material, typically modified silica (for example with aminopropyl or 
cyanopropyl functionalization) in the extraction of polar analytes. The matrix should be less 
polar than the analytes of interest in order to effect the separation and a solvent, of an 
44 
 
 
appropriate polarity to disrupt the binding mechanism of the analytes from the sorbent 
bed.189 
Reversed phase SPE uses the opposite mechanism to that employed in normal phase SPE: a 
non-polar packing material (for example, silica modified with alkyl or aryl functional groups) 
is used to extract non-polar analytes. Again, a solvent of appropriate polarity will be used 
to desorb the analytes from the sorbent bed.172 
Electrostatic interactions between charged groups of the analyte(s) and the adsorbent 
packing material are employed in ion exchange SPE to effect a separation: the cartridges 
contain either adsorbent for anionic or cationic exchanges. Packing material composed of 
sulphonic acid groups is an example of a strong cation exchanger and quaternary amine 
groups as an example of a strong anion exchanger.193 
Mixed mode SPE employs multiple retention mechanisms and is suited when analytes are 
to be extracted from a complex matrix.189 Only analytes which have the properties to 
interact with both of the adsorbent mechanisms will be retained and subsequently 
desorbed and all other components will pass through the cartridge.194  
 
2.1.5. Interpretation of oral fluid results  
The European Workplace Drug Testing Society (EWDTS) has provided guidelines195 for the 
use, analysis, detection and detection of drugs in oral fluid: the document covers points for 
consideration when carrying out this type of work and includes acceptable collection 
methods and guidelines for the interpretation of oral fluid tests. The EWDTS guidelines 
have included screening and confirmation cut-offs for the detection of opiates (morphine) 
in neat oral fluid and have incorporated the 40 ng mL-1  analytical cut-off set down by the 
Substance Abuse and Mental Health Services Administration (SAMHSA) in the USA.196 
However, due to the increased sensitivity of most analytical instruments employed in 
toxicology laboratories, 40 ng mL-1 is recommended as a screening.195 
If an oral fluid sample is found to be positive for only morphine, it can be interpreted as 
being due to the administration of morphine, use of heroin (diacetylmorphine) or because 
of the ingestion of poppy seeds. If the specimen is found positive for codeine alone, it can 
be interpreted as being due to codeine administration only.178  Where a combination of 
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morphine and codeine are present in oral fluid it can be interpreted in a number of ways: if 
the level of morphine is greater than that of codeine, it is assumed that this is as a result of 
the use of heroin or the administration of morphine.83 It has also been suggested that this 
finding could also be as a results of recent ingestion of poppy seed products.177 On the 
other hand, if the codeine level is greater than the morphine, it is proposed that this is due 
to administration of codeine.167 
By comparison, in order to establish if an individual has used heroin, it is necessary to 
identify either a combination of diacetylmorphine, 6-MAM and morphine, a combination of 
6-MAM and morphine or 6-MAM only.176,197 It has been reported that 6-MAM is found oral 
fluid samples when heroin has been used. However, it is also widely known that 6-MAM 
has a short half-life and so may not always be detected.179 
 
 GC-MS versus LC-MS 2.2.
In the field of forensic toxicology, gas chromatography-mass spectrometry (GC-MS) was the 
predominant analytical technique used in systematic toxicological analysis for many 
years.198  The theoretical and practical aspects of the separation of drugs and/or their 
metabolites and the subsequent fragmentation patterns produced by the hyphenated GC-
MS technique are well understood. The instruments and methods for the detection and 
quantitation of these analytes have been proven to be robust and reproducible and many 
commercially available databases were, and still are, readily available. These instruments 
became the work horses of many, if not all, forensic toxicology and drug analysis 
laboratories but in 1968, the work of a research group lead by Victor Tal’rose reported the 
first attempt to hyphenate a liquid chromatograph with a mass spectrometer.199  It was to 
take until 1980 before the first commercial instrument was built by Finnigan (now 
incorporated into the company Thermo Scientific) and until 1989 when Sciex (now 
incorporated into the company AB Sciex) introduced a more user-friendly model that LC-
MS finally started to take a place alongside GC-MS instruments.200  
It has taken many years for LC-MS, in its many forms, to finally be accepted in working 
forensic toxicology laboratories but the technique is now widely used in the field and has 
many applications.201-204 Although the reproducibility of this technique between systems 
has made the introduction of databases relevant to toxicological screening a challenge, 
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commercially available instruments and their software have made the transition from GC-
MS to LC-MS less of a chore. LC-MS appears now to be a well-established technique in 
many working laboratories and its applications in forensic toxicology are much reported in 
the scientific literature.172,202,204-208 It is for these reasons that LC-MS was employed in this 
work: the theory of LC-MS will be discussed in Chapter 3. 
 
 Research aims  2.3.
The main aim of this research is to establish an analytical method for the simultaneous 
detection of the five major opium alkaloids in poppy seeds by liquid chromatography-
electrospray ionisation-mass spectrometry (LC-ESI-MS). If opium alkaloids are detected in 
poppy seeds, a further aim is to carry out toxicological studies to establish if these 
compounds can be detected in oral fluid of participants who ingest poppy seeds products, 
and whether or not it is possible to differentiate between poppy seed ingestion and 
administration of other diacetylmorphine/morphine/codeine products.    
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3. LIQUID CHROMATOGRAPHY – MASS SPECTROMETRY (LC-MS) 
 LC-MS 3.1.
Liquid chromatography hyphenated to mass spectrometry (LC-MS) or tandem mass 
spectrometry (LC-MSn) are analytical techniques that have found favour and have been 
implemented in many analytical laboratories over the last 20 years or so. 79,201-203,205-209 LC-
MS is a hyphenated technique coupling a liquid chromatography separation technique with 
detection of the separated analytes by mass spectrometry, providing not only retention 
time data for each analyte but information on the masses of molecular ion(s) or fragments 
formed in reactions within the mass spectrometer. 
There are many options or parameter choices that can differ in LC-MS however the basic 
principles of LC-MS are constant through each form of instrumentation. The theoretical 
descriptions of the main components of typical instruments follow.  
 
 
3.1.1.   Liquid chromatography  
High performance liquid chromatography (HPLC) is a well-known chromatographic 
separation technique with a wide range of applications in many different fields of analytical 
science. It is used to separate mixtures of compounds into their individual components by 
means of an interaction between the compound, a liquid mobile phase and a stationary 
phase.  
The commonly used modes in HPLC are reversed phase, normal phase, and size exclusion, 
with reversed phase being widely used in both forensic drug and toxicological 
analyses.72,135,137,141,209,210  
In reversed phase liquid chromatography (RP-LC), separation of a mixture of compounds 
takes place as an interaction between the stationary phase packed within the column and a 
mobile phase. These RP-LC systems employ a non-polar stationary phase and a polar 
mobile phase. Typically the packing materials within the reversed phase columns are 
composed of spherical silica particles which are coated with hydrophobic alkyl chains of 
varying length. A longer chain length provides a more non-polar stationary phase than a 
shorter chain length. Other column packing materials can include phenyl groups. These RP-
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LC columns will be used with mobile phases containing mixtures of aqueous/organic 
solvents in order to effect an appropriate separation of compounds in a mixture.  
 
3.1.1.1. Column chemistry 
When using reversed phase chromatography, compounds are separated on the basis of 
their hydrophobic nature: each compound will exhibit an adsorption phenomenon in which 
it is adsorbed onto the stationary phase depending upon packing material and analyte 
chemistries. When the solvent strength of the mobile phase is sufficient to compete with 
the hydrophobic forces keeping the compound adsorbed to the stationary phase, it will be 
eluted from the column and subsequently detected.211 The most commonly used column 
chemistry used in RP-LC is a C8 or a C18 column.  Researchers employing LC-MS for the 
detection of opiates in a variety of matrices have also employed C18 columns in their 
analyses.50,57,209,210  
Reversed phase column chemistry is based on columns packed with spherical silica particles 
coated with hydrophobic alkyl (-CH2-) groups of varying length however in this case, the 
particles are coated with a dodecyl (C18) chain. Chromatographic separations occur 
predominantly due to Van der Waals interactions between alkyl groups of the compound 
and the functional groups of the stationary phase however, the actual separations are far 
more complex: multiple retention mechanisms may be taking place at the same time. 212 
The spherical particles are coated with the C18 chain but unreacted silanol groups (-Si-OH) 
are also present, as shown in Figure 3.1. These groups are present as they should serve as a 
support for the C18 alkyl groups but, due to factors such as steric hindrance, silanol groups 
are found unreacted: they are weakly acidic, hydrophilic in nature and are considered to be 
strong adsorption sites. These unreacted silanol groups can influence greatly the 
chromatographic properties which in turn can lead to poor resolution of peaks.213  
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Figure 3.1 Diagram representing silicon backbone of a C18 stationary phase with –Si-OH groups. Adapted from 
Restek HPLC column selection guide214 
 
 
3.1.2. Mass spectrometry  
Currently, many different types of mass spectrometers are commercially available which 
can be hyphenated to a liquid chromatograph instrument: each of the separated 
compounds to the MS instrument directly from the LC instrument. A basic block diagram of 
an MS instrument is shown in Figure 3.2. 
 
 
Figure 3.2 Block diagram of the processes involved in mass spectrometry after HPLC separation 
 
Depending upon the application, the commercial supplier and capital available to spend on 
an LC-MS instrument, many choices are possible with respect to the method of ionisation 
(ion source) and the analyser. The discussion of the many different types of LC-MS 
instruments available are out with the scope of this work however, a number of the 
commonly encountered instrument setups will be considered. 
 
 
3.1.2.1. Ionisation 
Ions can be formed by a number of mechanisms in LC-MS; the most widely available and 
therefore most commonly employed ionisation techniques are electrospray ionisation (ESI) 
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and atmospheric pressure chemical ionisation (APCI). Each of the ionisation mechanisms is 
useful depending upon the physicochemical properties of the compound(s) being analysed 
such as the molecular weight, and polarity but also instrumental parameters used in the 
initial separation using HPLC.215 For example, relatively low flow rates of mobile phase are 
required when using ESI in comparison to APCI where higher flow rates may be employed. 
Figure 3.3 shows the use of ESI and APCI depending upon polarity and molecular weight of 
the analytes.  
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Figure 3.3 Comparison of ionisation methods in relation to analyte polarity and molecular weight 
 
3.1.2.2. Electrospray ionisation (ESI) 
The ion sources used on all LC-MS instruments employed in this work use the principle of 
electrospray ionization to generate gas phase analyte ions from the liquid phase 
introduced from the HPLC instrument.216 ESI is a soft-ionisation technique whereby quasi-
molecular ions are formed: as positively or negatively charged ions depending upon the 
mode employed.217,218 
There has been much discussion over the years on the mechanism of formation of charged 
ions using ESI sources however it is thought that the charged ions are formed by the 
analyte(s) in the liquid phase being sprayed into a chamber maintained at atmospheric 
pressure.217-220 The liquid is introduced into the source in the presence of a heated drying 
gas, usually nitrogen, and a strong electrostatic field. The electrostatic field produced 
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causes dissociation of the analyte molecules, with the drying gas causing the solvent to 
evaporate. On evaporation of the solvent, the charge concentration of the droplets 
increases which in turn leads to the forces between ions of the same charge ejecting ions 
into the gas phase: this process is known as desolvation.221,222 This process finally gives rise 
to very small droplets containing single charged analyte molecules.217,219 A diagram 
representing the droplet formation in ESI is shown in Figure 3.4. Once the ions are formed, 
they then pass through a capillary chamber into the mass analyser.  
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Figure 3.4 Ion formation in an ESI source. Adapted from Bayne & Carlin (2010)172 
 
3.1.2.3. Atmospheric pressure chemical ionisation (APCI) 
APCI exploits similar ionisation methods as is used in ESI however in APCI the evaporation 
of the solvent and the formation of ions are two separate processes. With APCI, the ion 
source is set up in a similar way to ESI but a corona needle (Figure 3.5) is used to ionise the 
gas and solvent molecules. 
 
Figure 3.5 APCI ion source. Adapted from Bayne & Carlin (2010)172 
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These charged gas and solvent ions then interact with the analyte and cause ionisation 
through charge transfer.223 LC-MS with APCI ionisation has found application in drug and 
toxicological analyses.224-227 APCI is typically used with analytes that are not readily ionised 
with ESI and are small and thermally stable.223  
 
3.1.3. Mass spectrometry analysers 
The analyser in a mass spectrometer is essentially used to filter ions of a chosen mass-to-
charge (m/z) or m/z range before being detected. The filtering process occurs on the basis 
of the behaviour of the ions in either a magnetic or electric field. Mass analysers include, 
for example, single quadrupole, ion trap, and triple quadrupole.172,194 
 
3.1.3.1. Ion trap  
The ion trap analyser is an electric field instrument used to “trap” ions by applying a charge 
from the appropriate electrode of the analyser. Ion trap analysers consists of a doughnut 
shaped electrode alongside two other hyperbolic electrodes called end-cap electrodes, 
(Figure 3.6).  
 
Ions from ion source
Ions to the detector
Ring electrode
Exit end-cap electrode
Entrance end-cap 
electrode  
Figure 3.6 Trapping system of an ion trap analyser. Adapted from Bayne & Carlin (2010)172 
 
The ions are trapped in the centre of the ring electrodes by applying radio frequency (RF): 
the ion trap is filled with a damping gas, typically helium, which is used to collide with the 
ions thus reducing their kinetic energies. Ions are hence trapped and ejected to the 
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detector depending on their mass to charge ratio by selectively altering the RF voltage of 
the trap.228 
Ion trap analysers can be susceptible to space-charge repulsion effects as a result of too 
many ions being present in the trap generating a distortion of the electrical field. 
Consequently this can lead to a reduction in the overall performance of the analyser.229 Ion 
trap instruments have however been successfully utilised in forensic and analytical 
applications for many years.207,230-232  
 
 
3.1.3.2. Triple quadrupole  
Triple quadrupole analysers employs three quadrupoles in tandem (Q1, Q2 and Q3 in 
Figure 3.7) to separate and filter the ions of interest. Q1 is used to filter ions of a particular 
m/z value by altering the RF and DC voltages; Q2 is then used as a collision cell where the 
ion or ions from Q1 are focussed and can interact with a collision gas causing charged 
fragments to form. These fragment ions will then be filtered in Q3 in the same way as in 
Q1.231 
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Figure 3.7 Image of a triple quadrupole233 with block diagram outlining ion formation and separation 
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3.1.3.3. Orbitrap   
A relatively new type of analyser to commercial LC-MS instruments is an Orbitrap.234 This 
instrument admits ions from the ESI source into a linear ion trap. Here, ions of a particular 
mass range are “trapped” before reaching a curved quadrupole (C-trap) which is 
surrounded by two flat lenses with apertures that allow ion transport.235  
 
 
Figure 3.8 Diagram of a linear trap quadrupole Orbitrap mass spectrometer236 
 
The Orbitrap is a small electrostatic device with a single spindle-shaped electrode (Figure 
3.8). When the ions are injected into the Orbitrap, they are trapped by orbiting around a 
central electrode.237 The ions are detected when a stable electrostatic field is achieved.235 
 
 Analytical method development and validation  3.2.
One of the aims of this research is to establish an analytical method for the simultaneous 
detection of the five major opium alkaloids morphine, codeine, thebaine, papaverine and 
noscapine. When faced with a new analyte or mixture of analytes, it is necessary to 
develop an analytical method for the detection and, in this case, quantitation of these 
analytes.  
Method development in LC-MS involves the consideration of all aspects of analysis from 
sample preparation techniques to instrumental parameter settings to achieve an optimum 
output and data which can be analysed to provide meaningful interpretation. 238 Once a 
suitable sample preparation and analytical method for the detection and quantitation of a 
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method has been obtained, validation of that process is required to prove that method 
performs in the manner for which it is intended and that it performs consistently well. 
Peters et al.239 published a paper in 2007 outlining essential parameters required when 
validating a new analytical method with particular reference to methods in analytical 
toxicology. It was proposed by the authors that selectivity, linearity, accuracy, precision, 
limit of detection (LOD), lower limit of quantitation (LLOQ), recovery and robustness should 
be established and where appropriate, matrix effects should also be included when 
validating an analytical method. These validation parameters still stand today and are 
accepted in the field of analytical toxicology and drug analysis: they are briefly defined 
below. 
• Selectivity (specificity): the ability to unambiguously detect the analyte of interest 
in the presence of other components which may be expected to be present in the 
sample being analysed. 
 
• Calibration model: a relationship between analyte concentration in a sample and 
detector response must be established. This is predominantly linear however other 
models, such as quadratic models may be used.   
 
• Accuracy (bias): this is a measure of the closeness of agreement between an 
accepted reference value and an actual sample result.  
 
• Precision: this is the closeness of agreement between a series of measurements 
obtained from analysis of the same homogeneous sample under the prescribed 
conditions. 
 
• Limit of detection (LOD): this is the lowest analyte concentration in a sample which 
can be detected but not necessarily quantitated as an exact value. It is generally 
accepted that when a signal-to-noise (S/N) ratio is of ≥ 3:1 is achieved, LOD is 
established.  
 
• Lower limit of quantitation (LLOQ): this is the lowest amount of analyte in a 
sample that can be quantitatively determined with suitable precision and accuracy. 
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It is generally accepted that when a S/N ratio is of ≥ 10:1 is achieved, LLOQ is 
established. 
 
• Recovery: this is determined as a percentage of analyte concentration detected 
after extraction from a matrix in comparison to the concentration intentionally 
added to blank spiked matrix.  
 
• Robustness: this is a measure of the capacity of the method to remain unaffected 
by small but deliberate variations in the analytical parameters. 
 
• Matrix effects: these effects can either increase the ionisation (enhance) or 
decrease the ionisation (supress) of certain analytes. A number of factors such as 
sample preparation technique, matrix type, mobile phase additives and ionisation 
type can produce matrix effects.239 
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4. ESTABLISHING AN LC-MS TESTING METHOD FOR THE SIMULTANEOUS 
DETECTION OF THE FIVE MAJOR OPIUM ALKALOIDS 
 Experimental 4.1.
4.1.1. Chemicals and reagents 
4.1.1.1. LC-MS 
Organic solvents (methanol, acetonitrile, chloroform, isopropyl alcohol) of HPLC grade were 
purchased from Sigma-Aldrich (Poole, Dorset) as was acetic acid. Drug standards of codeine 
(1 mg mL-1) in methanol and morphine (1 mg mL-1) in methanol were purchased from LGC 
Standards (Teddington, Middlesex) and powder form drug standards of codeine,  morphine 
sulphate salt monohydrate, thebaine, noscapine hydrochloride hydrate and papaverine 
hydrochloride were purchased from Sigma-Aldrich (Poole, Dorset). Deuterated morphine 
(100 μg mL-1) in methanol was purchased from Sigma Aldrich (Poole, Dorset) and used as 
an internal standard. 
 
4.1.1.2. NMR 
Only thebaine was analysed using NMR and standards were prepared by dissolving 
approximately 10 mg of the powdered standard into a number of solvent ratios of 
deuterated water (D2O) and acetonitrile-d3 (CD3CN) incorporating 1% of deutero-acetic 
acid (CD3COOD) to mimic the mobile phase conditions of the liquid chromatograph. 
Deuterated solvents were purchased from Goss Scientific (Crewe, Cheshire). LC-grade 
water was obtained from a Millipore purification system.   
 
 
4.1.2. Instrumentation  
4.1.2.1. LC-ESI-MS (ion trap) 
HPLC was performed using an LC Surveyor system (Thermo Finnigan, Hemel Hempsted, UK ) 
which was equipped with a pump,  auto-sampler and column heater. 
A Gemini 3 µm C18, 100 x 2.0 mm column fitted with a Gemini C18, 4.0 x 2.0 mm guard 
column (Phenomenex, Cheshire, UK) was used and was thermostated at 30oC.  
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Mass spectrometry was performed using an LCQ Advantage (Thermo Finnigan, Hemel 
Hempsted, UK) ion trap mass spectrometer. The mass spectrometer was operated in a 
positive electrospray ionisation mode. Selection and tuning of the mass spectrometer 
settings for each of the drug analytes were performed using direct infusion, involving the 
direct introduction of each of the analytes in methanol.  
 
 
4.1.2.2. LC-ESI-MS (triple quadrupole) 
A comparative method was used in collaboration with the toxicology laboratory of the 
Institut de Recherche Criminelle de la Gendarmerie Nationale (IRCGN), Paris. The 
instrument used was a 1260 HPLC (Agilent Technologies, Paris, France) coupled to a 4500 
QTRAP tandem mass spectrometer (AB Sciex, Les Ulis, France). The mass spectrometer was 
operated in a positive electrospray ionisation mode. The column used was an Allure™ 
pentafluorophenyl phase with a propyl spacer (PFPP) column, 5 μm, 50 x 2.1 mm fitted 
with an Allure™, PFPP 10.0 x 2.1 mm guard column (Restek, Lisses, France) thermostated to 
40 oC. The auto-sampler tray was maintained at 8 oC. 
 
4.1.2.3. Nuclear magnetic resonance spectroscopy 
All 1H-NMR spectra were obtained using a JOEL ECS 400 NMR spectrometer operating at 
399.8 MHz.  
 
 
4.1.3. Analysis of results 
Data analysis was carried out using XCaliber 2.0 software package supplied with the 
ThermoFinnigan LC system and LCQ Advantage ion trap mass spectrometer.  
Analysis of data obtained using the Agilent HPLC 1260 hyphenated to the AB Sciex 4500 
mass spectrometer was analysed using Analyst 1.6 software package. 
All 1H-NMR spectra were analysed using the Delta 5.03 software package. 
 
 
59 
 
 
 Method development – LC-ESI-MS 4.2.
A paper published in 2006 by Sproll et al.76, reported the use of an LC/MS/MS method for 
analysing the presence of morphine and codeine in poppy seeds and carrying out a risk 
analysis of what happens to those alkaloids when they enter the food chain. Bucelli et al.230 
in 2009 also published a paper reporting the successful analysis of hair samples for the 
detection of drugs of abuse using LC-ESI-MS; using both of these published methods, 
instrumental parameters were chosen as the starting point for the initial method 
development although the detection of thebaine, papaverine and noscapine were not 
included in these articles. The initial LC method used is shown in Table 4.1 where the 
column used was a Gemini 3 µm C18, 100 x 2.00 mm column fitted with a Gemini C18, 4.0 x 
2.0 mm guard column; solvent A was acetonitrile + 1% acetic acid (pH 1.5); solvent B was 
water + 5% acetonitrile + 1% acetic acid (pH 2.5) and the mass spectrometer was run in 
positive mode electrospray ionisation using a capillary temperature of 230 oC, a spray 
voltage of 6 kV and capillary voltage of 36 V.  
 
Table 4.1 Initial LC-MS conditions used for attempted detection of opium alkaloids 
Mobile phase composition 
Solvent A: Acetonitrile + 1% acetic acid 
Solvent B: Water + 5% acetonitrile + 1% acetic acid 
Time (minutes) %A %B Flow rate (μL min-1) 
0.00 0 100 200 
10.00 65 35 200 
12.00 65 35 200 
14.00 0 100 300 
20.00 0 100 300 
 
At this point in the work, deuterated morphine was not available but solutions of 
morphine, codeine, thebaine, papaverine and noscapine were prepared at a concentration 
of 2000 ng mL-1 in methanol and water (50:50, v/v). All drug standards were prepared from 
powdered material as described in section 4.1.1. The mass spectrometer was set to 
perform analysis over a 12 minute run time and was set for selected ion monitoring (SIM) 
for morphine with a quasi-molecular ion, [M-H+], of m/z 286 ± 2.0; codeine with a quasi-
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molecular ion of m/z 300 ± 2.0; thebaine with a quasi-molecular ion of m/z 312 ± 2.0; 
papaverine with a quasi-molecular ion of m/z 340 ± 2.0 and finally noscapine with a quasi-
molecular ion of m/z 414 ± 2.0. 
The solution of morphine was introduced to the LC-MS as described above and the 
resulting chromatogram and associated mass spectrum is shown in Figure 4.1. Under these 
conditions, morphine was found to have a retention time of 1.33 minutes which shows that 
it is almost unretained by the column and has a high affinity for the mobile phase. The 
associated mass spectrum (Figure 4.1.a.) shows the [M-H+] at m/z 286.05 however a second 
peak also appears in the chromatogram with a retention time of 10.53 minutes and a [M-
H+] at m/z 340.24. It was assumed at this point, that this peak was due to carryover from 
previous injections when the mass spectrometry method was being established. 
 
 
Figure 4.1 Chromatogram and associated mass spectra for morphine injection for (a) peak 1 at 
1.33 minutes and (b) peak 2 at 10.53 minutes 
 
When codeine was introduced (chromatogram and associated spectra shown in Figure 4.2), 
it was noted that there was a peak found with a retention time of 1.33 minutes with the 
associated mass spectrum showing the codeine [M-H+] at m/z 300.06. The same or very 
similar retention time to morphine is not completely unexpected due to the similarity in 
chemical structures of the two compounds: the only difference is the replacement of an 
hydroxyl group on the 3-position with a methoxy group. 
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 Figure 4.2 Chromatogram and associated mass spectra for codeine injection for (a) peak 1 at 1.33 
minutes (b) peak 2 at 2.86 minutes and (c) peak 3 at 11.14 minutes 
 
There is also a peak with a retention time of 11.14 minutes with a mass spectrum that 
appears very similar to that of papaverine. In this chromatogram, there is also a third peak 
with a retention time of 2.86 minutes with a corresponding mass spectrum with the most 
abundant peak found with m/z 300.05.   
Possible explanations for the presence of two peaks with the same mass spectral output 
was that the solution was too concentrated resulting in more than one peak for one 
compound or that the powdered drug standard which had been purchased was not pure. It 
is well known that in the synthesis and preparation of drug standards, impurities, albeit in 
small proportions, will be present in the final product.240,241 In order to asses which, if any 
of these was true, the concentration of the drug standard was reduced and the resulting 
chromatogram was the same as shown in Figure 4.2 but with smaller peak areas. In order 
to assess this, a pure drug standard, purchased as a 1 mg mL-1 pre-prepared standard in 
methanol in a glass ampoule, was purchased from LGC Standards (Teddington, Middlesex) 
and from this, a 1000 ng mL-1 codeine standard was prepared and injected again. The 
resulting chromatogram produced only one peak for codeine with a retention time of 1.33 
minutes, proving that the presence of the second peak was due to an impurity in the 
standard.  
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When the thebaine drug standard was injected into the instrument, the resulting 
chromatogram, shown in Figure 4.3, was of a poor quality: the peak thought to be 
papaverine was still present but there were two peaks present (1.38 minutes and 7.26 
minutes) which showed the same ion with m/z 311.94. Due to the fact this this issue had 
also been seen with the injection of the codeine standard, it was initially thought that 
sample impurities explained the presence of multiple peaks. However, it was not possible 
to obtain a pure drug standard for thebaine and the fact that there was a large difference 
in retention time between the two peaks (which was not seen in the case of codeine) 
warranted further investigation (Section 4.3).  
 
 
Figure 4.3 Chromatogram and associated mass spectra for thebaine injection (a) peak 1 at 1.38 
minutes (b) peak 2 at 7.26 minutes and (c) peak 3 at 9.81 minutes 
 
Noscapine was then introduced to the system and again two peaks were noted (Figure 4.4): 
one peak was found at a retention time of 8.28 minutes with associated mass spectrum 
showing the most abundant ion m/z of 414 and, as with the previously injected alkaloids, 
an extra peak consistent with the quasi-molecular ion m/z of 340 for papaverine. 
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 Figure 4.4 Chromatogram and associated mass spectra for noscapine injection (a) peak 1 at 8.28 
minutes and (b) peak 2 at 9.66 minutes 
 
Papaverine was injected into the instrument and the resulting chromatogram and 
associated mass spectra are shown in Figure 4.5. It was initially thought that the extra peak 
found in the chromatograms for morphine, codeine, thebaine and noscapine with m/z of 
340 was due to carryover from early injections of papaverine which were used to establish 
the mass spectrometry method. However, two peaks were found again when papaverine 
itself was injected. 
In order to establish if both peaks were due to papaverine (one from column/system 
overload and the other from injection) it was necessary to consider alternative hypotheses. 
Although it was possible that column/system overload had  taken place, which can be seen 
from the high peak area values in most of the previously noted chromatograms, it was also 
possible that since the instrument was also used many other researchers in different fields, 
that the peak could be due to a compound that was not papaverine. 
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 Figure 4.5 Chromatogram and associated mass spectra for papaverine injection (a) peak 1 at 8.54 
minutes and (b) peak 2 at 10.32 minutes  
 
Blank injections of the solvent used to prepare the drug standards were injected into the 
LC-MS at the beginning of the sequence and between each of the standards; as can be seen 
from one of the blank injections shown in Figure 4.6, the extra peak was persistent. This is 
true for all of the blank injections therefore with this information, it was decided to reduce 
the concentration of the drug standards by half in order to avoid overloading the column 
but also to reduce or eliminate carry over in subsequent injections. This did not resolve the 
matter, as the extra peak was still present, even after column flushing.  
 
 
Figure 4.6 An example of the resulting chromatogram and associated mass spectrum from a blank 
injection  
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Since it was possible that the peak was carryover on the column, another C18 column was 
connected to the HPLC and morphine and codeine were injected under the same LC-MS 
method as previous alkaloid injections. It was found that the extra peak was still present 
which allowed the conclusion to be drawn that column carryover was not the reason for 
the presence of the extra peak. 
After establishing that column carryover was not the reason for the extra peak, a decision 
was made to carry out mass spectrometry/mass spectrometry (MS/MS) experiments. Using 
selective ion monitoring (SIM) and searching only for the quasi-molecular ion for each of 
the alkaloids did not provide sufficient discriminating power. Therefore, transitions from 
precursor ion (quasi-molecular ion) to product ions (fragment ions) were monitored.  
To optimize the mass spectrometer settings for each of the alkaloid compounds, a 100 ng 
mL-1 standards of morphine, codeine (both from 1 mg mL-1 drug standards in methanol), 
thebaine, papaverine and noscapine (from powder) were prepared and introduced to the 
mass spectrometer using positive electrospray ionisation. Each alkaloid solution was 
introduced using direct infusion: once the quasi-molecular ion (precursor ion) for each of 
the alkaloids was found, the collision energy of the mass spectrometer was increased until 
the peak for the quasi-molecular ion halved in abundance and other stable peaks were 
present (product ions). The optimised settings are provided in Table 4.2. 
 
Table 4.2 Optimised mass spectrometer settings for initial MS/MS experiments 
Compound Quasi-molecular ion 
(m/z) 
Monitored 
transition mass 
(m/z) 
Collision Energy 
(eV) 
Morphine 286 286 → 268 33 
Codeine 300 300 → 215, 243 34 
Papaverine 340 340 → 202 38 
Noscapine 414 414→ 220 27 
 
The chromatogram in Figure 4.7 shows that using this method it was possible to detect one 
peak for morphine, codeine, noscapine and papaverine but two peaks for thebaine. It 
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should be noted that in this mass spectrometry method, thebaine was monitored by SIM 
only which was an error. 
 
 
Figure 4.7 Single peaks for (a) morphine (b) codeine (c) papaverine (d) noscapine and (e) two 
peaks for thebaine  
 
The MS/MS transition for thebaine was subsequently included in the method but still the 
presence of the two peaks persisted.  At this point, it was decided that the issue of the 
presence of two peaks for thebaine required further investigations but these will be 
discussed in section 4.4. 
For the validation of an analytical method it is necessary to ensure, at the very minimum, 
that  selectivity, linearity, accuracy, precision, and limits of detection/quantitation should 
be considered.239 These properties were hence considered in relation to this analyte 
mixture. 
  
4.2.1. Selectivity 
Section 3.2 defines this validation parameter as being able to prove that the analyte, or 
analytes, of interest should be unambiguously detected in the presence of other 
components from the sample matrix. In this case, the matrix was aqueous mobile phase. In 
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order to assess this parameter, multiple blank samples were injected before, between and 
at the end of the sample sequences and all blanks showed the absence of peaks for the 
alkaloid compounds being analysed by this method. When morphine, codeine, papaverine 
and noscapine were injected individually, only one peak was found (Figure 4.7) therefore 
showing that selectivity was established. 
 
4.2.2. Linearity 
In order to assess if linearity was possible for each of the compounds using this analytical 
method, a series of calibration solutions were prepared in the range 0 – 1000 ng mL-1. 
Similar ranges had been used in published studies in the scientific literature in the analysis 
of opiates in poppy seeds and other biological matrices.70,140,177,242 Calibration graphs were 
constructed using concentration and peak area. The resulting calibration graphs were 
constructed using a minimum of five data points, including a blank as is suggested in the 
literature.239,243 The equation of the line and coefficient of determination (R2) for morphine, 
codeine, papaverine and noscapine are provided in Table 4.3. 
 
Table 4.3 Linear equations and associated R2 values for morphine, codeine, papaverine and 
noscapine 
Compound Linear equation R2 Concentration 
Range (ng mL-1) 
Morphine y = 14942x + 60372 0.9897 0 – 200 
Codeine y = 38087x + 0.9996 0.9999 0 – 1000 
Papaverine y = 95953x + 1x106 0.9989 0 – 1000 
Noscapine y = 182484x + 523763 0.9923 0 – 200 
 
It is generally accepted in method validation, that a minimum R2 value of 0.99 is expected 
to demonstrate linearity.244 Codeine, papaverine and noscapine calibration graphs meet 
these criteria and are therefore linear, however morphine fell slightly lower than the 
desired value. It should be noted that these graphs were constructed using only one data 
set therefore in order to determine if linearity was reproducible, precision should be 
determined. 
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4.2.3. Precision 
Precision has been defined in section 3.2 as the closeness of agreement between a series of 
measurements. Precision in chromatography methods is generally determined by repeating 
injections at different points along the linear range of concentrations and assessing the 
coefficient of variation (%CV) or relative standard deviation.244,245  
For morphine, codeine, papaverine and noscapine, mixed calibration solutions were 
prepared at 1, 10, 50, 100, 500 and 1000 ng mL-1; at each concentration four repeat 
injections were carried out. A blank was run at the beginning and end of the sequence and 
between each of the four injections of the same concentration. From the peak area for 
each of the alkaloids, the mean (x�) peak area for the four injections at each concentration 
point, the standard deviation (σ) and the percent coefficient of variation (%CV) was 
calculated: from this, a calibration graph was constructed.  
For morphine (Figure 4.8), it was not possible to detect morphine at the lower end of the 
concentration range. Other validated LC-MS methods have been published which included 
morphine: Coles et al.242 in 2007 reported LOD of 0.05 ng mL-1  and LOQ of 2 ng mL-1  and 
Taylor and Elliott209 in 2009 reported an LOD of 0.34 ng mL-1 and an LOQ of  10 ng mL-1. By 
comparison, the lowest detected concentration for morphine using this LC-MS method was 
50 ng mL-1: this is considerably higher than the values reported in the literature. The 
coefficient of determination (R2) value for this data is also poor: a value of 0.7758 is much 
lower than the expected value of 0.99 indicating substantial error associated with using the 
equation from this data. It should also be noted that the calibration graph from the 
available data has been constructed with only 4 data points plus the blank: 5 points plus 
the blank is the minimum requirement246,247 therefore it was necessary to increase the 
number of points in the range.  It is expected that the %CV values should be 15% or less 
and 20% or less239,244,245 at the lowest concentration points however, as can be seen from 
the tabulated data in Figure 4.8, only the repeat injections of morphine at 1000 ng mL-1 
would meet this criteria.  
69 
 
 
 Figure 4.8 Data and associated calibration graph for morphine 
 
When this data set was analysed for codeine concentration (Figure 4.9), it was possible to 
detect 10 ng mL-1, which is lower than that found for morphine. The published literature 
has several reports describing the detection and quantitation of codeine; Coles et al.242 in 
2007 reported LOD of 0.05 ng mL-1  and LOQ of 2 ng mL-1  and Newmeyer et al.177 reported 
an LOD of 0.5 ng mL-1 and LOQ of 1 ng mL-1. As was the case with morphine, the lowest 
detectable concentration for codeine from this work is considerably higher than those 
stated in the published literature. The R2 value of 0.9973, obtained when the average peak 
area values were plotted against concentration is greater than the minimum value of 0.99. 
However, when considering the coefficient of variation for each of the concentration 
points, the values far exceed the 15% or 20% threshold desired. 
 
 
Figure 4.9 Data and associated calibration graph for codeine 
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Papaverine injections provided linear data (Figure 4.10) with an acceptable R2 value of 
0.9996 with 6 data points and a blank but the %CV values at all the data points except at 
500  and 1000 ng mL-1, exceed the 15% (or 20% for lowest concentration) limit previously 
described. It was also possible to detect papaverine at a concentration of 1 ng mL-1. There 
are currently no comparable LC-MS quantitative methods for papaverine with available for 
LOD and LOQ data. Although the data obtained for papaverine is much better than that 
obtained for morphine and codeine, it still falls short of acceptable limits required to 
validate a method. 
 
 
Figure 4.10 Data and associated calibration graph for papaverine 
 
It was possible to detect noscapine at 1 ng mL-1 and to construct a linear calibration graph 
but with an R2 value of 0.985, it was with some error. Notably, if the 1000 ng mL-1 point was 
removed, an R2 value of 0.9977 was obtained. However, when the %CV values are 
considered, only the 500 and 1000  ng mL-1 data points meet the acceptable criteria with 
both having values less than 15%.  
 
Figure 4.11 Data and associated calibration graph for noscapine 
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4.2.4. Other validation parameters 
It is clear, that for morphine, codeine, papaverine and noscapine that the data, and 
therefore the method, did not meet the prescribed requirements for method validation. 
Since the validation parameters discussed above are not acceptable, it was decided not to 
continue with determining the other appropriate validation parameters but to assess 
where the method could be adapted in order to achieve a better outcome. With this in 
mind, it was decided to try to resolve the issue of two peaks with very similar mass spectral 
data appearing in the chromatogram for thebaine. If this issue could be resolved, the 
development of an analytical method for the simultaneous detection of all five alkaloid 
compounds might be achieved. 
 
 NMR analyses of thebaine 4.3.
It was noted that using the initial LC-ESI-MS method that all compounds could be detected 
but that there were two peaks present in the chromatogram for thebaine (Figure 4.12) with 
both having almost identical mass spectral data. There was also no linear correlation 
produced for either of the peaks when attempting to construct a calibration graph. A series 
of experiments were carried out using nuclear magnetic resonance (NMR) to investigate 
this finding.   
 
Figure 4.12 Chromatogram for thebaine showing two peaks: (a) mass spectrum for peak at 1.31 
minutes and (b) mass spectrum for peak at 8.62 minutes 
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NMR has been used to elucidate structures of molecules for many years248 but has been 
used more specifically to attempt to elucidate the structure of alkaloids since the 1970s. In 
1975, Terui et al.249 reported the 13C spectra for morphine alkaloids thebaine and 
sinomenine; Theuns et al.250,251 reported the structure of thebaine using both 13C and 1H 
NMR with the most recent article in this field published by Caldwell et al.252 who reported 
the configurational analysis of thebaine and codeine using 13C and 1H NMR in 1996.  
In the HPLC method described above, two separate mobile phases were used: acetonitrile + 
1% acetic acid and water + 5% acetonitrile + 1% acetic acid. It was decided to establish if 
there was any difference in the chemical structure of thebaine with varying proportions of 
the solvent acetonitrile to aqueous component and also to alter the amount of acid present 
in the solvent. It was hoped this would help explain why the chromatography showed two 
peaks. Solutions were prepared for 1H NMR in varying ratios of deuterated water 
(D2O):deuterated acetonitrile (CD3CN) + 1% deutero-acetic acid (CD3COOD) to investigate 
the effect of the mobile phase composition on the structure of thebaine. Figure 4.13 shows 
resulting 1H-NMR spectra with varying mobile phase composition. 
 
 
 
 
 
 
 
 
 
Figure 4.13 1H-NMR spectra for thebaine in (a) D2O:CD3CN ratio 80:20 (v/v), (b) D2O:CD3CN ratio 
50:50 (v/v), (c) D2O:CD3CN ratio 20:80. All solutions contain 1% CD3COOD 
 
It is proposed that in the presence of deutero-acetic acid the nitrogen atom of the thebaine 
is deuterated and thus promotes solubility in the polar mobile phase at the beginning of 
a. 
b. 
c. 
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the LC-MS method. The 1H-NMR spectrum shown in Figure 4.13 (a.) indicates the presence 
of two isomeric forms (epimers) of the thebaine-D+ complex ion in an approximate ratio of 
55:45. These ratios were determined from the integration of signals obtained from the 
spectra. The spectrum in Figure 4.13 (c.), in which the solvent is predominantly deuterated 
acetonitrile, is less complicated showing either the presence of one form of the thebaine-D+ 
complex ion or the presence of the two forms exchanging so quickly that the 1H-NMR 
cannot differentiate between the two and so and averaged spectrum is recorded. The 
spectrum shown in (b.) of Figure 4.13 shows a spectrum with broad signals obtained from a 
50:50 water:acetonitrile solvent indicative of a slow exchange between the two forms. 
When the acetic acid content was increased from 1% to 2%, no difference was noted 
between the spectra therefore concluding that the exchange was based on the solvent 
composition, rather than pH, which is consistent with the findings of Caldwell et al.252 
 
 
 
Figure 4.14 1H-NMR spectrum of thebaine in 100% D2O (+ 1% CD3COOD) 
 
For comparison, a spectrum was obtained for thebaine in deuterated water with 1% 
deutero-acetic acid (Figure 4.14): again two epimers are formed in the same ratio as found 
above. It is suggested that thebaine can exist in two epimeric forms shown in Figure 4.15 
(epimer A and B): in the presence of the acetic acid, it is thought that the epimers are 
protonated (HA+ and HB+). The presence of the lone pair on the nitrogen atom of the 
unionised form enables nitrogen inversion. Nitrogen inversion is the process by which the 
lone pair of electrons moves from one side of the molecule to the other via quantum 
mechanical tunnelling.253 In the process of inversion, the nitrogen starts off in the sp3 
hybridised form (tetrahedral); as the lone pair moves through the nucleus the nitrogen 
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becomes sp2 hybridised (trigonal planar) and then finally returns to the sp3 hybridised form 
when the lone pair makes it to the other side of the nitrogen to where it started.  
 
 
 
Figure 4.15 Formation of thebaine-D+ complex ions, HA+ and HB+ from epimers A and B254 
 
In order to establish if the conclusion drawn from this NMR study was replicated if the 
same sample conditions were analysed by the LC-MS, standards of thebaine of 
concentration 1000 ng mL-1 in acetonitrile with percent of acetic acid of 1, 2, 4, 6 and 8%. 
These standards were then analysed by the LC-MS method outlined in the experimental 
section. It was noted that the optimum solution for preparation of thebaine standards was 
acetonitrile with 1% acetic acid. All other acetonitrile/acetic acid combinations produced 
poor peak shape for both thebaine peaks. It was also noted that it was not possible to 
eliminate the second peak for thebaine from the chromatogram. It was possible to produce 
a stable form of the thebaine to construct a calibration graph in the concentration range of 
0-1000 ng mL-1 (5 points and a blank) with an R2 value of 0.9987. It was however decided 
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this was not acceptable and that a definitive identification and quantitation of one form of 
thebaine would be achieved by the elimination of the second peak. 
 
 Further method development 4.4.
An instrument failure occurred once this suite of experiments was complete, leading to a 
pause in experimentation. On resumption, a related but slightly different method using 
deuterated morphine (morphine-d3) as internal standard was investigated.  
As previously carried out and explained in Section 4.2, to establish the optimum mass 
spectrometer parameters for each of the compounds of interest, a solution of each alkaloid 
and the deuterated morphine were prepared in methanol at a concentration of 100 ng mL-
1; the solutions were then introduced to the mass spectrometer directly with the aid of an 
external syringe driver. The parameters were optimised automatically by the mass 
spectrometer for each of the compound masses and the settings were stored; these 
parameters are shown in Table 4.4.  
 
Table 4.4 Analyte specific parameters for LCQ Advantage mass spectrometer from HPLC (* - ion 
used for quantitation) 
Compound m/z Monitored transition 
mass (m/z) 
Collision 
Energy (eV) 
Morphine 286 286 → 201*, 229 33 
Codeine 300 300 → 215*, 243, 282 32 
Thebaine 312 312 → 183, 249, 281* 28 
Papaverine 340 340 → 202* 
202 → 171 
36 
32 
Noscapine 414 414→ 220*, 353 29 
 
Morphine-d3 289 289 → 201*, 229 30 
 
 
With the findings from the NMR study (reported in section 4.3) showing that the solvent 
choice for the sample preparation has a significant impact on the form that the thebaine 
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was found in, it was decided to include the use of a buffered mobile phase. Based on the 
experience of the author, and in discussion with colleagues from the department of 
toxicology of the French Institut de Recherche Criminelle de la Gendarmerie Nationale 
(IRCGN), Olivier Roussel255 and Sophie Salle256, a mobile phase composition of A: water + 2 
mM ammonium formate + 0.2% formic acid and B: acetonitrile + 2 mM ammonium formate 
+ 0.2 % formic acid was used with the details of the HPLC method shown in Table 4.5. The 
auto-sampler tray was held at 8 oC to reduce any effects that temperature may have on the 
thebaine epimer formation and the final standard opiate mix solutions (containing 
morphine, codeine, thebaine, papaverine, noscapine and  morphine-d3) were prepared in 
methanol:water (50:50, v/v), as had been used previously. When the method was run on 
the C18 column, single peaks were observed for all of the alkaloid compounds, including 
thebaine however the peak shape was poor, with tailing and fronting observed. An 
alternative to the C18 column is the Allure™ pentafluorophenyl phase with a propyl spacer 
(PFPP) column 5 μm, 50 x 2.1 mm fitted with an Allure™ PFPP 10.0 x 2.1 mm guard column 
(Restek, Buckinghamshire, UK). This column had a proven successful separation of 
morphine and codeine in the toxicology laboratory of the IRCGN, and had provided good 
peak shape.255,256  The HPLC gradient method is shown in Table 4.5 and the column was 
thermostated to 40 oC. The same mass spectrometer settings were used as shown in Table 
4.4. 
 
Table 4.5 Mobile phase composition and gradient program for the final LC-ESI-MS method on the 
PFPP column 
Mobile phase composition 
Solvent A: Water + 2 mM ammonium formate + 0.2% formic acid, pH 2.4 
Solvent B: Acetonitrile + 2 mM ammonium formate + 0.2 % formic acid, pH 4.8 
Time (minutes) %A %B Flow rate (μL/min) 
0.00 90 10 350 
2.00 90 10 350 
10.00 10 90 350 
11.00 10 90 350 
12.00 90 10 350 
14.00 90 10 350 
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Using this method and the new column, it was again found that single peaks were observed 
for all of the alkaloid compounds, including thebaine and that the quality of the peaks 
obtained was far better and that it was possible to achieve different retentions times for 
morphine and codeine, i.e. no co-elution as was found using the Gemini column. (Figure 
4.16).  
 
 
Figure 4.16 Extracted chromatograms from a mixed injection of (a) morphine, (b) morphine-d3, (c) 
codeine, (d) thebaine, (e) papaverine and (f) noscapine 
 
 Validation of the final LC-ESI-MS method 4.5.
4.5.1. Selectivity 
As discussed in section 4.2.1, selectivity was established by running blanks at the beginning 
and end of the sequence and in between each set of standards in the sequence. Since no 
peaks were found at the same retention time as any of the alkaloid compounds or the 
internal standard in any of the blank solutions, selectivity of the method had been 
established.   
 
4.5.2. Linearity 
Linearity of the method was established by preparing mixed calibration standards of 
morphine, codeine, thebaine, papaverine, noscapine and morphine-d3 at 10 points across 
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the concentration range 10 – 500 ng mL-1. Calibration standards were prepared in triplicate 
and each calibration point was injected in triplicate resulting in three separate data sets. 
Using the ions highlighted in Table 4.4 for quantitation, average peak area ratios (drug peak 
area/internal standard peak area) for each of the alkaloids were used to construct 
calibration graphs; the linear equations, R2 values and concentration range are provided in 
Table 4.6. The calibrations graphs were constructed with a minimum of 6 data points plus a 
blank. 
 
Table 4.6 Linear equations and associated R2 values for morphine, codeine, thebaine, papaverine 
and noscapine 
Compound Linear equation R2 Concentration range 
(ng mL-1) 
Morphine y = 0.0047x – 0.0100 0.9957 0 – 200 
Codeine y = 0.014x – 0.0675 0.9976 0 – 200 
Thebaine y = 0.0214x – 0.2152 0.9915 0 – 200 
Papaverine y = 0.019x – 0.1795 0.9952 0 – 400 
Noscapine y = 0.0735x – 0.6081 0.9985 0 – 500 
 
The coefficient of determination (R2) value for all of the alkaloid compounds is greater than 
0.99, as described in section 4.2.2, therefore this method can be described as linear for 
morphine, codeine, thebaine, papaverine and noscapine. 
 
4.5.3. Precision 
Precision was established as described in Section 4.2.3, by carrying out repeat injections at 
a number of points along the concentration range: from these repeat 9 injections, the 
percent coefficient of variation (%CV) was determined and the final results are shown in 
Table 4.7. 
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Table 4.7 %CV for morphine, codeine, thebaine, papaverine and noscapine with varying 
concentration 
Concentration 
(ng mL-1) 
Coefficient of variation (%) 
Morphine Codeine Thebaine Papaverine Noscapine 
0 0 0 0 0 0 
10 86 106 56 72 48 
15 84 69 45 117 37 
20 73 40 42 49 46 
30 47 31 44 46 33 
40 39 43 23 46 34 
50 32 47 37 36 29 
100 58 29 37 67 23 
200 30 52 52 64 122 
300 24 20 27 35 31 
400 15 47 64 57 24 
500 56 54 72 84 51 
 
From this data, it can be seen that the values are very high and in some instances, the 
coefficient of variation exceeds 100%. In validation of an analytical method, the acceptable 
coefficient of variation is 15% with 20% accepted at the lowest concentration values. In this 
case, all values, at all concentration points exceed the recommended limits. 
 
4.5.4. Solvent effects 
Due to the challenge of obtaining reproducibility of the method, a series of experiments 
were designed to establish if the solvent used for preparation of the calibration standards 
had any subsequent effect on the reproducibility of the method. Since it had already been 
found that solvent choice had significant effects on resulting chromatography in the NMR 
study (section 4.3), it was decided to vary the composition of the solvent and monitor the 
subsequent output from the instrument. Since it had already been established that the 
HPLC method produced five individual peaks for the alkaloids plus the morphine-d3 and 
that the response from a series of calibration standards was linear, it was the hypothesis 
that that the problem of variation was as a result of an effect of the mass spectrometer. In 
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order to test this hypothesis, the HPLC was excluded from this study and instead direct 
infusion to the mass spectrometer was employed. 
Mixed opiate solutions were prepared in acetonitrile, methanol: water (25:75, 50:50 and 
75:25, v/v) at concentrations of 50, 300 and 1000 ng mL-1. Each solution was introduced by 
direct infusion to the mass spectrometer and the output monitored for 2.00 minutes: each 
compound was monitored 20 times over the 2.00 minute time frame. The data for each 
compound was then used to calculate the mean ion intensity, standard deviation and the % 
coefficient of variation. Each solvent is discussed individually in the following sections. 
 
4.5.4.1. Acetonitrile 
Acetonitrile was used as the solvent and each %CV values for each of the individual 
alkaloids at 50, 300 and 1000 ng mL-1 are provided in Table 4.8, 4.9 and 4.10, respectively.  
Table 4.8 Effect on reproducibility of individual alkaloid compounds in acetonitrile (ACN) at 50 ng 
mL-1.  
 Coefficient of variation (%) 
Compound(s) Morphine Codeine Thebaine Papaverine Noscapine Morphine-d3 
Morphine (M) 67 - - - - - 
Codeine (C) - 16 - - - - 
Thebaine (T) - - 22 - - - 
Papaverine (P) - - - 12 - - 
Noscapine (N) - - - - 12 - 
M + C 99 117 - - - - 
M + d3 47 39 - - - 7 
M + T 36 - 33 - - - 
M + N 66 - - - 15 - 
M + P 80 - - 10 - - 
M + C + N 88 62 - - 14 - 
M + C + P 59 29 - 16 - - 
M + C + T 72 30 19 - - - 
M + T + N 60 - 20 - 19 - 
M + T + P 69 - 32 18 - - 
M + C + T + d3 42 22 42 - - 26 
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Table 4.9 Effect on reproducibility of individual alkaloid compounds in ACN at 300 ng mL-1 
 Coefficient of variation (%) 
Compound(s) Morphine Codeine Thebaine Papaverine Noscapine Morphine-d3 
Morphine (M) 45 - - - - - 
Codeine (C) - 16 - - - - 
Thebaine (T) - - 16 - - - 
Papaverine (P) - - - 10 - - 
Noscapine (N) - - - - 15 - 
M + C 36 23 - - - - 
M + d3 30 - - - - 16 
M + T 50 - 13 - - - 
M + N 53 - - - 11 - 
M + P 67 - - 12 - - 
M + C + N 42 18 - - 16 - 
M + C + P 21 22 - 15 - - 
M + C + T 23 15 16 - - - 
M + T + N 14 - 19 - 13 - 
M + T + P 52 - 29 10 - - 
M + C + T + d3 29 23 42 - - 7 
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Table 4.10 Effect on reproducibility of individual alkaloid compounds in ACN at 1000 ng mL-1 
 Coefficient of variation (%) 
Compound(s) Morphine Codeine Thebaine Papaverine Noscapine Morphine-d3 
Morphine (M) 42 - - - - - 
Codeine (C) - 27 - - - - 
Thebaine (T) - - 15 - - - 
Papaverine (P) - - - 15 - - 
Noscapine (N) - - - - 19 - 
M + C 135 34 - - - - 
M + d3 21 - - - - 12 
M + T 24 - 14 - - - 
M + N 86 - - - 16 - 
M + P 68 - - 79 - - 
M + C + N 29 18 - - 20 - 
M + C + P 54 26 - 26 - - 
M + C + T 58 11 30 - - - 
M + T + N 44 - 17 - 13 - 
M + T + P 46 - 46 18 - - 
M + C + T + d3 23 17 39 - - 16 
 
In acetonitrile, it appears from the data obtained that there is no correlation between the 
concentration of alkaloid and the variation observed.  
 
 
4.5.4.2. Methanol:water (25:75, v/v) 
Methanol:water (25:75, v/v) was used as the solvent and each %CV values for each of the 
individual alkaloids at 50, 300 and 1000 ng mL-1 are provided in Table 4.11, 4.12 and 4.13, 
respectively. 
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Table 4.11 Methanol:water (25:75, v/v) at 50 ng mL-1 
 Coefficient of variation (%) 
Compound(s) Morphine Codeine Thebaine Papaverine Noscapine Morphine-d3 
Morphine (M) 24 - - - - - 
Codeine (C) - 18 - - - - 
Thebaine (T) - - 19 - - - 
Papaverine (P) - - - 17 - - 
Noscapine (N) - - - - 21 - 
M + C 26 25 - - - - 
M + d3 23 - - - - 20 
M + T 21 - 40 - - - 
M + N 26 - - - 29 - 
M + P 21 - - 18 - - 
M + C + N 16 18 - - 18 - 
M + C + P 16 26 - 20 - - 
M + C + T 26 31 39 - - - 
M + T + N 17 - 40 - 44 - 
M + T + P 26 - 49 19 - - 
M + C + T + d3 28 - 39 - - 18 
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Table 4.12 Methanol:water (25:75, v/v) at 300 ng mL-1 
  Coefficient of variation (%) 
Compound(s) Morphine Codeine Thebaine Papaverine Noscapine Morphine-d3 
Morphine (M) 11 - - - - - 
Codeine (C) - 16 - - - - 
Thebaine (T) - - 19 - - - 
Papaverine (P) - - - 22 - - 
Noscapine (N) - - - - 22 - 
M + C 15 14 - - - - 
M + d3 18 - - - - 14 
M + T 17 - 23 - - - 
M + N 25 - - - 13 - 
M + P 21 - - 13 - - 
M + C + N 17 19 - - 14 - 
M + C + P 20 21 - 14 - - 
M + C + T 22 28 32 - - - 
M + T + N 24 - 25 - 11 - 
M + T + P 21 - 36 11 - - 
M + C + T + d3 24 26 41 - - 22 
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Table 4.13 Methanol:water (25:75, v/v) at 1000 ng mL-1 
  Coefficient of variation (%) 
Compound(s) Morphine Codeine Thebaine Papaverine Noscapine Morphine-d3 
Morphine (M) 15 - - - - - 
Codeine (C) - 18 - - - - 
Thebaine (T) - - 21 - - - 
Papaverine (P) - - - 11 - - 
Noscapine (N) - - - - 18 - 
M + C 20 24 - - - - 
M + d3 19 - - - - 16 
M + T 19 - 29 - - - 
M + N 16 - - - 18 - 
M + P 28 - - 22 - - 
M + C + N 26 26 - - 24 - 
M + C + P 20 20 - 16 - - 
M + C + T 22 29 47 - - - 
M + T + N 21 - 21 - 14 - 
M + T + P 15 - 25 17 - - 
M + C + T + d3 24 22 32 - - 24 
 
When methanol:water (75:25, v/v) was used, it appears that the reproducibility of this 
solvent is better when compared to the values obtained when acetonitrile was used as the 
solvent. At the lowest concentration of 50 ng mL-1, the %CV values are generally higher for 
individual alkaloids and combinations of alkaloids than were found at the highest 
concentration of 100 ng mL-1. It should be noted that the data shows that when individual 
alkaloids are introduced in this solvent, the %CV values are lower than when the compound 
is injected in a mixture with other alkaloids.   
 
 
4.5.4.3. Methanol:water (50:50, v/v) 
Methanol:water (50:50, v/v) was used as the solvent and each %CV values for each of the 
individual alkaloids at 50, 300 and 1000 ng mL-1 are provided in Table 4.14, 4.15 and 4.16, 
respectively.  
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Table 4.14 Methanol:water (50:50, v/v) at 50 ng mL-1 
 Coefficient of variation (%) 
Compound(s) Morphine Codeine Thebaine Papaverine Noscapine Morphine-d3 
Morphine (M) 7 - - - - - 
Codeine (C) - 6 - - - - 
Thebaine (T) - - 11 - - - 
Papaverine (P) - - - 3 - - 
Noscapine (N) - - - - 4 - 
M + C 16 13 - - - - 
M + d3 12 - - - - 7 
M + T 14 - 30 - - - 
M + N 12 - - - 15 - 
M + P 19 - - 9 - - 
M + C + N 10 9 - - 13 - 
M + C + P 14 8 - 9 - - 
M + C + T 14 13 21 - - - 
M + T + N 10 - 16 - 8 - 
M + T + P 15 - 23 9 - - 
M + C + T + d3 17 19 11 - - 14 
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Table 4.15 Methanol:water (50:50, v/v) at 300 ng mL-1 
 Coefficient of variation (%) 
Compound(s) Morphine Codeine Thebaine Papaverine Noscapine Morphine-d3 
Morphine (M) 7 - - - - - 
Codeine (C) - 3 - - - - 
Thebaine (T) - - 5 - - - 
Papaverine (P) - - - 3 - - 
Noscapine (N) - - - - 4 - 
M + C 18 23 - - - 6 
M + d3 6 - - - - - 
M + T 7 - 13 - - - 
M + N 8 - - - 5 - 
M + P 7 - - 7 - - 
M + C + N 14 9 - - 8 - 
M + C + P 8 5 - 5 - - 
M + C + T 8 9 10 - - - 
M + T + N 4 - 5 - 4 - 
M + T + P 10 - 12 9 - - 
M + C + T + d3 7 6 6 - - 5 
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Table 4.16 Methanol:water (50:50, v/v) at 1000 ng mL-1 
 Coefficient of variation (%) 
Compound(s) Morphine Codeine Thebaine Papaverine Noscapine Morphine-d3 
Morphine (M) 4 - - - - - 
Codeine (C) - 2 - - - - 
Thebaine (T) - - 4 - - - 
Papaverine (P) - - - 2 - - 
Noscapine (N) - - - - 3 - 
M + C 2 6 - - - - 
M + d3 3 - - - - 4 
M + T 4 - 5 - - - 
M + N 4 - - - 4 - 
M + P 4 - - 3 - - 
M + C + N 5 6 - - 4 - 
M + C + P 4 5 - 4 - - 
M + C + T 4 4 6 - - - 
M + T + N 5 - 6 - 4 - 
M + T + P 5 - 7 2 - - 
M + C + T + d3 4 3 6 - - 3 
 
 
From the data obtained for methanol:water (50:50, v/v) as the solvent, this is the best 
solvent to use as in comparison to the other two solvents discussed, this solvent has 
provided the lowest variation values at all concentrations. The %CV values found for 
individual alkaloids and for all combinations of alkaloids at 1000 ng mL-1 is very good (Table 
4.16). These results show that, in comparison to the %CV values obtained for other solvents, 
the solvent composition can have a significant effect on the reproducibility of the final 
method employed in the mass spectrometer. 
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4.5.4.4. Methanol:water (75:25, v/v) 
The final solvent used in this study was methanol:water (25:75, v/v) which was used in the 
same way as the previous solvents were. Each %CV values for each of the individual 
alkaloids at 50, 300 and 1000 ng mL-1 are provided in Table 4.17, 4.18 and 4.19, respectively.  
 
Table 4.17 Methanol:water (75:25, v/v) at 50 ng mL-1 
 Coefficient of variation (%) 
Compound(s) Morphine Codeine Thebaine Papaverine Noscapine Morphine-d3 
Morphine (M) 48 - - - - - 
Codeine (C) - 29 - - - - 
Thebaine (T) - - 48 - - - 
Papaverine (P) - - - 16 - - 
Noscapine (N) - - - - 30 - 
M + C 24 29 - - - - 
M + d3 27 - - - - 27 
M + T 29 - 40 - - - 
M + N 29 - - - 22 - 
M + P 34 - - 22 - - 
M + C + N 44 24 - - 24 - 
M + C + P 30 45 - 21 - - 
M + C + T 41 43 52 - - - 
M + T + N 37 - 38 - 18 - 
M + T + P 25 - 54 18 - - 
M + C + T + d3 36 40 51 - - 25 
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Table 4.18 Methanol:water (75:25, v/v) at 300 ng mL-1 
 Coefficient of variation (%) 
Compound(s) Morphine Codeine Thebaine Papaverine Noscapine Morphine-d3 
Morphine (M) 31 - - - - - 
Codeine (C) - 26 - - - - 
Thebaine (T) - - 38 - - - 
Papaverine (P) - - - 16 - - 
Noscapine (N) - - - - 20 - 
M + C 23 24 - - - - 
M + d3 39 - - - - 23 
M + T 22 - 33 - - - 
M + N 24 - - - 27 - 
M + P 27 - - 14 - - 
M + C + N 42 26 - - 27 - 
M + C + P 30 24 - 17 - - 
M + C + T 17 33 36 - - - 
M + T + N 32 - 26 - 15 - 
M + T + P 21 - 43 13 - - 
M + C + T + d3 57 23 36 - - 193 
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Table 4.19 Methanol:water (75:25, v/v) at 1000 ng mL-1 
 Coefficient of variation (%) 
Compound(s) Morphine Codeine Thebaine Papaverine Noscapine Morphine-d3 
Morphine (M) - - - - - - 
Codeine (C) - 14 - - - - 
Thebaine (T) - - 42 - - - 
Papaverine (P) - - - 13 - - 
Noscapine (N) - - - - 21 - 
M + C 37 33 - - - - 
M + d3 26 - - - - 27 
M + T 31 - 30 - - - 
M + N 27 - - - 11 - 
M + P 27 - - 16 - - 
M + C + N 44 20 - - 21 - 
M + C + P 25 19 - 14 - - 
M + C + T 24 27 42 - - - 
M + T + N 30 - 24 - 18 - 
M + T + P 25 - 34 16 - - 
M + C + T + d3 27 16 32 - - 20 
 
 
When the proportion of methanol was increased to 75% (25% water), the variation also 
increases: even at the highest concentration of 1000 ng mL-1, high %CV values were 
obtained for individual alkaloids. Again, as is seen with acetonitrile, there appears to be no 
correlation between the concentration and the combination of alkaloids in solution. 
When considering all of the data for all of the solvents in this study, the variation of %CV 
values when other alkaloids are present may be due to a phenomenon known as matrix 
effects or competitive ionisation, which has been reported to occur in the ionisation step 
LC-MS methods.238,257-259  Matrix effects can be defined as the variation of ionisation 
efficiency due to the presence of co-eluting or other interfering substances from the 
matrix.257 In 2004, Tang et al.260 reported that it was possible to obtain linearity with a 
mixture of compounds (reserpine, caffeine and MRFA) even though competitive ionisation 
using ESI-MS was found. It was found in this study that it was possible to prove that the ion 
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signals for caffeine and MRFA were suppressed in the presence of caffeine in a solvent 
system of methanol:water (50:50, v/v) + 1% acetic acid: the authors suggested that 
reducing the flow rate of mobile phase greatly increases the sensitivity of the ESI-MS 
system. The suggested flow rates were found to be in the nano range (10 – 100 nL min-1). In 
the same article, it was stated that the competition between the compounds will be 
affected by the number of ions in solution. At this current time, the exact mechanism of 
action of competition between ions remains unknown.257 
It was not possible to adapt the LC-MS method being employed in this work to nano range 
flow rates due to the limitations of the instrument. However, in 2002 it was reported by 
Matz and Hill261 that the solvent can significantly affect the ionisation in ESI-MS systems. In 
an experiment where methanol:water (50:50, v/v) was used in the analysis of a mixture of 
amphetamine compounds, it was found that at high concentration, competitive ionisation 
occurred in the presence of six amphetamine compounds in a mixture. It was found that 
the solvent decreased the competitive ionisation but also reduced the sensitivity of the 
method. However, by adding either 5% acetic acid or 1% formic acid, it was also shown that 
the competition between ions was greater. Since the established LC-MS method in this 
work required the formic acid in order to maintain the thebaine (and the other alkaloids) in 
an appropriate form to obtain one peak and a linear relationship between concentration 
and peak area ratio, it was concluded that the removal of the modifier (formic acid) was 
not appropriate. 
From this point on, even though it had not been included in the solvent study, the mobile 
phase A (water + 2 mM ammonium formate + 0.2% formic acid) was used to prepare the 
standards and any samples/quality control (QC) solutions. It is recommended that 
samples/standards are prepared in the mobile phase used at the beginning of the HPLC 
method in order to avoid potential problems with mixing of different solvents which 
ultimately have an impact on ionisation.262   
 
 Comparison with LC-ESI-MS (triple quadrupole) 4.6.
In order to determine if the results obtained from the method used on the LC-ESI-MS 
method were due to limitations of the particular instrument or were in fact the true results, 
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the method was transferred to a LC-ESI-MS triple quadrupole instrument in the toxicology 
department of the Institut de Recherche Criminelle de la Gendarmerie Nationale (IRCGN).  
Instrument specific information is provided in section 4.1.2.2. In order to establish the 
method using the triple quadrupole instrument, it was necessary to prepare stock solutions 
of each of the five opium alkaloids in methanol at a concentration of 100 ng mL-1. Each 
individual standard was directly infused to the mass spectrometer, including the internal 
standard (morphine-d3) and the instrument set to optimise the system for each compound 
as had been carried out in the development of the LC-ESI-MS method recently discussed. 
The Q1 and Q3 masses obtained for each of the five alkaloids are shown in Table 4.20. Each 
of the Q3 ions were extracted, the signal and peak shapes produced were examined and a 
decision made on which ions were best to use for identification and subsequent 
quantitation. These decisions were based on the quality of the peak produced and the 
strength of the signal for each ion. 
 
Table 4.20 Analyte specific parameters for 4500 QTRAP tandem mass spectrometer. DP-
declustering potential; EP – entrance potential; CXP – collision cell exit potential. (* - ion used for 
quantitation) 
Compound Q1 mass Q3 Mass 
transitions 
(m/z) 
Collision 
Energy 
(eV) 
DP 
(V) 
EP 
(V) 
CXP 
(V) 
Morphine 286 286 → 153 
286 →165* 
49 
47 
90 
90 
10 
10 
10 
6 
Codeine 300 300 → 215* 
300 →165 
33 
43 
91 
91 
10 
10 
6 
6 
Thebaine 312 312 → 266* 
312 →152 
21 
29 
50 
50 
10 
10 
8 
6 
Papaverine 340 340 → 171* 
340 →324 
45 
39 
81 
81 
10 
10 
14 
10 
Noscapine 414 414→ 353* 
414→220 
29 
27 
90 
90 
10 
10 
10 
6 
Morphine-d3 289 289 →152 
289 →165* 
47 
47 
90 
90 
10 
10 
12 
4 
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As described in Section 3.1.2.1, the method of ionisation can vary in mass spectrometry 
depending upon the type of instrument used. In this work, both instruments employed 
electrospray ionisation (ESI) but the energy used to cause the ionisation varies. The energy 
required to cause fragmentation is specific to the instrument and to the analytes. In the 
case of the LC-ESI-MS instrument, the specific energies required to cause fragmentation are 
shown in Table 4.4 and the energies employed with the LC-ESI-tandem mass spectrometer 
are provided in Table 4.20. Depending upon the energy used, different product ions 
(fragment ions) can be formed: the suggested fragment ions formed in both instruments 
are provided for morphine (Figure 4.17), codeine (Figure 4.18), thebaine (Figure 4.19), 
papaverine (Figure 4.20) and noscapine (Figure 4.21).  
 
 
 
Figure 4.17 Proposed fragments formed from morphine during ionisation in (A) LC-ESI-MS and (B) 
LC-MSn instruments263-265 
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 Figure 4.18 Proposed fragments formed from codeine during ionisation in (A) LC-ESI-MS, (B) LC-
MSn and (C) both instruments263-265 
 
 
 
Figure 4.19 Proposed fragments formed from thebaine during ionisation in (A) LC-ESI-MS, (B) LC-
MSn instruments232 
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 Figure 4.20 Proposed fragments formed from papaverine during ionisation in (A) LC-ESI-MS, (B) LC-
MSn and (C) both instruments266 
 
 
Figure 4.21 Proposed fragments formed from noscapine during ionisation in both LC-ESI and LC-
MSn instruments266 
 
Once the optimum settings for the mass spectrometer were established the instrument 
was set up with the HPLC mobile phase gradient method, and the Allure™ 
pentafluorophenyl phase with a propyl spacer (PFPP) column as used previously in this 
work. An initial injection of a mixture of morphine, codeine, thebaine, papaverine, 
noscapine and morphine-d3 was introduced in order to establish if the method still 
provided detection of all alkaloids and the internal standard. Resulting chromatograms for 
all compounds are shown in Figure 4.22 proving that the method successfully detected the 
alkaloids of interest. 
97 
 
 
 Figure 4.22 Chromatogram showing all five alkaloids separated using PFPP column and LC-MSn 
tandem mass spectrometer. The quantitation ion highlighted in Table 4.20 was used (a) morphine, 
(b) morphine-d3, (c) codeine, (d) thebaine), (e) papaverine, (f) noscapine 
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To establish if linearity was achieved using this method on the LC-MSn instrument, three 
mixed calibration solutions containing morphine, codeine, thebaine, papaverine and 
noscapine were prepared in the aqueous mobile phase at 20 ng mL-1 and at 200 ng mL-1 
and each solution was analysed in triplicate. The resulting chromatograms are shown in 
Figure 4.23. Blanks of aqueous mobile phase were run at the beginning and end of the 
sequence and in between solution run in triplicate. To the mixed solutions, deuterated 
morphine (morphine-d3) as an internal standard was added at a concentration of 100 ng 
mL-1; these are the same conditions as had been used in the LC-ESI-MS (ion trap) method. 
Only the lowest concentration and highest concentration values were used to verify that 
linearity could be established and to determine the relative standard deviation for 
comparison with the current data set. This limited data acquisition was due to constraints 
of instrument time.  
As can be seen in the chromatograms shown in Figure 4.23, the repeat injections for 
morphine, codeine, thebaine, papaverine, noscapine and morphine-d3 all show good peak 
shape and reproducible retention times using this instrument. Even though the peaks for 
papaverine and noscapine have similar retention times (8.99 and 9.01 minutes, respectively) 
because different ion transitions are being monitored it is possible to be certain that each 
peak relates to a separate compound. 
In order to assess precision of the method and thus compare the findings to the original LC-
ESI-MS method, a 20 ng mL-1 and a 200 ng mL-1 mixed solution was prepared three times 
and each was injected in triplicate. Blank aqueous mobile phase was injected at the 
beginning and end of the sequence, as well as between each data set. The resulting peak 
area for each of the alkaloids and peak area for morphine-d3 were used to obtain peak 
area ratios with the final data provided in Table 4.21. 
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a.           d. 
  
b.          e. 
  
c.          f. 
  
Figure 4.23 Chromatograms for (a) morphine, (b) codeine, (c) thebaine, (d) papaverine, (e) noscapine, (f) morphine-d3 in triplicate 
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Table 4.21 Peak area ratios for morphine, codeine, thebaine, papaverine and noscapine 
 Coefficient of variation (%) 
Data 
set 
Concentration 
(ng mL-1) 
Morphine Codeine Thebaine Papaverine Noscapine 
1 20 22 18 71 97 105 
 200 6 47 5 8 7 
2 20 21 14 11 9 10 
 200 25 27 12 11 13 
3 20 46 16 8 10 8 
 200 2 6 9 7 5 
 
It can be noted that for data set 1 the coefficient of variation values for morphine, thebaine, 
papaverine and noscapine do not meet the ≤ 20% accepted response for the value close to 
the LOQ of 20 ng mL-1. Only codeine has a value of 18% which is just under this 20% limit. In 
comparison, codeine is the only compound of the 5 alkaloids to be in excess of the 15% 
limit whereas the others fall considerably below, showing acceptable results for the 
solutions at a concentration of 200 ng mL-1. For data set 2, morphine has a %CV value of 
21%, just over the 20% limit but all other alkaloids are below 15% at 20 ng mL-1; in 
comparison, at 200 ng mL-1 morphine and codeine are considerably higher (25% and 27%, 
respectively) than the 15% limit expected at this concentration. On the other hand, 
thebaine, papaverine and noscapine all have %CV values lower than 15%. 
Finally, for data set 3, morphine shows a large %CV value of 46% at 20 ng mL-1 however 
codeine, thebaine, papaverine and noscapine all fall considerably below the acceptable 
limit of 20%. For the alkaloids at 200 ng mL-1, all were found to be considerably lower than 
the 15% limit.  It appears that there are limited data consistencies between the three data 
sets. For example, if all of the %CV values for all of the alkaloids at 20 ng mL-1 were 
consistently higher than 20% it might be considered that 20 ng mL-1 was below the 
acceptable lowest limit of quantitation however, this is not the case. It may also be 
expected that at a higher concentration of 200 ng mL-1 that there may be less variation due 
to the fact that peak area are larger however, again, this is not seen to be the case in this 
instance. A comparison of the combined data for all 20 ng mL-1 injections and all 200 ng mL-
1 injections was carried out and the results provided in Table 4.22. 
101 
 
 
Table 4.22 Mean (x�), standard deviation (σx) and co-efficient of variation (%CV) for cumulative 
data for each of the five alkaloids at 20 ng mL-1 and 200 ng mL-1 
Compound Morphine Codeine Thebaine Papaverine Noscapine 
Concentration 
(ng mL-1) 
Parameter  
20 x� 0.06 0.97 2.05 5.24 6.58 
 σx 0.02 0.15 0.70 2.19 2.89 
 %CV 29 16 34 42 44 
200 x� 0.62 10.64 22.84 74.83 75.35 
 σx 0.12 3.14 5.72 24.31 7.06 
 %CV 19 29 25 32 9 
 
Using this combined data, calibration graphs were constructed in order to establish if the 
data obtained using this instrument was linear. Although using a two-point calibration , 
including a blank is not best practice for method validation, it was employed only to 
determine if the relationship between concentration and peak area ratio and the values for 
coefficient of determination were acceptable; the linear equation and R2 values for each of 
the alkaloids is provided in Table 4.23. 
 
Table 4.23 Linear equations and associated R2 values for the five major opium alkaloids 
Compound Linear equation R2 
Morphine y = 0.0031x + 0.0009 1 
Codeine y = 0.0534x – 0.0461 0.9999 
Thebaine y = 0.1147x – 0.1152 0.9999 
Papaverine y = 0.3791x – 1.106 0.9992 
Noscapine y = 0.3789x – 0.4734 0.9999 
 
 
As was found with the LC-ESI-MS method, linearity can be achieved using the LC-ESI-MSn 
method however an unresolved issue with reproducibility remains.   
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5. ANALYSIS OF POPPY SEEDS AND POPPY SEED CONTAINING FOOD PRODUCTS  
 Experimental 5.1.
5.1.1. Chemicals, reagents and poppy seeds 
Organic solvents (methanol, acetonitrile, chloroform, isopropyl alcohol) of HPLC grade were 
purchased from Sigma-Aldrich (Poole, Dorset). Deuterated morphine (100 μg mL-1) in 
methanol was purchased from Sigma Aldrich (Poole, Dorset). Liquid nitrogen was obtained 
from BOC Industrial Gases (Manchester). Poppy seeds were purchased from a number of 
supermarkets in the UK with the country of origin, where available, provided in Table 5.1: 
the supermarket name has not been included but each brand has been assigned a number 
for reference. 
Table 5.1 Poppy seed brand and country of origin 
Poppy seed source 
reference 
Country of origin 
#1 China 
#2 Unknown 
#3 Turkey 
#4 Unknown 
#5 Holland 
#6 Netherlands 
#7 Unknown 
#8 Netherlands 
 
 
5.1.2. LC-MS instrument 
HPLC was performed using an LC Surveyor system (Thermo Finnigan, Hemel Hempsted, UK ) 
which was equipped with a pump,  auto-sampler and column heater. Mass spectrometry 
was performed using an LCQ advantage (Thermo Finnigan, Hemel Hempsted, UK) ion trap 
mass spectrometer. The mass spectrometer was operated in a positive electrospray 
ionisation mode using the method established through the studies reported in chapter 4. 
103 
 
 
5.1.3. Calibration graphs and calculations 
Calibration solutions were prepared in mobile phase on the day of analysis of each of the 
poppy seed extractions. The resulting equations from the calibration were used to 
determine the concentration of the solution of poppy seeds and the final alkaloid levels in 
ng g-1 were determined by taking into account the dilution factor from the solvent and the 
original weight of the poppy seeds used.  The method for the extraction of alkaloids from 
poppy seeds included the addition of deuterated internal standard prior to extraction (see 
section 5.2.1). 
 
5.1.4. Preparation of poppy seeds and poppy seed containing products  
5.1.4.1. Poppy seed muffins 
Mini poppy seed muffins were prepared by mixing together 175 g of self-raising flour, 112 g 
of caster sugar, 50 g of poppy seeds, ½ teaspoon of bicarbonate of soda, 70 g of melted 
butter, two small eggs, the zest of one lemon and 175 mL of skimmed milk. The ingredients 
were mixed into a batter and added to each of the dimples of mini-muffin trays purchased 
from Lakeland (Cumbria). The trays were then placed into an electric oven set to 180 OC 
and left to cook for 15 minutes. The final weight of poppy seeds in each mini-muffin was 
approximately 1.8 g. They were then left to cool to room temperature. Each poppy seed 
muffin weighed approximately 20 g.  The poppy seed muffins were immersed in liquid 
nitrogen, crushed using a mortar and pestle and transferred to a spice blender for 
homogenisation prior to extraction and analysis by LC-MS using the method detailed 
below. 
 
5.1.4.2. Poppy seed topped rolls/buns 
A comparative study was carried out to establish if there was a difference between alkaloid 
levels resulting from poppy seeds incorporated into the matrix of the muffin to those 
resulting from poppy seeds coated onto a bread roll. The dough for the rolls was prepared 
using 280 g of strong white bread flour, 1 ½ tablespoons of sugar, 1 teaspoon of salt, ¾ 
teaspoon of fast action yeast, 2 tablespoons of skimmed milk powder, 150 mL of water and 
2 tablespoons of oil. The dough was mixed in a commercially available Morphy Richards 
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compact bread maker (using the “dough” program) made available in the food technology 
laboratory. The dough was then split into 4 equal portions and each one was pressed into 
poppy seeds. The rolls were then placed into an oven at 190 OC and left to cook for 25 
minutes, according to the recipe of the bread mix. The rolls were left to cool to room 
temperature and the poppy seeds were scraped from the surface using a metal spatula and 
homogenised in a spice blender prior to extraction and analysis by LC-MS using the method 
detailed below. 
 
5.1.4.3. Thermally processed poppy seeds  
In order to assess if the muffin matrix had any effect on the level of alkaloids found in the 
poppy seeds, raw poppy seeds from different suppliers were placed on a baking tray and 
heating at 180 OC for 15 minutes: they were then left to cool to room temperature, 
homogenised in a spice blender prior to extraction and analysis by LC-MS using the method 
detailed below. 
 
 Results and Discussion 5.2.
5.2.1. Extraction of alkaloids from poppy seeds  
Meadway, et al.70 reported a method for the extraction of alkaloid compounds from poppy 
seeds which included the use of an aliquot of a solution of saturated ammonium chloride 
with concentrated ammonium solution at a pH of 9.0. The alkaloids were then extracted 
using chloroform:isopropanol (90:10, v/v) and back extracted into 0.5 M sulphuric acid. 
When this method was attempted in the laboratory, it was found that the final extracted 
product contained mostly oily residue, which was not readily miscible with the aqueous 
mobile phase used as the solvent for reconstitution. Since it is known that poppy seed oil 
can be extracted from poppy seeds8,267,268, it was concluded that the extraction method was 
not as selective as desired and an alternative extraction method should be identified.  
Seven solvents, which covered a broad range of polarity index values, and the 
chloroform:isopropanol (90:10, v/v) solvent used in the above-mentioned study were 
chosen for comparison. A list of the solvents and associated polarity index values are 
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provided in Table 5.2, where a lower polarity index value indicates a solvent of lower 
polarity. 
Table 5.2 Extraction solvents and associated polarity index values 
Solvent Polarity index 
(Snyder)269 
Diethyl ether 2.8 
Dichloromethane 3.1 
Chloroform 4.1 
Isopropanol 4.3 
Acetonitrile 5.8 
Methanol 6.6 
Water 9 
Chloroform/isopropanol (90:10, v/v) Unknown 
 
For each solvent, extractions were carried out at pH 3.5, pH 5.0, pH 7.0 and pH 9.0 in order 
to obtain the optimum extraction conditions for the alkaloids from the poppy seeds. In 
order to avoid contamination by plastic residues from pipette tips by the solvents, glass 
pipettes were employed.  
Poppy seeds from a batch of the #1 seeds were homogenised using a spice blender and 
approximately 200 mg of the seeds were weighed into glass tubes (4 tubes for each of the 
solvents). For each solvent, pH was altered to produce a solution of poppy seeds and 
solvent (1 mL) at pH 3.5, pH 5.0, pH 7.0 and pH 9.0. To each solution, deuterated internal 
standard (morphine-d3) was added. The tubes were then capped and placed into an 
ultrasonic bath for 10 minutes, centrifuged at 4000 rpm for 10 minutes. The appropriate 
layer was transferred to a clean glass tube, where it was dried down under nitrogen at 40oC 
and reconstituted in 100 μL of aqueous mobile phase: extracts were filtered using a 0.22 
μm nylon syringe filter before being transferred to a glass insert held in an auto-sampler 
vial for the LC-MS instrument.  
The resulting chromatograms were obtained for each of the alkaloid compounds and were 
compared with respect to the presence of alkaloid and internal standard peaks, peak shape, 
and interferences from the matrix/solvent combination. It was found that at the extremes 
of the polarity scale (diethyl ether, dichloromethane and water), the chromatograms 
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produced were very complex and peak shape of alkaloids was very poor, independent of 
pH.  
In contrast, the best result, in terms of alkaloid presence and peak shape, was obtained 
using chloroform:isopropanol (90:10, v/v) but at pH 3.5. For this reason, this extraction 
solvent was used for the extraction of alkaloids from harvested (raw), and all thermally 
processed poppy seeds. 
 
5.2.2. Alkaloids in poppy seeds and poppy seed products 
5.2.2.1. Harvested poppy seeds  
Raw/harvested poppy seeds were purchased from different supermarkets: the source 
reference and country of origin for each of the poppy seed batches is provided in Table 5.1. 
No information was available from the supermarkets on processing that may have occurred 
prior to packaging and distribution of the poppy seeds and no information was available on 
the exact sub-species of Papaver somniferum L. plant harvested for the supply of the poppy 
seeds to the supermarkets. Seeds were extracted using the method described in section 
5.2.1 and analysed by LC-MS using the method described in section 4.4.  From each batch 
of poppy seeds, a minimum of 6 different portions weighing approximately 200 mg were 
extracted and analysed. 
For each source, the mean weight of each of the alkaloids in poppy seeds was calculated 
and the range was identified. When the levels of morphine in poppy seeds from each of the 
different sources was compared (Table 5.3), it was found that there was much variation 
within batch but also between sources of poppy seeds. For example, no morphine was 
identified in any of the 15 randomly selected portions of seeds from source #4 however 
from source #2, when 15 randomly selected portions of these seeds were analysed, the 
levels of morphine ranged from 2,638 – 63,994 ng g-1. The country of origin for both of 
these sources is unknown. 
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Table 5.3 Range and mean weight of morphine (ng) per gram of poppy seeds 
Poppy seed source 
reference 
Mean weight of morphine 
(ng g-1) 
Range 
(ng g-1) 
#1 1233 233 – 3,197 
#2 29,652 2,638 – 63,994 
#3 121 0 – 769 
#4 ND ND 
#5 5,840 864 – 10,837 
#6 1,620 141 – 4,223 
#7 1,059 0 – 4,754 
#8 62 0 – 312 
ND – not detected 
 
When the same comparison was carried out for codeine (Table 5.4) it was also found that 
there was much variation within batch and between sources of poppy seeds as was the 
case with morphine. Source #2, which was found to have a level of morphine much higher 
than the other sources, was also found to have a higher level of codeine. No other 
similarities can be drawn from the data. 
 
Table 5.4 Range and mean weight of codeine (ng) per gram of poppy seeds 
Poppy seed source 
reference 
Mean  weight of codeine 
(ng g-1) 
Range 
(ng g-1) 
#1 2,308 1,426 – 4,520 
#2 8,507 474 – 23,307 
#3 157 0 – 651 
#4 72 52 – 106 
#5 2,610 0 – 5,441 
#6 153 61 – 349 
#7 5,688 236 – 14,607 
#8 117 94 – 157 
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When this same comparison was carried out for thebaine (Table 5.5) it was found that of 
the poppy seeds analysed, 50% of the sources seeds did not contain thebaine. It was found 
that the same source with the highest levels of morphine and codeine also exhibited 
highest levels of thebaine.  
 
Table 5.5 Range and mean weight of thebaine (ng) per gram of poppy seeds 
Poppy seed source 
reference 
Mean weight of 
thebaine (ng g-1) 
Range 
(ng g-1) 
#1 1,251 285 – 2,480 
#2 42,950 1,977 – 133,493 
#3 ND ND 
#4 ND ND 
#5 6,363 841 – 12,561 
#6 112 0 – 343 
#7 ND ND 
#8 ND ND 
ND – not detected 
 
Noscapine was identified in only 2 of the 8 sources of poppy seeds (Table 5.6). It was found 
that the seeds from source #7 contained the highest levels of noscapine of the two sources 
where noscapine was identified. When the levels of the other alkaloids present in source 
#7 seeds, it was found that morphine (0 – 4,754 ng g-1) and codeine (2,361 – 14,607 ng g-1) 
were also identified at levels in the higher range with the respect to the other sources.  
Papaverine was detected in some of the analysed seeds but peaks were so small that it was 
not possible to quantify them.  
Source #2 was found to contain morphine (2638 – 63,994 ng g-1), codeine (474 – 23,307 ng 
g-1) and thebaine (1,977 – 133,493 ng g-1) at levels higher in comparison to other sources. It 
has been identified that sub-varieties of Papaver somniferum L. will have different alkaloid 
content and compositions.57,88 However, this taxonomic information was not available from 
the suppliers of the seeds. 
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Table 5.6 Range and mean weight of noscapine (ng) per gram of poppy seeds 
Poppy seed source 
reference 
Mean weight of 
noscapine (ng g-1) 
Range 
(ng g-1) 
#1 ND ND 
#2 ND ND 
#3 ND ND 
#4 ND ND 
#5 534 0 – 2,970 
#6 ND ND 
#7 2,224 291 – 10,700 
#8 ND ND 
ND – not detected 
 
It has been known since 1920270  that factors, such as, the season in which the plants are 
grown, weather conditions and quality and type of fertiliser used can greatly affect the 
levels of alkaloids biosynthesised by Papaver somniferum L. In turn, the levels of alkaloids 
found in opium latex will also be affected. No data currently exist that compares levels of 
alkaloids in opium latex and alkaloids from the same plant but it is assumed that the levels 
would correlate. On this basis, the country of origin, where the plant was grown in the field 
(e.g. in the shade or direct sunlight), the quality of the soil can all affect the levels of 
alkaloids in the poppy seeds obtained from the plant.76,87 This means that if a batch of 
poppy seeds are harvested from one field, naturally there will be variation in the levels of 
alkaloids from each of the plants. It is also possible that a batch of poppy seeds is the 
combination of multiple fields in one country. These factors may explain why there is such 
variation within batch and between sources of poppy seeds as discussed above. 
 
5.2.2.2. Harvested versus thermally processed poppy seeds  
A comparison was carried out to establish if there was a difference in the levels of alkaloids 
identified between harvested poppy seeds, as described above, poppy seeds which were 
baked on top of a bread roll, poppy seeds incorporated into a muffin matrix, and poppy 
seeds heated in an oven in the absence of bread/muffin matrix.   
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Harvested poppy seeds were prepared for analysis as described in Section 5.2.2.1. 
Thermally processed poppy seeds were prepared for analysis as described in Section 
5.1.3.3. Poppy seed muffins and poppy seed topped rolls were prepared for analysis as 
described in Sections 5.1.3.1 and 5.1.3.2, respectively.  For each source of harvested poppy 
seeds, poppy seeds heated without matrix, and poppy seeds scraped from the bread roll, 
15 randomly selected portions weighing approximately 200 mg were extracted and 
analysed.  
For the poppy seed muffins, approximately 400 mg of homogenised poppy seed/muffin 
mixture was extracted. However, the muffin matrix greatly interfered with the extraction 
process. When the chromatograms were analysed for the extracted muffins, no alkaloids 
were identified therefore results have not been included in this discussion. 
The seeds from 3 randomly selected sources were extracted and analysed with the results 
shown in Table 5.7. Again, as was established with extractions of harvested poppy seeds 
(Section 5.2.2.1) there was much variation in the alkaloids identified and also in the levels 
of those alkaloids present. 
 
Table 5.7 Comparison of levels of alkaloids identified in harvested poppy seeds, seeds from the surface of 
bread rolls and seeds heated with no matrix   
 Harvested Seeds on bread roll Heated (no matrix) 
Source 
reference 
Alkaloid Mean 
(ng g-1) 
Range 
(ng g-1) 
Mean 
(ng g-1) 
Range 
(ng g-1) 
Mean 
(ng g-1) 
Range 
(ng g-1) 
#1 Morphine 
Codeine 
545 
82 
8 – 1,888 
0 – 284 
11 
3 
0 – 33 
0 – 27 
63 
5 
0 – 304 
0 – 54 
#6 Morphine 
Codeine 
Papaverine 
Noscapine 
217 
175 
11 
34 
0 – 431 
0 – 418 
0 – 64 
0 – 80 
1 
3 
ND 
ND 
0 – 11 
0 – 21 
ND 
ND 
ND 
ND 
ND 
ND 
ND 
ND 
ND 
ND 
#8 Morphine 
Codeine 
25 
30 
0 – 96 
0 – 81 
ND 
5 
ND 
0 - 19 
15 
11 
0 – 49 
0 – 52 
ND – not detected 
 
What was identified from this data was that whether the seeds were heated on the surface 
of the bread roll or were heated with no bread matrix, the levels of alkaloids (if detected) 
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were considerably lower than in the harvested seeds. Koleva et al.271 reported that 
morphine content could be reduced by 10-50% in the process of baking and Sproll et al.75 
reported that the process of grinding and baking could reduce the morphine content of 
poppy seeds by up to 84%. 
When comparing the results from the current work to levels published in the literature 
(Table 5.8) it can be seen that these findings are in-keeping with those published by Sproll 
et al.76, published in 2006. This group of researchers employed an LC/MS/MS method for 
the detection of morphine, codeine, papaverine and noscapine in poppy seeds. The work 
published by Grove et al.272 from 1976 appears to show much lower levels for morphine 
and codeine. However, this could have been due to the sensitivity of the GC-MS instrument 
employed.  
 
Table 5.8 Comparison of alkaloids identified in poppy seeds 
 Current work Grove et al.272 (1976) Sproll et al.76 (2006) 
Compound Range (ng g-1) 
Morphine 0 – 63,994 600 – 2,300 1,000 – 270,000 
Codeine 0 – 23,307 100 – 500 0 – 56,000 
Thebaine 0 – 133,493 NI NI 
Papaverine ND NI ND 
Noscapine 0 – 10,700 NI 0 – 21,000 
ND – not detected; NI – not included in the study 
 
The levels of alkaloids identified in the current work are generally lower than those found 
by Sproll et al.76 but this could be due to the same factors that may influence the levels of 
alkaloids in poppy seeds (highlighted in section 5.2.2.1). 
It was clear from the data obtained in this current work, and from other studies published 
in the literature, that there is much variation in the levels of alkaloids identified in poppy 
seeds. This variation can be attributed to a variety of natural parameters, such as weather 
and soil conditions, but also in the way that the seeds are harvested.72  Processing methods 
prior to packaging and even the baking process has been shown to greatly affect the level 
of alkaloids.75 The findings of this study correlate with the studies published in the 
literature.  
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When poppy seeds are consumed on a bun or roll, it has been estimated that each roll 
contains 1 – 4 g of poppy seeds.72 Due to the reduction of the levels of alkaloids in the 
baking process, it has been estimated that if the poppy seeds contained 100,000 ng g-1 of 
morphine, the amount of seeds ingested would not cause any significant effect on an 
individual.76 The implications of the ingestion of 1-4 g of baked poppy seeds with respect to 
workplace and roadside drug testing will be discussed in Chapter 6. 
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6. TOXICOLOGY OF POPPY SEED ALKALOIDS IN ORAL FLUID 
 Experimental  6.1.
6.1.1. Reference material and intermediate stock solutions  
Morphine, codeine and morphine-d3 were all prepared from reference standards in 1 mL 
ampoules purchased from Cerilliant (LGC Promochem). These morphine and codeine (1 mg 
mL-1) standards were transferred into 10 mL volumetric flasks and filled to volume with 
methanol producing 100 μg mL-1 intermediate stocks.  
Thebaine, papaverine hydrochloride and noscapine were all purchased in powder form 
from Sigma Aldrich and stock solutions of approximately 1 mg mL-1 in methanol were 
prepared. The final concentrations of free opiate for thebaine, papaverine and noscapine 
were 1.15 mg mL-1, 1.26 mg mL-1 and 1.21 mg mL-1, respectively. A mixed intermediate 
stock solution in methanol of approximately 10 μg mL-1 was prepared for thebaine, 
papaverine and noscapine (11.5, 12.6 and 12.1 μg mL-1, respectively). 
Phosphate buffer was prepared by dissolving 6.8 g of potassium dihydrogen phosphate in 
400 mL of deionized water, the pH of which had been adjusted to 6.0 using 1 M potassium 
hydroxide solution. This was then made up to 500 mL in a volumetric flask with deionized 
water. 
Morphine-d3 was used as the internal standard and was purchased from LGC Promochem 
as a 100 μg mL-1 reference standard in methanol. This was transferred to a 10 mL 
volumetric flask and filled to volume with methanol, producing a 10 μg mL-1 intermediate 
stock. From this, a 1000 ng mL-1 working solution of the morphine-d3 was prepared in 
methanol.  
 
6.1.2.  LC-MS instrument and analytical method  
Due to instrument failure of the Thermo LC-ESI-MS and it being decommissioned, it was 
necessary to transfer the original method to another LC-MS instrument in the Faculty. The 
instrument made available was a Dionex™ UltiMate™ 3000 liquid chromatograph 
hyphenated to a Q-Exactive™ hybrid quadrupole orbitrap mass spectrometer (Thermo 
Finnigan, Hemel Hempsted, UK) and was employed for the toxicology study. The column 
used was the same Allure™ pentafluorophenyl phase with a propyl spacer (PFPP) column, 5 
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μm, 50 x 2.1 mm fitted with a guard column (Thames Restek, Buckinghamshire, UK) 
thermostated to 40oC, which had been employed previously. The HPLC method used is 
shown in Table 6.1. 
 
Table 6.1 Mobile phase composition and gradient program 
Mobile phase composition 
Solvent A: Water + 2 mM ammonium formate + 0.2% formic acid 
Solvent B: Acetonitrile + 2 mM ammonium formate + 0.2% formic acid 
Time (minutes) %A %B Flow rate (μL min-1) 
0.00 90 10 350 
2.00 90 10 350 
10.00 10 90 350 
11.00 10 90 350 
12.00 90 10 350 
14.00 90 10 350 
 
The mass spectrometer was operated in a positive electrospray ionisation mode with the 
analyte specific settings shown in Table 6.2. As with all other mass spectrometers 
employed in this research, the mass spectrometer settings were established by directly 
infusing a 100 ng mL-1 solution of each of the five alkaloids and the deuterated internal 
standard (morphine-d3). 
 
Table 6.2 Analyte specific parameters for Q-Exactive™ mass spectrometer. CID – in-source collision induced 
dissociation energy. *-ion used for quantitation 
Compound [M-H+] mass 
(Da) 
Monitored transition 
mass (m/z) 
CID  
(eV) 
Morphine 286* 286 → 201, 229 55 
Codeine 300* 300 → 215, 243 52 
Thebaine 312* 312 → 58, 249, 281 20 
Papaverine 340* 340 → 202, 324 40 
Noscapine 414* 414 → 220, 353 25 
Morphine-d3 289* 289 → 201, 229 55 
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Data obtained from the Q-Exactive™ instrument was analysed using XCaliber 3.0 software 
package supplied with the ThermoFinnigan instrument.  
 
6.1.3. Solid phase extraction procedure 
Bond Elut Certify (130 mg bed mass, 3 mL volume) mixed mode cartridges were used. The 
cartridges employ both a non-polar sorbent (C8) and a strong cation exchanger and these 
types of mixed mode SPE cartridges have been successfully employed in the extraction of 
opiates from biological matrices.79,191,273-276 The SPE method was designed using a 
combination of a number of scientific papers, SPE guides from SPE column manufacturers 
and personal experience.74,79,154,185,277 
The cartridge was conditioned with 2 mL of methanol followed by 2 mL of phosphate buffer 
(0.1 M, pH 6.0). The oral fluid sample was loaded and allowed to drip through under gravity. 
The cartridges were then washed with 1 mL of water, followed by 500 μL of 0.01 M formic 
acid. The cartridge was then air dried for 10 minutes under full vacuum, then 50 μL of 
methanol was added and the cartridge was dried for a further 2 minutes. 
The basic opiate drugs were eluted using 2 x 1 mL of methanol: ammonia (98:2, v/v) which 
was prepared on the day the extractions were carried out. The final extracts were 
evaporated under nitrogen at 40oC and reconstituted in 100 μL aqueous mobile phase (A). 
Each reconstituted extract was subsequently filtered through a 0.22 μm nylon syringe filter 
before being transferred to a glass insert held in an auto-sampler vial for the LC-MS 
instrument.  
 
6.1.4. Preparation of poppy seed containing products – mini muffins 
Mini poppy seed muffins were prepared by mixing together 175 g of self-raising flour, 112 g 
of caster sugar, 50 g of poppy seeds, ½ teaspoon of bicarbonate of soda, 70 g of melted 
butter, two small eggs, the zest of one lemon and 175 mL of skimmed milk. The ingredients 
were mixed into a batter and this was added in equal amounts to each of the dimples of 
mini-muffin trays purchased from Lakeland (Cumbria). Twenty-eight mini muffins were 
prepared which equates to approximately 1.8 g of poppy seeds per muffin. 
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The trays were then placed into an electric oven set to 180 OC and left to cook for 15 
minutes. They were left to cool to room temperature and then 2 muffins were weighed and 
placed into zip lock bags for the toxicology study (kits 1-6). Two sets of mini poppy seed 
muffins were also prepared, weighed, frozen for one week, defrosted at room temperature 
then used in the toxicology study (kit A and B). The weights of the mini-muffins are 
provided in Table 6.3. 
 
Table 6.3 Weights of muffins provided in each of the kits for the toxicology study 
Kit number Weight (g) of muffin 1 Weight (g) of muffin 2 
1 19.9 19.6 
2 20.1 19.5 
3 21.7 22.1 
4 21.6 21.0 
5 18.6 18.5 
6 19.2 19.3 
A 19.6 19.5 
B 18.5 18.3 
 
 
 Toxicology study  6.2.
This small scale pilot study was designed to establish if eating two mini poppy seed muffins 
made it possible to exceed the 40 ng mL-1 analytical cut-off established by SAMHSA for 
opiates in oral fluid, as discussed in Section 2.1.5, was carried out. 
Six participants were provided with an information sheet outlining the steps to be followed 
in the collection of the oral fluid samples for the toxicology study. They were also provided 
with seven Quantisal™ oral fluid collection kits, 2 mini poppy seed muffins, a collection bag, 
a pen and paperwork from ethical approval (which included consent form, medical 
questionnaire and research proposal). Participants were provided with training on how to 
use the Quantisal™ collection kits prior to commencing the study. The mini poppy seed 
muffins were prepared in the food technology laboratory of Northumbria University as 
outlined in Section 6.1.4 in the same week that the toxicology study was carried out. Each 
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of the participants carried out their sampling on a different day of the same week. All of the 
oral fluid samples, with the adsorbent pad removed, were frozen at -20 oC until the 
following week when defrosting at room temperature, extraction and analysis by LC-MS 
took place.  
Two of the participants (numbers 4 and 6) also agreed to repeat the study the following 
week: four mini poppy seed muffins from the original batch were frozen, defrosted and the 
toxicology study repeated. These oral fluid samples were refrigerated overnight at 4 oC, 
after which extraction and analysis by LC-MS took place. These samples were collected and 
stored overnight in order to compare the results with the oral fluid samples which were 
frozen to establish if freezing the oral fluid had a detrimental effect on the results obtained. 
For the collection, participants were asked to rinse their mouth out with water, wait ten 
minutes and collect the first oral fluid sample which was to be labelled CONTROL. Next, the 
two mini poppy seed muffins were to be consumed and 5 minutes should be allowed to 
pass before the next oral fluid sample was collected: this was to be labelled SAMPLE 1. Oral 
fluid samples 2 – 6 were then to be collected at 20 minutes, 1 hour, 2 hours, 4 hours and 8 
hours post-ingestion of the muffins. These collection times were in-keeping with other 
toxicology studies investigating the detection of opiates in oral fluid after controlled opiate 
or poppy seed ingestion.74,85,177,278  All oral fluid collection was carried out by all six 
participants in the same week. The oral fluid samples of the two participants who repeated 
the study where the oral fluid samples were refrigerated (not frozen), were labelled A 
(originally participant 6) and B (originally participant 4).  
Finally, two working solutions containing morphine, codeine, thebaine, papaverine and 
noscapine at concentrations of 200 ng mL-1 and 1000 ng mL-1 were prepared in methanol 
using the intermediate stock solutions prepared above. The final concentrations for each of 
the compounds are provided in Table 6.4. 
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Table 6.4 Final concentrations for intermediate stock solutions of morphine, codeine, thebaine, papaverine 
and noscapine 
Compound Final concentration in 1000 
ng mL-1 intermediate stock 
Final concentration in 200 
ng mL-1 intermediate stock 
Morphine 1000 ng mL-1 200 ng mL-1 
Codeine 1000 ng mL-1 200 ng mL-1 
Thebaine 1150 ng mL-1 230 ng mL-1 
Papaverine 1260 ng mL-1 252 ng mL-1 
Noscapine 1210 ng mL-1 242 ng mL-1 
 
Using the 1000 ng mL-1 and 200 ng mL-1 working stocks, calibration solutions at 
concentrations of 10, 20, 30, 40, 50, 100 and 200 ng mL-1 were prepared in 1 mL of  blank 
oral fluid.  The blank oral fluid was pooled oral fluid collected by expectoration by the 
researcher over the period of two days. The oral fluid was refrigerated prior to preparation 
of the calibration solutions. Each of the calibration solutions was then added to 3 mL of 
buffer solution in a Quantisal™ oral fluid collection kit and frozen alongside the oral fluid 
samples provided by the participants from the toxicology study. Calibration solutions were 
prepared in triplicate. 
Five separate quality control (QC) samples were prepared in 1 mL of oral fluid, resulting in 
approximately 100 ng mL-1 of morphine, codeine, thebaine, papaverine, noscapine and 
morphine-d3. For the 100 ng mL-1 QCs the concentration of morphine, codeine and 
morphine-d3 was 100 ng mL-1, 115 ng mL-1 for thebaine, 126 ng mL-1 for papaverine and 
121 ng mL-1 for noscapine.  
 
6.2.1. Matrix-matched calibration solutions 
On the day of analysis, calibration solutions were defrosted at room temperature and to 
each of the calibration oral fluid solutions, 100 μL of the 1000 ng mL-1 working solution of 
morphine-d3 was added, resulting in a final concentration of morphine-d3 of 100 ng mL-1. 
The concentration of each of the alkaloids present in each of the calibration solutions is 
provided in Table 6.5.  The calibration solutions were extracted by SPE and prepared for 
analysis, as described in Section 6.1.3. 
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Table 6.5 Concentration of alkaloids present in calibration solutions 
Calibration 
concentration 
(ng mL-1) 
Compound Actual 
concentration 
(ng mL-1) 
10 Morphine & codeine 10 
Thebaine 12 
Papaverine 13 
Noscapine 12 
20 Morphine & codeine 20 
Thebaine 23 
Papaverine 25 
Noscapine 24 
30 Morphine & codeine 30 
Thebaine 35 
Papaverine 38 
Noscapine 36 
40 Morphine & codeine 40 
Thebaine 46 
Papaverine 50 
Noscapine 48 
50 Morphine & codeine 50 
Thebaine 58 
Papaverine 63 
Noscapine 61 
100 Morphine & codeine 100 
Thebaine 115 
Papaverine 126 
Noscapine 121 
200 Morphine & codeine 200 
Thebaine 230 
Papaverine 252 
Noscapine 242 
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 Results and discussion  6.3.
6.3.1. Selectivity 
When selectivity was established in Section 4.5.1, mixed alkaloid solutions of known 
concentrations were prepared and compared to a blank matrix. For the method 
development phase (Chapter 4) the matrix was blank mobile phase A, which was composed 
of  water + 2 mM ammonium formate + 0.2% formic acid. For this toxicology study, the 
matrix used was oral fluid therefore, a mixed alkaloid solution containing all five alkaloids 
plus the internal standard was prepared in oral fluid: extraction was then carried out using 
the SPE method (Section 6.1.3) and the extract analysed. A mixed alkaloid extract with 
approximately 200 ng mL-1 of each of the five alkaloids (+ 100 ng mL-1 morphine-d3) was 
analysed using the instrument methods (Section 6.1.2).  
 
 
Figure 6.1 Chromatograms for (a) morphine, (b) morphine-d3, (c) codeine, (d) thebaine, (e) papaverine, (f) 
noscapine 
 
All chromatograms (Figure 6.1) are the result of extracting the quasi-molecular ion for each 
alkaloid: as can be seen, there appears to be no interferences from the oral fluid matrix. An 
aqueous mobile phase blank was injected into the LC-MS instrument and no interferences 
for the alkaloids were found. However, in order to assess the selectivity in the case of a 
biological matrix, oral fluid spiked only with morphine-d3 (100 ng mL-1) was prepared in the 
same way as described for the known mixed alkaloid extract. The quasi-molecular ion was 
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extracted for each of the alkaloids and the internal standard and the subsequent 
chromatograms are shown in Figure 6.2. 
 
 
Figure 6.2 Extracted chromatograms for (a) morphine, (b) morphine-d3, (c) codeine, (d) thebaine, (e) 
papaverine, (f) noscapine 
 
When the chromatograms were examined from the blank oral fluid spiked with morphine-
d3, it can be seen that, as expected, there is a large peak observed for the internal standard 
(Figure 6.2.b). For morphine, codeine and thebaine there were no matrix peaks which 
caused interference at the expected retention times for each of these alkaloids (1.87, 4.29 
and 7.11 minutes, respectively); the chromatogram for papaverine shows baseline 
fluctuation which could be due to increased pressure in the system due to changes in the 
mobile phase gradient. Other blank oral fluid samples were injected (post SPE extraction 
but no morphine-d3) and also showed a similar baseline but when the mass spectra were 
analysed, the expected ions indicative of the presence of papaverine were not found.  
In the chromatogram for noscapine (Figure 6.2.f),  a peak was found between 8.00 – 8.24 
minutes which has a retention time similar to that expected for noscapine (8.21 minutes): 
the mass spectrum of this peak was compared to the mass spectrum from a known 
injection of noscapine (Figure 6.3.). As can be seen, all of the expected ions for noscapine 
(m/z 220, 353 and 414) are not found in the mass spectrum for the peak of similar 
retention time in the oral fluid blank (Figure 6.3.d) therefore this component of the matrix 
would not affect the interpretation of the presence of noscapine in a sample. 
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 Figure 6.3 (a) Extracted chromatogram using m/z 414 for a known injection of noscapine, (b) mass spectrum 
of noscapine, (c) extracted chromatogram using m/z 414 for blank oral fluid spiked with morphine-d3, (d) 
mass spectrum of peak of retention time 8.00-8.24 minutes from chromatogram (c) 
 
Since it was possible to show that blank oral fluid spiked with only morphine-d3 internal 
standard showed no interferences for the five alkaloids it can be assumed that the method 
is selective based upon the recommendations for analytical method validation published in 
2007 by Peters239, and explained in section 4.5.1. 
 
6.3.2. Linearity 
Linearity was established using the extracted calibration samples, prepared as in section 
6.2.1. In practical method validation, a minimum of 5 data points should be used to prepare 
a calibration graph and each point should be prepared a minimum of three times.243 
Therefore in this study, three separate calibration sets were prepared in oral fluid, 
extracted using SPE and the data produced was used to calculate the peak area ratio 
(opiate drug/internal standard), mean and standard deviation for each of the concentration 
points. The ratio of the peak area produced for the drug compound divided by the peak 
area obtained for an appropriate internal standard is recommended for reliable 
quantitation in analytical methods applied to biological matrices and has been used in the 
previous chapters.239  
The data obtained was used to construct calibration graphs: a minimum of five 
concentration points plus a blank were used. The concentration range, linear equation 
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from the line of best-fit for the calibration data and the co-efficient of determination (R2) 
obtained for each of the opiates are provided in Table 6.6. 
 
Table 6.6  Calibration range, linear equation and R2 values for morphine, codeine, thebaine, papaverine and 
noscapine. 
Compound Concentration range 
(ng mL-1) 
Linear equation R2 
Morphine 0 – 200 y = 0.0092x – 0.0059 0.9994 
Codeine 0 – 200 y = 0.0194x + 0.0055 0.9975 
Thebaine 0 – 200 y = 0.0437x + 0.0682 0.9985 
Papaverine 0 – 200 y = 0.2066x + 0.6244 0.9983 
Noscapine 0 – 200 y = 0.1095x + 0.7234 0.9954 
 
Since the R2 value for each of the five alkaloids is greater than 0.99, it can be concluded 
that the data is linear.  
 
6.3.3. Precision  
In order to assess the quality of the data produced using this method, pooled oral fluid was 
used to prepare 10 separate spiked samples containing approximately 200 ng mL-1 of each 
of the five alkaloids plus internal standard (100 ng mL-1), extracted using the SPE method 
outlined in Section 6.1.3 and analysed by the LC-MS method described in Section 6.1.2.  
The peak area ratios for each of the alkaloids for the 10 injections, mean values, standard 
deviation and co-efficient of variation values are provided in Table 6.7. 
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Table 6.7 Mean (𝐱𝐱�), standard deviation (𝛔𝛔𝐱𝐱) and co-efficient of variation (%CV) for 10 injections of mixed 
alkaloid oral fluid samples of 200 ng mL-1, containing 100 ng mL-1 morphine-d3 
Sample 
number 
Peak area ratios (opiate/morphine-d3) 
Morphine Codeine Thebaine Papaverine Noscapine 
1 1.7820 2.9968 9.0411 30.4039 17.8829 
2 1.7987 3.2099 9.1101 31.6306 20.1764 
3 1.7504 3.1078 8.8784 29.8126 19.2470 
4 1.7467 3.1437 9.0107 30.7348 19.7190 
5 1.7702 3.2083 9.2064 31.3650 19.6585 
6 1.7298 3.0515 8.9459 30.7253 19.0242 
7 1.7689 3.1582 9.1664 31.1406 19.3667 
8 1.7737 3.0598 9.0140 30.7827 18.6688 
9 1.7685 3.0225 9.1758 31.2501 18.8078 
10 1.7693 2.9875 8.7978 30.3220 18.4352 
?̅?𝑥 1.7658 3.0946 9.0347 30.8168 19.0986 
𝜎𝜎𝑥𝑥 0.0193 0.0831 0.1341 0.5473 0.6788 
%CV 1.09 2.69 1.48 1.78 3.55 
 
When assessing the precision, the recommended acceptance criteria is obtaining 
coefficient of variation values of 15% or less.246 As can be seen in Table 6.7, all five alkaloid 
compounds have a %CV of less than 4% which is much lower than the 15% limit therefore 
showing that the method is precise, or more specifically, repeatable. Accuracy was 
determined to be less than 15% variation for all alkaloids except papaverine: for this 
compound the variation was found to be 26% which exceeds the recommended limit.239 
 
6.3.3.1. Repeatability 
As part of the validation process, quality control (QC) mixed opiate samples were prepared 
at concentrations of 100 ng mL-1, including morphine-d3 at 100 ng mL-1. These QC different 
QC samples were prepared, extracted and analysed in the sample way as calibration and 
participant samples. The QC samples were bracketed between participant samples and 
blanks. Table 6.8 shows the repeatability of the combined QC data. 
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Table 6.8 Peak area ratios for morphine codeine, thebaine, papaverine and noscapine, showing mean (𝐱𝐱�), 
standard deviation (𝛔𝛔𝐱𝐱) and co-efficient of variation (%CV) for 10 QC samples analysed a period of four days 
Parameter Morphine Codeine Thebaine Papaverine Noscapine 
QC1 0.9612 1.5742 1.4634 6.2556 4.5583 
QC2 1.0447 1.7298 1.6943 7.1971 5.1888 
QC3 1.0006 1.6423 1.6555 6.9561 5.0065 
QC4 1.0272 1.7944 1.6525 6.9377 4.8596 
QC5 0.9758 1.8000 1.6281 6.6821 4.8853 
QC6 1.0283 1.7208 1.6356 7.0490 5.0805 
QC7 1.0099 1.7108 1.6939 7.3957 5.1580 
QC8 1.0377 1.8387 1.7176 7.6651 5.3115 
QC9 0.9891 1.7646 1.6284 7.1578 4.8177 
QC10 0.9612 1.5742 1.4634 6.2556 4.5583 
?̅?𝑥 1.0083 1.7306 1.6410 7.0329 4.9851 
𝜎𝜎𝑥𝑥 0.0288 0.0825 0.0739 0.4057 0.2301 
%CV 2.86 4.77 4.51 5.77 4.61 
 
All co-efficient of variation values are less than 6% and since it acceptable to have values of 
less than 15%246, these findings show that the method is repeatable. 
 
6.3.4. Matrix Effects  
It is recommended in bio-analytical method development that matrix effects should be 
evaluated and that this can be assessed by preparing five samples of the biological matrix 
and spiking with the analytes of interest for subsequent extraction and analysis.257,258,279 
The data obtained can then be used to determine if the analytical method is affected by 
matrix effects. When precision of the method was assessed (section 6.3.3), 10 separate 
aliquots of oral fluid were spiked, extracted and analysed by LC-MS: this data was used to 
assess the precision of the method but it can also be used to evaluate potential matrix 
effects. In 2006, Matuszewski, et al.280 recommended that the co-efficient of variation 
should not exceed 3-4% in order to consider the method practically free from matrix effects 
and reliable: since the precision data obtained for each of the alkaloids (Table 6.7) shows 
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that the %CV values are all less than 4%, it can be concluded that any matrix effects from 
the use of oral fluid are minimal and do not greatly affect the analytical method. 
 
6.3.5. Toxicology study  
As described in section 6.2, control oral fluid samples were collected by participants prior 
to consuming the poppy seed muffins, followed by further samples collected at 5 minutes, 
20 minutes, 1 hour, 2 hours, 4 hours and 8 hours post-consumption. Six participants were 
involved in the study with two participants repeating the study one week apart and all 
samples were treated in the same way as the calibration standards, which were matrix 
matched (section 6.2.1). Using the peak area ratio, the concentration of any of the alkaloid 
compounds identified in the oral fluid samples was calculated. It should be highlighted that 
all of the peak area values obtained for the alkaloids identified in the oral fluid samples 
were below the 10 ng mL-1 peak area ratio values. The linear equations were still used to 
calculate an approximate concentration in order to assess if any correlation between 
participants could be identified. The same six participants were recruited to repeat the 
toxicology study: the only difference from the previous study was that samples were stored 
overnight in the refrigerator (not frozen and defrosted). The two poppy seed muffins 
consumed were prepared in the same way as described in section 6.1.4 and the poppy 
seeds in each muffin weighed approximately 1.8 g (~3.6 g in total). 
 
6.3.5.1. Morphine 
Morphine was identified in the first 1 or 2 oral fluid samples (collected at 5 and 20 minutes) 
of all participants, except participant A (Figure 6.4). Participant A and participant 6 are the 
same person but samples were collected one week apart. It should be noted that although 
the morphine concentration appears to “peak” in the 5 minute and 20 minute sample, the 
y-axis scale does not exceed 1.2 ng mL-1, which is considerably lower than the 40 ng mL-1 
analytical cut-off recommended by SAMHSA196 in the United States of America and by the 
EWDTS195 in Europe. SAMHSA have recently drafted a proposal for Federal workplace 
testing programs to use a screening cut-off of 30 ng mL-1 for opiates with a 15 ng mL-1 
confirmation cut-off281: even if these cut-off values were used in this case, the 
concentrations found would not exceed the proposed concentration limits. 
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 Figure 6.4 Combined participant time-concentration profile for morphine 
 
After the 1 hour post ingestion sample, there is no change in the concentration, i.e. the 
concentration of morphine remains at zero. In order to compare the participant differences 
in the first hour, the x-axis of the graph in Figure 6.4 was amended to remove the later time 
points (Figure 6.5). 
 
 
Figure 6.5 Combined participant time-concentration profile for morphine (reduced time points on x-axis) 
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When the study was repeated and the oral fluid samples were refrigerated rather than 
frozen, the findings (Figure 6.6) were different to those previously found. For participants 3, 
5 and 6, morphine was identified in the 4 hour post ingestion sample and in participant 5, 
morphine was even noted in the 8 hour post ingestion samples. As mentioned above, it 
should be noted that the values are very low and below the lowest concentration point of 
the calibration solutions. 
 
 
Figure 6.6 Combined participant time-concentration profile for morphine obtained from the repeat study 
 
All participant numbers allocated in the original study were allocated to the same person in 
the repeat study, to avoid confusion. As can be seen in Figure 6.6, morphine was identified 
in the oral fluid of all participants in at least one of the collected oral fluid samples. If the x-
axis of the graph is modified to make the initial data easier to view (Figure 6.7) it is possible 
to see that in the 5 minute and 20 minutes post ingestion samples, morphine was detected 
in all six participants.  
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 Figure 6.7 Combined participant time-concentration profile for morphine obtained from the repeat study 
(reduced time points on x-axis) 
 
 
6.3.5.2. Codeine 
Codeine was identified in the 5 minute oral fluid samples of only 2 of the 6 participants 
(Figure 6). As was found in the case of morphine, the graph appears to show a “peak” in the 
first sample but again, the y-axis scale should be noted: the highest value is less than 3 ng 
mL-1, which is also much less than the SAMSHA analytical cut-off of 40 ng mL-1 and the 
proposed cut-off of 15 ng mL-1 as was also the case with morphine. 
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 Figure 6.8 Combined participant time-concentration profile for codeine 
 
In the repeat study, codeine was identified in the oral fluid samples of participants 1, 2 and 
3 (identified in participants 1 and 2 in the original study). When the data was analysed, the 
results from participant 1 (Figure 6.9) show that there is an initial detection of codeine in 
the 5 minute post ingestion sample which then decreases until the 1 hour post ingestion 
samples was collected. However in the 2 hour post ingestion sample, the level of codeine 
increases to approximately 28 ng mL-1. If the 40 ng mL-1 SAMSHA analytical cut-off is 
employed, this sample would still be classed as a negative however, if the suggested 15 ng 
mL-1 cut-off was used, this sample would be classed as positive. This result was only seen 
for participant 1 and is the only one sample to come close to the 40 ng mL-1 SAMSHA 
analytical cut-off. 
 
0
0.5
1
1.5
2
2.5
3
0 100 200 300 400 500
Co
nc
en
tr
at
io
n 
(n
g/
m
L)
 
Time (minutes) 
Time-concentration profile (Codeine) 
Participant 1
Participant 2
131 
 
 
 Figure 6.9 Combined participant time-concentration profile for codeine obtained from the repeat study for 
participant 1 
 
Codeine was also identified in the oral fluid sample of participants 2 and 3 (Figure 6.10) but 
the extrapolated concentration values were more similar to those found in the original 
study (Figure 6.8).  
 
 
Figure 6.10 Combined participant time-concentration profile for codeine obtained from the repeat study for 
participants 2 and 3 (reduced time points on x-axis) 
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6.3.5.3. Thebaine 
Currently, the guidelines for the presence of opiates in oral fluid are confirmed by the 
presence of morphine and codeine only: if heroin administration is suspected, this is 
usually confirmed by the presence of 6-MAM (see Section 2.1.5). Thebaine, was proposed 
by Cassella, et al.78 in 1997 as a potential marker in urine for poppy seed consumption. In 
2007, El-Haj, et al.282 showed that thebaine was a useful marker, also in urine, for opium 
use (this included poppy seeds). In the latter study, users of illicit heroin were included in 
the study and no thebaine was detected. However urine is a different matrix to oral fluid. 
As yet, there are no guidelines to provide interpretation of thebaine in oral fluid, or in 
biological matrices in general. 
When the oral fluid from all participants was analysed for the presence of thebaine, it was 
identified in the samples 4 of the 6 participants (Figure 6.11).  
 
 
Figure 6.11 Combined participant time-concentration profile for thebaine 
 
As with morphine and codeine, the y-axis scale is small which makes the results appear 
more pronounced than in reality. However, for participants 1 and 4, thebaine was found in 
the 5 and 20 minute samples, at concentrations less than 5 ng mL-1 but thebaine was 
detected for up to 1 hour for participant 2 and 2 hours for participant 5.  
Thebaine was not detected in any of the oral fluid samples of any of the six participants in 
the repeat toxicology study. Thebaine has not been reported in oral fluid in the scientific 
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literature to date. Whether these findings are significant warrants further investigation as it 
is necessary to establish if thebaine can be detected in the oral fluid of individuals who 
have consumed diacetylmorphine (in the form of heroin), morphine or codeine 
preparations. 
 
6.3.5.4. Noscapine 
No data currently exists in the published literature with respect to the interpretation of 
noscapine presence in oral fluid. Noscapine was identified in the oral fluid of 4 of the 6 
participants (Figure 6.12). 
 
 
Figure 6.12 Combined participant time-concentration profile for noscapine 
 
For participants 2-4 noscapine was identified in the 5 minute sample (all with less than 6 ng 
mL-1) but when the 20 minute sample was analysed, no noscapine was identified: when the 
1 hour sample was analysed, it was found that noscapine was again identified in the oral 
fluid of participants 3 and 4, albeit at less than 3 ng mL-1 for both.  Noscapine was not found 
in the 1 hour sample of participant 2, but was then identified in the 2 hour sample: no 
noscapine was identified in the 4 hour sample. In the case of participant 2, no noscapine 
was identified in the 20 minute or 1 hour sample but was identified in the 2 hour sample. 
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 Figure 6.13 Combined participant time-concentration profile for noscapine (reduced time points on x-axis) 
and participant 1 removed 
 
The results obtained from the oral fluid samples of participant 1 were different to all of the 
other participants: it was found in this case that the noscapine level increases to a point in 
the 5 minute sample and then continued to be identified until the final 4 hour sample.  It is 
possible that the oral cavity of the participant was contaminated with poppy seeds for the 
duration of the study. However, if this was the case, it would be expected that similar 
results for this participant would also be seen for the other alkaloids. Since this was not the 
case, the reasons for this are unknown and since no literature in relation to the 
pharmacokinetics of papaverine in oral fluid exists, it can be deemed an anomaly. It should 
however be taken into account that these values are so small, and below the lowest 
calibration standard, therefore the findings may be as a result of the limitations of the 
method used. 
Noscapine has not been reported in oral fluid in the scientific literature to date. As was 
highlighted in the case of thebaine (Section 6.3.5.3), whether these findings are significant 
warrants further investigation to establish if noscapine can be detected in the oral fluid of 
individuals who have consumed diacetylmorphine (in the form of heroin), morphine or 
codeine preparations. 
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6.3.5.5. Papaverine 
Papaverine was only detected in oral fluid samples in the repeat study (Figure 6.14) and 
was detected in 3 of the 6 participants. Again, it should be noted that in all samples, 
papaverine was found in concentrations lower than the lowest concentration point of the 
calibration solutions. Papaverine was also identified in the control sample for participant 1, 
which is unexpected. However, the same participant also had noscapine identified in the 
control sample and continued to be identified throughout the full sample collection time in 
the original study. On further investigation, the participant collected the samples as 
outlined in the instruction sheet and as per the training provided and had not consumed 
any other pharmaceutical/over-the-counter preparations or used any topical treatments 
therefore this remains an anomaly, currently unexplained. 
 
 
Figure 6.14 Combined participant time-concentration profile for papaverine obtained from the repeat study 
 
Papaverine has not been reported in oral fluid in the scientific literature to date. As was 
highlighted in the case of thebaine (Section 6.3.5.3) and noscapine (Section 6.3.5.4). 
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6.3.5.6. Interpretation of oral fluid results 
In 2003, Rohrig and Moore published their findings in relation to the presence of morphine 
and codeine in oral fluid of participants who consumed poppy seeds.74 As discussed in 
section 2.1.2.1, the researchers found that it was possible to exceed the 40 ng mL-1 cut-off 
with the presence of morphine in oral fluid post-consumption of poppy seed bagels and 
loose poppy seeds.  Since 2014, a group of researchers from the National Institute on Drug 
Abuse (NIDA), in the United States of America have published a number of papers on the 
interpretation of the concentration of morphine and codeine in oral fluid and urine of 
participants who consumed poppy seeds.74,85,177,278 These studies report the findings of 
what appears to be one larger study where two quantities of 45 g of raw poppy seeds were 
consumed 8 hours apart by participants and oral fluid was collected (Section 2.1.2.1 for 
more information on the studies). From these publications, it was reported that it was 
possible to exceed the 40 ng mL-1 cut-off by the presence of morphine up to 1 hour post-
consumption of the seeds. However, 90 g of raw poppy seeds does seem unrealistic, even if 
over an 8 hour period. As discussed in Section 5.2.2.2, the average poppy seed bread roll 
contains 1 – 4 g poppy seeds.72 In this study, approximately 3.6 g of poppy seeds were 
ingested since two mini-muffins were consumed: none of the participants exceeded, or 
even came close to the 40 ng mL-1 cut-off recommended by SAMHSA and EWDTS. There are 
however a number of factors that should be considered in the overall interpretation of 
these findings.  
It has been reported that the circadian rhythms of salivation in human biological systems 
can have an effect on the transfer of drugs from blood into saliva.163 It is also possible that 
in the process of cooking the poppy seeds in the muffin matrix, the alkaloid content of the 
poppy seeds was reduced as it has been shown by a number of researchers that the 
cooking and processing of poppy seeds can greatly affect the alkaloid content: in 1998, 
Meadway, et al.70 demonstrated that a difference in the opiate content of cooked, sieved 
and raw poppy seeds and concluded that the processing method prior to consumption 
would affect the alkaloid content ingested. Other studies showed that washing, grinding 
and baking could reduce the alkaloid content by up to 70%, depending upon the 
combinations of parameters used.75 Since the poppy seeds used in this study were 
purchased from a supermarket and limited information was available on the treatment of 
the seeds, it is not possible to determine at this point if the processing of the seeds had any 
effect on the results obtained. A number of researchers72,278 have also reported that the 
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variety of poppy seeds and the geographical origin can have an effect on the alkaloid 
content: again, this information was not available for the poppy seeds used in this study 
therefore it is possible that these parameters could have had an influence on the findings 
of this study. 
Factors such as disease of an individual can greatly affect the production of saliva and the 
quality of the saliva, thus affect the transfer of drugs (Section 2.1.2): all participants in this 
study were healthy, drug-free individuals with no known sensitivity to opiates. The findings 
of this limited toxicology study are interesting since it has been reported by other 
researchers that it is possible to exceed the 40 ng mL-1 cut-off recommended by SAMHSA 
and EWDTS.  However it is the opinion of this researcher that based on the reduction of 
alkaloids as a result of the baking process (Section 5.2.2.2) and the average of 1 – 4 g of 
poppy seeds consumed, that a negative roadside or workplace drug testing result in oral 
fluid would be found.  In order to establish if these findings are representative, the study 
should be increased to include more participants, collection at different times of the day 
and to have more control of the amount of poppy seeds (and level of alkaloids) consumed 
by individuals. 
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7. CONCLUSION AND FURTHER WORK 
 
 Conclusion 7.1.
The aim of this work was to establish and evaluate an LC-ESI-MS method for the detection 
and quantitation of morphine, codeine, thebaine, papaverine, and noscapine: the five 
major opium alkaloids.  
The LC-ESI-MS method was initially developed using a reversed phase LC column and an ion 
trap octopole mass spectrometer: there were many challenges to overcome to achieve a 
method for the simultaneous detection of the five alkaloid compounds. The biggest 
challenge was solving the problem of the appearance of two peaks in the chromatogram 
for thebaine; both of which had very similar mass spectral data. Experiments were carried 
out using NMR, which established that two epimers of thebaine were being formed in the 
solvent chosen for sample preparation. When this solvent was changed to the aqueous 
mobile phase used in the LC method, one peak in the chromatogram was eventually 
achieved for thebaine.  
The method was finally modified to include the use of a pentafluorophenyl phase with 
propyl spacer (PFPP) column and finally all five compounds could be detected and 
quantified. The established method included the use of water + 2mM ammonium formate 
+ 0.2% formic acid mobile phase (A) and acetonitrile + 2mM ammonium formate + 0.2% 
formic acid mobile phase (B). The gradient method commenced with 90% mobile phase A, 
which was held for 2 minutes and then altered to 10% A over 8 minutes and held for 1 
minute. The instrument was then re-equilibrated to 90% over 3 minutes. The ion 
transitions monitored were m/z 286→201 for morphine, m/z 300→215 for codeine, m/z 
312→281 for thebaine, m/z 340→202 for papaverine,  m/z 414→220 for noscapine and 
m/z 289→201 for morphine-d3, although at least two product ions were used to qualify 
each compound. This method was then transferred to an LC instrument hyphenated to a 
triple quadrupole mass spectrometer in the IRCGN toxicology laboratory in Paris for 
comparison and the results correlated to those found with the original method.  
For evaluation, this method was applied to the analysis of poppy seeds for the detection of 
alkaloids: a comparison between harvested (raw) seeds, seeds which were baked on the 
surface of a bread roll and seeds thermally processed without bread matrix. The extraction 
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method employed chloroform:isopropanol (90:10, v/v) at pH 3.5 with ultrasonication for 10 
minutes, followed by 10 minutes of centrifugation at 4000 rpm.  
The extract was transferred to a clean glass tube, where it was dried down under nitrogen 
at 40 oC and reconstituted in 100 μL of aqueous mobile phase and filtered using a 0.22 μm 
nylon syringe filter. 
Morphine, codeine, thebaine and noscapine were identified in poppy seeds from a number 
of supermarkets in the UK. There was much variation in the levels of alkaloids identified in 
poppy seeds. This variation can be attributed to a variety of natural parameters, such as 
weather and soil conditions, but also in the way that the seeds are harvested. Processing 
methods prior to packaging and even the baking process has been shown to greatly affect 
the level of alkaloids. When these results were compared to those of thermally processed 
poppy seeds, whether from the surface of a bread roll or were heated with no bread 
matrix, the levels of alkaloids (if detected) were considerably lower than in the harvested 
seeds. These findings correlate with the studies published in the literature.  
Due to technical issues, the method was modified for use with an LC instrument 
hyphenated to a hybrid linear orbitrap for a toxicology study. For this study, two poppy 
seed muffins were consumed (~ 3.6 g of poppy seeds) and oral fluid was collected using 
Quantisal™ oral fluid collection kits at 5 minutes, 20 minutes, 1 hour, 2 hours, 4 hours and 8 
hours post-consumption. Oral fluid was used as the biological matrix as it has been shown 
that opiate drugs will transfer from blood to saliva and thus to oral fluid; it can therefore 
provide information on recent drug use, and is easily collected and stored. 
Extraction was carried out using Bond Elut Certify (130 mg bed mass, 3 mL volume) mixed 
mode cartridges; the method of extraction included conditioning of the cartridges with 
methanol and phosphate buffer (0.1 M, pH 6.0). The oral fluid sample was then applied and 
allowed to drip through under gravity. The cartridges were then washed with water and 
0.01 M formic acid before being air dried for 10 minutes under full vacuum. 50 μL of 
methanol was added and the cartridge was dried for a further 2 minutes and the alkaloids 
were eluted using methanol: ammonia (98:2, v/v).The final extracts were then evaporated 
under nitrogen at 40 oC and reconstituted in 100 μL mobile phase A with each extract being 
filtered through a 0.22 μm nylon syringe filter. 
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Morphine was detected in oral fluid in the 5 minute sample in 5 out of the 6 participants; 
codeine was identified in the 5 minute oral fluid samples of only 2 of the 6 participants; 
thebaine was identified in 5 out of the 6 participants for up to 2 hours post-consumption; 
noscapine was identified in the 5 minute sample for 3 participants then decreased to zero 
before being identified in the oral fluid of 2 of the participants in the 1 hour sample. The 
noscapine level then decreased to zero at 2 hours and was not detected in any of the later 
samples collected.  Papaverine was detected in the oral fluid of 3 of the 6 particiapnts but 
was not identified in the 4 hours post ingestion sample or in the subsequent sample 
collected. For all of the opium alkaloids identified, they were found in concentrations less 
than 10 ng mL-1, apart from codeine identified the oral fluid of participant 1 (27 ng mL-1 at 
the 2 hour post ingestion time point).   
In conclusion, a simultaneous LC-MS method for the detection and quantitation of five 
major opium alkaloids has been established and has been used to detect alkaloids in 
harvested poppy seeds and oral fluid samples. The method has been shown to be selective, 
precise and linear. From a small pilot toxicology study, oral fluid results indicate that levels 
of morphine and codeine do not exceed the SAMSHA and EWDT 40 ng mL-1 cut-off after 
ingestion of a realistic amount of poppy seeds contained within bakery products. Thebaine, 
papaverine and noscapine were also identified in the oral fluid samples for many of the 
participants and since this has been previously unreported in the scientific literature, this is 
a significant finding. Further investigation is however required to establish if these findings 
could add to the debate on whether it is possible to differentiate between poppy seed 
ingestion and administration of other opiate preparations, including heroin.  
 
 
 Further work 7.2.
Although a sensitive and linear method was established for the detection and quantitation 
of five major opium alkaloids, the coefficient of variation values in repeatability studies for 
morphine, codeine, thebaine, papaverine and noscapine exceeded the 15% limit expected. 
In order to account for this factor, calibration graphs were produced on every occasion that 
poppy seeds or oral fluid extractions were analysed. Quality control samples were included 
at various points throughout the entire run to ensure the calibration graph produced was 
fit for purpose to determine concentrations of alkaloids in the samples. Other researchers 
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have published reproducible LC-MS methods for the detection of multiple alkaloids in 
poppy seeds and biological matrices. Newmeyer et al.177 reported coefficient of variation 
values of less than 9% for morphine and codeine in both blood and oral fluid. Sproll et al.76 
also reported values of 9% or less for an LC-MS method where morphine, codeine, 
papaverine and noscapine were detected and quantified. Whether the inclusion of 
thebaine in the method has affected the overall repeatability of the method in this work 
should be investigated.  
Since this method includes five alkaloids and morphine-d3 as an internal standard it is 
possible that competitive ionisation is taking place in the process of electrospray ionisation. 
Competitive ionisation can take place in ESI methods where multiple analytes are present 
in a mixture: ions are formed however factors such as the chemical structure of the 
analytes, the concentration of analytes in solution and the mobile phase used to introduce 
the analytes to the mass spectrometer have all been shown to have an effect in these 
cases.217,222,238,259,260,283 In order to attempt to achieve repeatability, competitive ionisation 
could be investigated. 
It was shown in this work that there is much variation in the levels of alkaloids present in 
poppy seeds and that this can be explained by the fact that they are a natural product 
which can be affected by external environmental factors that cannot be controlled. 
However, the method of extraction should be further investigated to establish overall 
extraction recoveries. In this work, a known amount of deuterated internal standard was 
added to the poppy seeds prior to extraction however, it should be considered that this is 
not a true representation of the “extracted” alkaloids. Most researchers in this field assume 
that most of the alkaloids identified from poppy seeds are as a result of external 
contamination of the surface of the seeds72,75,76 but it is possible that alkaloids are present 
in the matrix of the seeds, even if it is a small amount. When the poppy seeds incorporated 
into a muffin matrix were analysed, the resulting chromatograms were very complex and it 
was concluded that the extraction method was not selective enough when the muffin 
matrix was present. Further work is required to modify the extraction and sample 
preparation method to eliminate the muffin matrix from chromatograms. An alternative 
method for the separation of the poppy seeds from the matrix could be identified as the 
results from poppy seeds in this matrix would add to the findings of this study.  
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In relation to the toxicology experiments carried out, it is proposed that the sample size of 
participants should be increased to determine if the findings are representative. Only 6 
participants were included in this pilot study however using this data and from other 
publications, a power calculation should be carried out to establish the number of 
participants required for a full toxicology study.284,285 In this work, it was found that based 
on a realistic ingestion of poppy seeds, no alkaloids were detected in oral fluid above the 
SAMSHA and EWDT 40 ng mL-1 cut-off. To extend this study, other biological matrices could 
be included. Blood is the best matrix as it can provide information on what compounds are 
present in the body at a given time: this makes it easier to interpret symptoms or effects 
that may be experienced by the individual.144 Urine can provide a longer window of 
detection of since it is an elimination product of the body: drugs and/or metabolites can be 
detected in urine for up to 24 hours post-administration.145,286 On this basis, it would 
advantageous to repeat the toxicology study to include the collection of oral fluid, blood 
and urine for the best conclusion to be drawn. Obtaining blood as part of the toxicology 
study would also allow for the determination of the saliva or oral fluid:plasma ratios of 
opium alkaloids. A number of articles published in the literature report the saliva:plasma 
ratios for morphine and codeine83,167,170 but no reports currently exist with respect to 
thebaine, noscapine or papaverine. Establishing the saliva:plasma ratios  for these 
compounds could make a good addition to knowledge on the subject.  
At this current time, there is no published literature in this field which includes the 
detection of thebaine, papaverine or noscapine in oral fluid. When the toxicology study is 
continued, further work should include the investigation of the presence of these 
compounds in oral fluid. It would be beneficial to establish if these compounds can be 
identified in the oral fluid of individuals who use illicit heroin and in the oral fluid of 
individuals who administer legitimate opiate containing preparations. If thebaine, 
papaverine and noscapine are not detected in the oral fluid of these individuals, it may be 
possible to differentiate between the ingestion of poppy seeds/poppy seed products and 
other opiate containing drugs (both licit and illicit). However, much work will be required to 
establish if this is the case.  
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